var title_f35_16_36096="Balloon tamponade to manage liver injury";
var content_f35_16_36096=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F78494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F78494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    Balloon tamponade to manage liver injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 500px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH0Ac0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoqOWRYomkkO1EBZj6CvE/Efj3UZ71zb3Mlrbg/JHGcHHYk96wrV40VqduCwFTGNqGiXVnuFFedfDvxjNqdwthqLeZI4zFLgAkgcqfw5zXotXSqxqx5omWKw08NU9nMKKM56UVoc4UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEF1Atxbywv9yRSh+hGK+ZfE1m9nqEsNxwYXKN+Br6H1PVTFN9mtMPP0ZtpYJ+A6n27d/fmbvwtBd6m+r6hBJO/BEUhBJIH3mwMD6CuHF0/a2tuj2Mqxn1XmUlo/zOO8H6PqDy2moWq/ZoIWD+ZIdoc+mcH9M16Bc2uoXcXmNFFcs3IPmiQD/gLAAfhVaWZ2co54A+UAYAHoBWnoE53GEnkHI+lZ07RfKuoYuc637yW6/IXw7BPY3SRXCiPz0c+WuAFKkY4HAJ3NnHoK6asYZOvWw7iOU/+gD+tbNd1P4Tyqm4UUUVoQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHOxI+nSmCfG2RyUm6BySTgns3P49vSr0THymXO4jsetaMscc0bRyorowwysMgj3FZcmmzQ4NlNlR0imJI+gfqPxzWEqbTujWM09GZF5brM/mQjBHUd6NPjK3kTrwdwB+lZniPxbFod4LW+0vUZLp03qLS2e4yMkZzGDjofvYriL74lXg1uLT/AOybrQzLGZUvdUiIjABHOEJ+uGZMDqa53G7ujsVW8bHsNkQ+s3khICxRpGM9ick/+y1rKwYZUgj2rhfC2m2rtcyX0ov724YTSTyKpD/KFBUYwBgKMDt6nmt06VZIcwxiB+zRExn8xit4VNNEcs6bTs9zeorl9V1a80Kwnumil1CGJC/lJgSkgZwDwD+NcN4Z+PnhbVY5U1GK+0u6jOGikgaXj1ygP64rRVI9xRoVJfCrnsNFebXHxn8IRxkwXF7ckfwx2jg/+PACse4+OukqcW2iapJ7uY0/9mNDrQXU0jgsRLaDPYaK8X/4Xvad/D19j/rslWIPjro7Y8/R9Vj908th/wChCl7eHcp5fiV9hnsFFeaWnxn8JzY897+0/wCutqx/9A3VuWPxI8H3pAi8QWSMe07GE/8Aj4FUqkXszKWGrQ+KD+46+iqljf2d8m+yure4X1ikDj9Kt1Zg1bcKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKyde1q10eBDPJGLicmO2hZsGWTBIUD8OvYUviLXNN8PaZJf6zdx2tsn8Tnlj2CjqT7Cvn3TvF8/jX40WlzKkkNjb2rmzt3xmMEgFm/wBo9fbgdqxq1VBWW51YfCyrJz+yj2+GwWDT3nuJEa5k+eSRsAs39B2xVH+zPtDJOwjZlyVLAEjg5we3XFZfia6lkggJc7N3I/CtfwzeLNY+WzZaPpn0rn5YtnRFuEboyNWFxYyrJAxjZRgFfTFcy+v3sUh+0XD71PIHFdprUqTyGMc+9efeL7CRIhcxjOzhh6jsawvyystj0IJThdrU7/w/4gi1K2EFw4LEYBPr718y/EXQV0j4r3tvp7LCtxiUAEnaGXceOwyK9P0e+SztTPcypCifMWY4AFeVanqT+JfG+ta9Ez/Y9q20TsCN+ABkf985/Grk7oMHDkrXS0GaZKZHKSsWb3rVEI7CqNva7pvNjGCo+Yeo9a0UbIrCW57lN3Qzyx6VG8QxxVk0xhmlcsoOpU0gyRg8j0NW3jBpoiFMmxWREVw6qFYdGXgj8a1bDXta09s2Gs6nB7JdOR/3ySR+lVfKo8qmm1sTKnGXxK52GnfFTxhZEb9Rt71R2urZT+qbTXV6d8cbpdq6poMcg7yWtzg/98sP615EYjSbCK0Vea6nJPLsNPeH3aH0bpXxe8LXqj7TLd6e/pc27Ef99JuH6112j+ItG1pf+JTqlndnusUqsw+o6ivkLcynjIoZg7BnQMw5D4wwPseorWOKl1Rw1Mkpv4JNH2pRXyXpXjnxVpKhbLXbpox0jusTgD0ywz+tdTpHxW8VSShZ77TS56LLZnafxVxWyxUHucM8nrx2aZ9F0V5CPitqVhEG1LQEukxlpbGYgD/gLDj67qjHx30nOG0TVQfYxH/2ar9vDucrwGI/lPYqK8kT44aM3XSNWH08k/8As9Sj43aF30rWP++YT/7UqvbQ7i+o4j+Rnq1FeVj42aEf+YVrX/fuL/45TT8btDH/ADCdZ/79xf8Axyj20O4fUcR/Iz1aivJz8b9FxxpGsn/gMQ/9qVE3xx0rPy6Hqx+piH/s9L21PuH1DE/yM9dorxxvjjaf8s9AvT/vTxj/ABqvL8cH/wCWHhzP/XS9A/khpfWKfctZbiX9g9rorwG6+NWuOD9l0nTYT2MjySfy21j3fxW8Y3Odl5Y2o/6YWgP/AKGWqXiaaNY5RiXukvmfS1RTyxwRl5pEjQdWcgAV8qXXi7xRfE/a/EOpEHtDIIR+SAVSigjupQ95vun/AL1w5kP5sTUPFx6I6FklT7ckfT83i7w/FJ5b61YGT+4k6sfyBJqxF4g06cZgnMgPdUbH8q8E0QxwFViREHYKAK7/AESfKrVRruRlVy6NNbtnpEF5HN9wH8eKtCsLS2yRW4vSuhO6PMqR5XYWiiimQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXCfEb4h2Hg+3aBAt5rEi5htFbGP8AakP8K/qe3tz/AMUfiimkNNpHhp45tUGVmueGjtT6Y/if26Dv6V4BNK8ksk0skk08rFpJXYs7nuSe5rlrYhR92O57GAyx1rVKuke3cveJde1TxJqIvtcujczrkRxqMRQj0Re31PJ7msfwzrN3o/j+zuYzI0KYMoU4ymcMMd+P1xSkmqVyoF1HOBiRPut3Fcald3Z70qUeTkirI+o9aVJLQsrAxsBJGR0I68Vyd34m0/woIbvVrowQyuIkCqXZz3G0DJryfSviDrejr9nSFb7SywAinfDQsT1RsH5fY5pfFN1J4tv9P1ERyxtHbhRaOQRG+4kkYH+7yeTVuStc86ngZqXLLbufRiywanp8d5plxG8bnIdeemcgjsexB5Bqjqd1p8Fk8mpTRJGEJkBPAGOc+1fPi2M6MZLlAJzlg4cqwOOoIPB9+tZ06eIdStVstUvXa3b/AFhLAlx6E1F0awwUubSRs634pHiWWWz062NrYNIRE7glpY15yRj5QeO/Sp2V7qKOIgJHGNqqowB9BVmzhK2qJjhEVF4A4UBQPyApyqQalyuzuhRjBWQ21thA24cnv9Khu4PIkVk/1b9PY9xWnEAanFuk0bQyfdbofQ9jUmifKYW09e1IVOKt+U0MjQyjDqcUMgpGq1KWKAoqy0OelN8o0DsRACnbRT/KNOEZpiItooMYNTbSKWgCo8IPaq7w46VpYzTGUUBYyyCvWjPerrxg1UliI6U0yWjr/BmvxJMtpqTEIeI5c/dPoa1vFXg2K7RriwVIbo/MAvCTfT+6f0rzQMUbNej+AvE6yqumak+VPETt1HsTWkbPRnFXhKD9pA83uIJbeZ4p0KSISrKwwQajC17F4y8LJqluXhAW7QZjfpvH90n+teSXNvLazvBcIUlQ7WVuCDUtWNaNZVV5iRjBqyiAjNVoz2q5Ce1QzpQojFKEqdUyKXbilcqxDspfLFS4paAsRbRS7akooCxHsFW7VgGFQUqMQ2aAcbo6Wwk6Yrs9BuvugmvPbCbpzXV6PMQynNbwlqefiKd0es6JJuIrpU+7XFeGptzKM12sf3RXo03dHy2KjyyHUUUVZzBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXh/xW+JzMbjRPC9wVIJjur+M/dPeOI/3uxbt256J8XfiM0r3OgeHp9sa5jvb1Dg+hijI79mbt0HPTxYkABUAVAMADoBXHXr/Zie9l2W3tWrL0X+Y3hV2INqjoKTFPCk1IsRNcR9AVitMaAOMGtDyaBDRcOUr6bZxCcJJ91+OfXtXS20SQLtjQAjgnvWKITnd3HSty0YTwq/8AEPlb60XE4pDZVEh+YZp0UCYyF5FSmPmpIk2sDSJ0I/KLIQOo5FMKEqW/iHB/xrR8rgMBxUnlBlJx160h3MyNcHNXYcEe9QyRGN8duxp0ZKmmJ6hqdsZ4RNGP30Y5H94VmL8wBrfhJyGFZup2ZsblHQf6NPyp/unuKRUJJOzKwWkK1MBSFaDZkO0UoWnFcUoFAhu0GmmMdqlwKMUAVmQimMKtkA1G6A0AUyKjkQEVadcVEVNMTM6aH0qFGeKQMp2sDkEVpSLVKaPvTTJaPV/APiVdWtfsV0cXMY4J/iFReO/Co1KM3douLtF6D/loPT6//qryyxu57C7juLZykkZBBFe3+GNai17SUl4WXG119DWyakrM8uvTdCXtIbHhjq0blWGGHBBqzbNmu58e+HBsk1G0TBB/eoOgPqK4CJij81lKNtD0KNVVI8yNWM9ql25FQQnODVtMGoOlFdkIppBFXWUEVE0RoGV6MVJ5ZFKEoAixShTU6x5qVIRSAWyyGFdTpLciuegjw1b2mHBWri7HPWjdHpXhR/3qivQYvuCvNfCjf6Qtekwf6sfSvSoO8T5LMI2mSUUUVueeFFFFABRRRQAUUUUAFFFFABRRRQAV5F8Y/HraeJPD+hzlL51H2u5Q4NuhHCqf77Dv2HPXFdN8UfGQ8JaKv2YI+q3hMdqjdFIHMjf7K5H1OB3r5luJnkd3llkmmkYvJI5y0jE8sfc1y4ityrlW57GV4D2z9rUXur8SGRhgKg2oOABSIuaQDcasxrgVwH06BEAFTKtCrmp0WpKSGqlP2CnhafigqxDsqWylFtcjf/qn+Vvb0NKFp/lhlwaBNXRrtDtbB6dQfUU5YxUWky+fCbZv9fEMqT/EvpVtQDTRyy0HwAfcPQ9KlClGweh6VEBirBjNxFgffHShi5ivPFuXHfsaqhDnFakClo/nHzglT71FcQ4+YD60i1LQhtvlODWk1rHe2clnMcLIPlb+4/Yis4DFX7R93ymqRlPXVHLqksEslvcrsniO1h/Ij2qTFdF4l057yxF/brm6tVxKB1kj9fqK5uGQSIGHQ0mrHRSq868xSopm2piKTFI1IcUVKVphU0ANxRilxRQAxlBqFkFWaaRmgRTdKqSpWk61WlXIoEZEyYNbXgzWH0nVUBbEMpAYds9jWfOlUWBVsjqOlWmROKkrM+hHEVzFlgHhmXaw7HivFvFmkvpOrzQkfITuQ+o7V6N4E1Uaho6xOf3kYxUPxD0o3+lLdRjMsGc+pHetZe8rnmUJOjVcHseZ2UvG09q04TzWFGxjkrXtm3AVzs9mLLyinFeKbHyKlApFEG0UhQVIwwaQCkA1RU8YFR7aljFAE6CtOxbBFZyLV22JBFNESV0egeEnzcL+Feowf6lfpXkng5/9LUfSvWrX/Ur9K9PDO8T5LNY2qEtFFFdJ5QUUUUAFFFFABRRRQAUUUUAFVNTv7fTNOub6+kEVrbxmWR26KoGSat14h8fvFG+SDwzZSZHFxfEen/LOM/U/MfYD1qKk1CNzowtB4iqqaPMvFniK68T63careZTzfkghJ4hiBO1frzkn1rCOSadIxJoVcmvKbbd2faU6cacVCOyJIVqyq02NcCpkXJqGaj4171MBQowKfQUNAp2KAKcBQAKtSAUgFPUUDI2LwyJPCdsiHINb8bJc26XcH3G4Yf3G7g1khcjFGm3v9m3+2bJs5vlkHYDsw9xTRz1Y6XRtqlTQnYwIp8kJifGdyMNysOQw7EUgWqOVssyqWAdTmoLtzHErqoZc4YH0qxasM7G+6f51I8IRyjjKN1BqRqV0ZTKCFdM7G5Ge3qKdFlGBFaH2JIomRCSrNuGe3GKpFSG2nqKY73VzY0+4KsrLyRwR2I7iuX8TaYNKvlntVxYXPzR46I3da17aQxt7VsrHBqNjJZXf+olHDd427EU9zJTdKXN0OBUgilxTZ7efTr2Wzu12yxnHsR2I9qf1HFQeimmrobSYp1FAyMikIqQimEUANxSEU6igCJhkVXkWrRFROtAFKZMisy4Ta1bLrVC7j4qkSzZ+H9+1rqnlZwrcge9euBVuYWQjcki9PbFeCaZObXUYJc4AYZ+le46BciSKM5yCOPpWkHrY83GQ1UkeOeJ7A6brFxBjChty/TtUVhJyBXd/FTSyRDfRr0+RiP0rzq2bZJiomrM7sPU54KR0UZ4qUVXt23IDVkLWbOoRlzzQq1KFpwWkBGFqRFpwUUooAkQVYh4NQJU8fWmJnX+Dm/05R7ivYbX/AFK/SvGPBzf8TBPqK9ms/wDUL9K9HC/CfK5yrVET0UUV1nihRRRQAUUUUAFFFFABRRRQBn61qdvo+kXmo3rbbe1iaZz7AZ/OvkLUr641K/u9QvWzd3krTSn0JPCj2AwPoK9p/aG10x6fp/h+FsG8b7Tcgf8APJCNoPsXx/3ya8MkOTXBip3lyrofS5Nh+Sm6r3e3oIKmiWolFWYlrkZ7SJVFWIhUKDJFWlGBSLQ+gCgCnCgoMU4CkFOFAxwFPQUijNTItBLYoFR3MImjKnr2NTAUoFBL1Lvhe9EoGk3bYdcm3dvXupraaFkJVhhhwR71x95ATiSMlXUhgV4IPYg12Wh341vTTJIR9vgws6jjcOzAfSrTucGIg4PmWw1VxV1MTw7T98dD61WddppY2KMGHUU2rmClZksRzmN+o6VXuYc/MPvDr7ip75nESXEGMDIYEZ596kRlnhWRP4hn/EfnUWtqaxkm7GWBxVi2mMZwelJNH5bZH3W/Q1GRg1SYSXQua/pw1zThLAM6jbKSuOsq9Sv1/wA964q3l3DB4I6iuysbp7eVWU4KnINZ/jDS02DWdPTEbH/So1/gbswHoaGrlUKns3yPZ7GGRSYpIXDqKkK1B3keKQin4pCKAISKMU8jmm4oAQio2WpcUEUAVmXNVLmPitArUE6ZWgRz867TXqXgW+M+lRNnLJ8przW8jIzkV0/w1u8XFxaseoDAVa7nNiI3gem65aDVNHlgIyZEIB9+orwi4iaC4ZGGCDg19AWhzAUPUcivH/HNiLXWpiowjHcPoauorq5zYKdm4FfTX3R1qRjisLTJMDFbsLAgVgz1kSAUtFFIYUtFFAD0qePrVdTU8Z5oEzqPCB/4mCfUV7TZf8e6fSvFPCJ/4mKfUV7VY/8AHun0r0cJsfL518aLFFFFdh4YUUUUAFFFFABRRRQAUUVg+ONY/wCEf8Iatqg+/b27NGPWQ8IPxYgUm7K7HGLk1FdT5v8AiTqy63461m8jffAkgtYTnI2RjacexbefxrlT1p0aGKBEJ3MByT1J7n86Z3ryJPmbZ91SpqlCMF0RIg5q0g4qvEOasqOKlmqJ4Fyc1ZAqKAcVMKRaAUtFOoGgFOFNWnqOaBk0a1LikjXin0EMQU8CminCgTFxkc1Whmn0rUI76z++h5Xs691PtVsU2RA6kGgmUVJWZ2LtBeWsV7ZNvt5hlT3U91Poc1VI5rnPDWpDSL97W7bGm3bAOT0ifs49ux/PtXWXdu0EzI/UdD2I7EVqnc8qpB05crG2soRtrDKHgg9KlkjFuy7FCx+g+uaq1ct3EsflP1/hP9KUkEHrqMmjDrwMqfSs8qVJRuo6GrVzG7QSQKxV+GUg4yc9KrWsjXUTrJ/x8RdSf4h7+9Qu5tfoMxV/TL028hWRQ8TDa6NyGHcEVSPI96SrIkk1ZmT4k0gaTdrNa5bTZzuhfrsPUoff+lUo2DCuwtJ4JbaWw1Fd9lMMH1Q9mHvXJanYT6PqDWtz8wxujkHSROxFTJdTqoVW/clv+Y0rTCKlQhh701hUnSREU3FSGmmgdxKMUUooEMZajZanIppWgDIvo8oeOlR+Frg2fiG2bOFZtpq/dR5U1hnMF1HIOqsGH51SZE1dNHvUbhGjf+E/Ka4v4lWW+2huVH3WMbH26j+tdVYP9q0yJ16sgYH3xVfxfaGfRLpMZPliQfUH/wDXW9ro8inLkqI8ctHKORW7ayEqKwWGyf681pWUmDiuZntxZsqcinVFG1S0jQWikopAOHWp4zzVepozQI6fwif+Jin1Fe2WP/Hun0rxLwgf+Jin1Fe2WH/Hun0r0cJsfMZ18aLNFFFdh4QUUUUAFFFFABRRRQAV5L+0VqBh8M6bpqHBvrsM49UjG/8A9C2V61Xz3+0Hfifxdp9gpytnZmQ+zSvj+UY/OscRK1NnfltPnxMfLX7jy9zUY605zTVrzD7AniFWQOlV4asoPmFSykW4xhakpidKfQUFKKSlFBQ9akjHNRrU0XWgTLCjApaKKCBMU4UlFAMkBpajzS7qBEV5As0RBGcjkV0PhHUX1G0bSrpt17aput3brLH0Kn1I/l+NYe+qkwlinjuLVzHPEwaNx1B/wpxdjGtS9pG3U7dhg0ikqwIOCOQaktbtNY01NRhUI+dlxEP+Wcnf8D1qPFao8vbRluQC4hEi8OvUU2IJIGbaBKRhjjk/Wo4JTFJu6qeCPUU+7dLZ0lClo3ySynp+GOaza1Noz01Kt1FtO9fxFViRWrKVdNwwykZ9iKyJwY3x2PQ0I0tfVC5qyyx6vZDTrsgSrk2sx6o390n0PT/IqhuozTDlMGRJbWeSC4UpLGdrKexqQMGFdDqFqdbswyAf2lAvB7zJ6fUVy6MQSp4I4IPBBqWrHZSqc68yQ0ynZprUjUTNOFMpQaAaJaaRSA0uaBEMy5U1iX0XJNbzjis27TOaYmekeBroTaDb7jllG010GoKJrQ5+6ylT9OlcP8O5sWTxn+FzxXf2qCWJkP4VvB3PFrrkm2eE61bG2vJEI5jcr+Hao4GwQa7Hx/pnl3CzqvyuNjH37GuJiJVtp6ispqzPWoT54Jm/bybgKtg8VjwSFCPStOFww61mdKJqKKKQxRUiGogakRhQB03hA/8AExT617fYf8eyfSvDfCLf8TFPrXuOn/8AHsn0r0MJsfMZ38aLVFFFdp4IUUUUAFFFFABRRRQAV8o/E68+3fEXxDNnKJOLZfYRoFP/AI8Gr6tJABJ6CvjC7ujfXl5eE5N3cSzk/wC/IT/WuTFvRI9rJIXqyl2X5ldzQtI/WlWuE+lLENWo/vVViPNWo+tSykXE6CnUxelPoKClFJSigoetTR1CDU8dAmTjpS0goNBAtJmiigAzRRRQAUhXIxS0tAWHaLqT6HqRn2l7WQbLiIfxL2I9x/8AWrsbuMROrRsHhkUNG46Mp6GuHlUMPetPwtqTEf2Rdt8py1q5/hPUoT6f59KqLOLE0b++vmbbPT4pldDBL9xuh9DVRyQxVhhgcEehqMtVHMo2Lyg26rHu3KM4PtnOKhuFDDH4g0+J/OTa33xTJmaOB2C7mUZAP1qDoi0ilggkHqKcBTwy3EXmxjDDhh3FNBpoGOiZ4pFeNtrqcgjsabr1gL6B9Us1AkXH2mJex/vj2p1TWdy9pOJYuSOCp6MO4NMlNp8y3OWVs0prT8Q6clqUvbEFtPnPA7xP3U1lhsioasd0JqauhCKSnGkoLQA08Go6cpoEPIyKo3S4Jq+DVS7HFCJNTwVKY5Jl/wBoGvSrOQhlGeCK8w8I4N3IvqQa9KgOEDegraB5eLXvDPEGnJe2z7xlXG1h3B7EV49rmmy6ffMj9M8H19690jIkiKnkEc1zniPw6uo2rADEqj5T/SqnG6Iwtf2bs9jyiNgQKtQTFD7VVuoJLK6eGVSjqcMp4IpQ1c+x7SaaujailDjNSbqyrWUg47VfDZFIolzSq1RA09aQzpvB7f8AEyj+or3bTv8Aj1T6V4T4MGdTT6ivd9P/AOPZPpXoYPZnzOefGizRRRXaeAFFFFABRRRQAUUUUAZviO4Np4f1S5BwYbWWTP0Umvji2XZZ26+kaj9BX114+Yp4H8QsOo064P8A5Davkhf9TH/uj+VcOL3R9Dka92b9CN+tOWmP1pyVyHuonQ4NW4TmqSg1bgOKTLTLy9KeKjQ8U8Uix9IKTNKKBjxUsZqIVIlAmThqfUQNPU0EDsUYpaQmgApaSigQtBpKMGgYhqrcxE4ZCVYEEEcEHrkVbxTSuRQBs2V8dUsvOYYvIcLOo/iHZhUq/MMiubguJdMvUu4RuA4kTs6dxXTsYmiiubRt9rONyH09QffNWtTgqQ5HboOjYowYdRV7iRQy9+o/pWfuqa2l2Ng/dPWhohOwRWqwyyPG3ysuNnocg1DMmxsj7p/nWiVAORyKhmQEEdjU+ZouxRBpc0jKUbaaKoTVixaTInmQXC77ScbZU9R2I9653VrF9KvPLZt9tJ80EvZ1/wAa2TUu2C+s2sbw4UndE/eJ+x+lJq44S5HzI5oHIpKbNHLZXclpcjEsZ69mHYj2p3WpO1NNXQlKtFKooGPFV7sfKasYxUF190/ShEknhaTbqDj2FepWxMkMarwoAya8i8PybdTI9RXr9gwa0jK/dxxnufWtoHmYzSVyzE4jOB07Z7/WtaOFZrcMD2rnppMkgdO5qzb6i8EOxuE7eprWL7nBODeqOB+K1skb2V2oAdmMLHuwxkfyrh1bcoxW78RtSjvtXiht2JWLLMM5APb8a56GueerPcwkXGmkyzExU1pRklRWYpyRV9GG0DNZnWicNinq4qqzhRkmqU17ltsdFgbsd14NnB1SNV9a9803/j1T6Cvnf4exsdVjLdc19E6eMWyfSvSwqtE+VzmXNURZooorqPFCiiigAooooAKKKKAMLxunmeC9eTrusJx/5DavkaM5t4j6oD+lfZGsw/adIvoMZ8yB0/NSK+NLQ7rC2b1iXP5CuLF7o+hyJ+7Negj9aENDdaVRzXGe8TpUyHFRIKkFSykW434qZWzVRDUqtigosU4VGhzUlA0OBxTg1RE0oNAE6tUgaqytUqtmglosBs07NRLTxzQIeKWgLTgKBCBacFFGKcKBDcCjbTjQKAIpYwy4qbw/fLaTnTro4s52yhP/ACzf/A0hqneQiRDxQnYmcVNWZ0UqtDKUccg4p6mq2i3o1OxMEx/0+3HOesidj9amUkHBrRHC1bRl6Fi8ZQEhxyuO/tU8QEsZ3feBwf6Gs9WKkHOCKvLdB488Bu+O5pMSTuRXEAI/2h0qgzBeKuzzbh15rLuXXJcMD2ODnmpWhslzIc8lR7+aqvcKO+aha6xTbLUDWvrVNatFQEJqEKnyXPG8ddprnIHJyjgq6kqwPBB6EVb+3upBVtpHII65qtqE4uZPtHCz/wAeON3v9aT1LpxcH5EuKeorOFx/tUv2j/apG5okZqneNjio/P8A9qqV1OSCQelCJasGiTD+2lX1OBXstj8tnGucjblj6D0rwO2n8rU4pAcFXBNet2OvR3KRQQMMYyf6k1tA8/FxbaaOikdQRxk9h/U1xfi/xMbbfb2TBp2+VpeoX1A9TUXi/wATLaKbO1fMzD944PIHoDXnk9080hZjkmiUugYehf3pbEwJLMzEs7HJJ6k1IrY71UMwC471EZWbvWdj0E7Gmsyr1ND3237tZygsavW1rnBIoaBSbGmWac4HAq7Y2mCGbk1PFCFHSrkCjIpXBnXeAIsamn1r3ux/490+leI+AkAv0Ne32f8AqF+lelh/hPlc1d6hPRRRXQeUFFFFABRRRQAUUUUAIQCCD0PFfFzQm2MtuesEskJH+6xX+lfaVfIvjK2+x+MvEVvjATUJmA9nbeP/AEKuTFrRM9zI5WnOPkc+T81PSo2+/Ui1wn0SJlNSrUCmpVNItEyVIKiQ1MDSKJYzUuarBsVMrcUDHUopM0hOKAQ7NPRuag3U+LJNAmXFNTxioY16VaQYFBDHAUYpaXFAhtKKCKAKACkNPpuCaAEph61KEJoMYAyaLCuUMy2V5FeW3Ekbbh6EdwfbFdM88F1bR3ltwsn3k7o3cGsCRgwK9qg0+7NhcSI3zW8v3h6HsRVIxqw5tVubkk/HpUC3uxsrz61QuZW3nniqxmA70NijS0NaW6Zuc8Gs2WQpKWXlSeahN0oHJqtJfYOF5osVoizI5B68VC8oHVqpSTTScDofSq7W879c0JF3vsXXuUHVqgkvol53VTNlLnmq81rNyEjdyMAhRnGSFGfTkgc9zTsgu1qyy+oxA8Zpv9pR+hrLtFNzNNAVeK5hYrJDIMMp+ncfSp2s3BxinZDTbV0XG1MY+VTVSe/dgQBjNMNq69az7iYLKyA5K9cdqEkKTaQ8St5u4nmuu8PXLW2kXl6T84Gxc/59TXFht1dFbyEeHxCD/rJAP1zVmEtVYo3EknmN5rb5CTuJ7mowxouzm4Y+oH8qRBmkaoeoLGrUUPrSW8Y61bAAqWy0PtoRurUiUAVRtjzWinSpZSQ6p7dcsKgq3aD5hQgm7I7vwKuLxK9ptf8AUr9K8c8Dr/piV7Ha/wCpX6V6VD4T5LMtahNRRRW55oUUUUAFFFFABRRRQAV8wfGK1Nr8S9XOMLcxQXA9/kCZ/NK+n68C/aGs/K8UaReAf8fFm8Wf+ubgj/0ZXPiVeB6mUT5cSl3TPIJOJDUiGopuJKfGa85n1RMDUimohT1PFJlJk6tUqtVYGpkNJlIlqVDUINPVsUDJSaYTmkLUCgByirEK1Ei1agXmgTLUS1OBTIxgVKKCAFLQKKBBTguaVFqZVppCbIhGTTxHip1WmyOiDk4p2JvcjIxUE5AU5NMnvUX7vJrNnuWcnmlcpRCWUkkDpVeQhhzTXcAEk1m3d+qZVTS3L0RoLeLt8pm+cfd9x6Vm3F8ckLWTPO7tuU4I6GpkYzANjGeo960SMmXImeV8Ak1qwWwCgvyaxnvINNtHuJ92xcA7Rk9cUzVPEDrKLDR4ftuquxQQIwzGQOSw9Md+nvRq9EFowXNNm/Lc21qoM8sUa+rsBUcF3HfNIumt9qZACRCDJj06d6l0T4Y3d9atea2RLeuPmTl1QHkDGRu/QV6D4E8E2fhizuIbby2kkcu7quAW9QM8Dtj0pcumpjUxkI6U9fvOEt9F1mYxsyW8ZOWYSEtt9F2jHPvurRTwXqmr3MP297aCzhYMsdmhjMh3Bv3hJJI44Gfeu81KAW7GeNeP4h6H1rJm8QC16tVRtujkq1qstLnM+OPh5qlzcpq+hrE9/EuGifIEgwccjoeevIPQjFcj5u2UW12jWuoKuZLOUjzF9x/eXjqK9i0jxUksgBNV/iB4Mg8bQWV5YXK2Gr27ZiulXJx3BwckVTimRRxlSk+WesfyPGdZufItHcH5scfXoKwEQLEO7Hkn1Pc1W12PU9K8T3Gg6tL500Ep3N0zgbgR7Hg1cPC4o5eU7vaqrrHYEODW3BJ/oMS+kgNYYq+kmIdvoQaGNEk/+t/CpIVzTLj/AFufUA1LB1pM0iXI+KlFQg1MhqC0TxHFXYpKoKasRtxSKLysCav2fLCseKQFyoBOBn/D+VX9NnZ5zDx5pbAA52jHU/y+tVExqTVj03wOv+loa9et/wDVL9K8r8EQ7Zo+pxjk9a9VgGIx9K9GivdPlce71CSiiitjgCiiigAooooAKKKKACvHv2jbUnStBvgOIbt4W9g6E/zQV7DXA/HGyN58NdUZVy9qY7pfYI4LH/vndWdZXg0dWCnyYiEvM+Ybj79EZp1z96o4zXln2nUsLT161GtPFSxokFTJVcGp1PFIokBozTN1LmgZKGzUiDNQKeatRdKBkqLVyIYFVoxzVhTQSyyjVKDVZTViIZNCIY8KTUirSgelP4AyxwKdibgq055EjHJ5qlc3gUEIfxrLmus8ls0XGot7mpPf4OFrNnumYnJqjJcg9DVOe9SPPzZPpS3LSSNF5jVK4vUjB5yaybi/d+AcCqjSFjzVKInIt3V88mQDgVQLEnJOac3NMNWlYhu4bsGp1udo4FVGYDk8VWlvIlOCT9cGixLlY6OylgeJ/tJTy8EsHxjHvW38PtLtYdS/tuSGO2M8ey2hVcEx5zub3JAPsK4LSLIap4jsY7rdLaXEwhRVk2qTwQMYxntg9cgcV6rqNrPa35huIzFNCdpQjGPTHtinGNtjlxVZ2VN7bnb2tw6XAf8AhPBHqK6CMBQrxcq3OaydBtxeWUZ6tjmut0fTvKUrIMo3QHsapU3LY8uWIUdGYl5CXQsFyrDBHqK8o8XaZPY3ZbJaB8lG9PY+9fQktggQjFcX4m0mK6t5beUfI3Q45U9iKUoOm7mtGsqq5TxSxupIZRg969X8HXzy2gVjnHIrzS60mW01BoJVwynr2I7Ee1ejeD4DFaknspNMmrseT/GzTIYviLJfKP3lxbxuceoGz+SiuOJ6V2/xhmE3imHn5hbgH/vo4riSKD0cOrU0IgyRVpTjNV0HOanQFpAo70jZFuXllP8AsinRNg02UEN9BTQcUjRGgjZFSKcVSikxVpGBqWWWEbmrCsApLfdHJqCJQauRwhxtYZUjBFCRMpWKamSSWJlyCX3cdeoH8iRXR+FbKXz2nmXa0mCB3GQCeO3bj1FMsbEyFVRPlGMV3fhvRnLKxWtYRuzz681HVs7Dwda7XVsV6FGMKK5/Q7LyQvGK6FRgV3wVkfOYifPK4tFFFWc4UUUUAFFFFABRRRQAVna/YLquh6jYP927t5ID/wACUj+taNFA07O6PiFSzW0RcYcKFYHsR1H5ikTrXQeONOGl+LtdslG1IryRlHornzFH5OK54HBryGrOx91CXPFSXVFhaeKjXpUi1JohwqQGoxT1pDHZNLmkFFAyRWq1C1UlPNWoDzSYF+PpUyDJqGOrcQoEySNKnQ7TTMhRk8CqN1eYyE4HrQStTUedEGTWXeajkkA8VlzXbnOW4rMu70Lnnn0p7j5UtzRnvevNZtxfKvfJrMkuHlPXAqPb681SiJz7FmW9d+BwKgLE9TSYFFUSFKBRxRmgEOpMUtITxQMr3CbhgHFYOoWrPKds0yem1q6BqgmjDqciqTsY1IKRyskF7BtKXEk0SOJAhODn1z6+9fRfgzWLbx5osMc9wD4is4gGLYBuohwGx/eHQ/n348NkhINJY3F1pOpQajp0hgvIHDxyJ1B+nf0weoqr3OKpQTi0t+h9N+Grt9NuxDNwucHNeo2ckU8CshBBFeJeDvE9l45sfl8u21+JczW2cCT1dPUe3Ufqeis9avNLcxyg4HGDVwlys8qtSctOp6fLKqRlWPOOK5G8lE0ro3rxWVdeJRcR5LlWH86LbUobyMvGf3q/eA/n9KmtO/oaYWny+pS1jRftu0qMTR8qfUdwav6Tam305gww5wuO+c1s6eqXMIcEEDqf51z19ql5rUlxB4ViSSCHKyai43RI+CPkGR5hB9CAPXPFZxTsa1pqT13PBfiJqEd/431MwHdDBKbdSOQdnBI9s7qxFrvNR+EmqWSebp92l6BklZVEbE+u4MefqAPeuLvLWexuJLe6heGeNtrxyDBU+/8AiOD2ps9GhOMopJ7EI9a1tIsHmV5sfKtVNMtWvLpY1GSa9Ig09LSw2Ac7efriok7GspWOAnX94RUYQk1avEIunAHepba2aQ9KaN7qxUSPFTRo2fatNNNc9FNXrXRZZGGVIppNkOol1M22UkgAc102jaPNcspKkLW3oPhgEq0i5+tegaTo6RBQqc1tCmcGIxajojG0Lw8ECllrvdI0pYlHy1Z07TwoBIraiiCDArqhCx4dfEuYkMQQcVNRRWpxt3CiiigQUUUUAFFFFABRRRQAUUUUAfNHx0sTa/EW4lI+S9tIZwfdcof0Va81PDYr3b9o6w+TQNTA4SWW0c/76h1/WM/nXhc4w9eZWVqjPr8uqc+Gi+2hLGcipBUUPSpRWJ6CHinio161IKTGOooooHcAeasQnmqw61ahXjNIDStyMc1aVgoyelZol21HPdnG0GgVrlq6ui2QDwKy7iYc81HLMcVj3l0ZCUQ8dzTSuNtRRLd3ucrGfqaoEFjljk0oWpreB55AsalmPYVexi3fVkJIUU6GOW4fbBE8jeiAk112k+Ew7CS8Jf0QcD8fWuwsNHjhQJFGEUdlGBScjjq4yENtTzO28O6rPyLfYPV2A/TNaMPg2/bHmTwp9Mn+lenx2IUYxU6WoHapvI45Y+fQ8yHgm5/5+0/74P8AjUcvg2/QfJLbv7HIP8q9UNuMdKjaEelF2T9eqnj9x4f1GDO+1cgd0IYflmsyaF42KupVh1BBBH4V7c0KnqKz9R0m2vIis8SP6EjkfQ9qOZm0Mwa+NHjLAjrUZFdXr/huW03SW2ZIhyV6lR/WuWdatST2PQp1Y1VzRZWkQE1XeLNXGqMr3qwaRTgE9pcx3FpLJBPEwZJY2Ksp9Qe1eseFvitBPGln42tixUBV1C3TJ+sid/qv5V5kQCKgkjBp3OerQjUWp9Iafb6BrvzaLrVlcg/wJIA4+qnkfjWtB4XOm77oziMKpJdyNgGOp5HH418mzW/cdexqpKJmOySSR19GYkflVbnE8LJPSR9E6J4eu/EPi64ul1R/+EWZB5sMMYhS9fJy5APKZyMn7+OcjFeyQrBp9ukFuiRRRqFVEAAA7YFeUfBbX4bnwjbxTELJbxmxk+qktGfxVsfUGu31HXLaHRhfzfO8LbFQHiU9AD/OplLuc6oNytYreLby0t9k800kMi4byoSDJIScDHoPc8fWvC/iHqseveIg9uIisEIhMkWCrHcxIB/iA3Yz3OT0r0O9P2/fdM3mPISXzzn/AOtXnetaIbG8DwD/AEaRvlH9w+hrJVLuzPXpYRU0pp7Gh4C00ZnnccqAB+tdTcoWGAOtS+DNJKaSGP3pGLfh0/pXS2+i7pQGHFK3MzCpVSkzy2TSXe8cleCa6HSdEAUFlrvf+EdiaTIXmrMejGIYArohEyni+ZWRy8Olxrj5K0rLTVLDCVuLpxB6Vp2Nhgjitkkcs6+hDp1htAAWum0+xCgEilsbQDBIrWRQoxW0Ynm1atwRAowKdRRWpzBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHn/wAcrH7b8N9SkUZks2ju19tjDd/46Wr5juRzkV9l6/Yrqeh6jYOMrdW8kJHsykf1r4zXLW0bN94qM/XFcOKVpJn0eSTvTlDsx0PSpaiiqWuQ9xDhTlNR0oNAyYYpcVGGqReaQEkS5OTVgEAVCGAFI8mBQMdLJge9VySaaWLNTJ3EcZPftS3K2RUv5yPkU896oKKV2LuSe9BOATWqVjCTuyS3he5nSGEZcnFei+H9Dis4VLDMh5JNc94DtQ7XFwwyQQo/ma7mNjkYrOUux5uKqt+6jQgjRQOKuRsF7VQi3EZqwjetSmeW9zSjYMOlP4qtb5I4qz5bHtWqENYjGKrvipZInqBgRwetDRSihCoNROoxTskGmucms2DVjNu4hknHBrhfFPh4KGvLFPeSMdPqP8K9DnAKGs5gDlSMg9RWd+V3RVGrKlLmieNsuaiKkV6LrfhiK8Yy2rCKY9Rjg/WuVuvD+pQMQ1sXH96Mgg1uppns08TTqLexhmoiMmrtxaywnEsbofR1Iqv5ZFWmjXfYgKZqI24LdKubKcqU7icbm54G12Xw1qnniD7TZSgLcW2QC4BJBU9mGT7EEiuvv/GkOp3cKCykt7BcjMhUFSSMbUXIA9ySTXnkR21M8xbjsKmS5lZhGlGM/aLc9Qsrg2kwRjuhboe2KuX1tHLGTtDxN1Fch4Uupbm3NnMC4UZjbqQO4PtXUaZdFGNvP0PQmua1nys6X/PH5naeGliksk8oYCAKR6GumtoBwcV53p12+lX6yLloW4ZR/EP8a9QsDHNDHNCweNwGUjoRXRRaenU8HH0nSfMtmSxQAEHFSvCD2qZVqULkV1o8ptlNYBnpVy2gGelSxw1biUCtIozlMkiQKtSUDpRW6VjnbCiiimAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV8WX8Jtry8tz1huJYiP8AdkI/pX2nXx/4ziEHi7X4wMAajc4HsZWYfzrkxa0R7eSP95NeRhoakBqEH5qkBrhZ9GiSikBozQMeKlU1CpqUMAKTGPLYqMnNNZiTQKRSQ4YrPvZt7bR0FWLmYIpUdTWaxJJqooib6Daa/wB008CmSA4qzNnZ/D9s6fcevmf0FdhbgFq4T4ez4kuoD3AYf1ruYW2tWD3Z5Nde8zXgUY5qWKISThM4zVSOUYHNSrMUYOOoppo4ZXub0NsUA44qcIMc1lJqGVHrTWvH7NitVOJlZmlKqAE5xWazAuarS3Lt1aoRMc1MpotIuSKMVXlwBmozO1QyykjrUOSYCTNwQKrrFk807dk04MBWb1DXoL5IxTHtdwqyjADpQXNPlQrMxrjTQ6lSAynqCMiua1XwzE+WhXyX/wBnp+X+Fd3uGaHSORcMKSi46o0hOdN3izxnUNOnsXxKvydnHQ1Tr16+0qOWNlKh0IwQa8/1vQJbORnt1Lwnt1K1rCpfRnq4fGKp7s9GYYzU0UTSOqIMljgAVraH4cv9Tl2x28gBxgkYFeneHvCVhoKxz3KG5vByD/Cp9h/WtOZLQ2qV4w82WPAXhT+z7Bbi7X9/IuQv90elL4q8OzWQS6iX9w5OMfwnrg13GmJJMFdxtHYelbFzBHc2rW8y7o2GCP6ih0uZa7nmQx8qNXmeqe55Bp9wLqHyZeJF4Ga6vwRrRsLwafdn/R5W+RieI2/wP865nxRpMui6mzJnH3gR0YdjSoy3luJE++OtYptPzR7FSEK1Oz+GR7cBg1IgFcn4G1xtStTaXTZu4AME9XToD9e1dYK7qcuZXPlsRRlRm6ct0WFIxU0VVowTVuJcCumGpyS0JKKKK2MwooooAKKKKACiiigAooooAKKKKACiiigAooooAK+S/iTH5XjzxEp/5/Wb80Rv619aV8r/ABZiMfxA8RH1uY2/OCI1y4r4Uevkz/fteRwxPzVKhzURGWqVRiuBn0yJBRSCilcsctPwaatKWobGkLwKjllCD3qOWYL061Vdi55ppCcrCOxc5pAmakRamVOKozKxSo2XirpWo2SncLDNDvTpuqxTnhM7X+nevUI3WRFkjYMhGQR0IryeeMjmtzw1r5sgttc8wZ+U91/+tWdSN9UcOIouXvI9AViOhqUSnuapxyh0DIQykZBFPDVgefKNy8k2O9SecfWs/dilEtFzPkLxl96aZaqGYU3zhRcOQtmY1C8pNV2mzUbSUmw5S2JcdaesgPesxpDVS71CK0XM0yJ7E8/lQmylBvY6NZgo5NMkulA4rhrnxXGpIiR39zwKzJvE105OxI1Hvk/1rRRk+htHCzfQ9IivE3YY1cSRHHykGvJv+Ehvc9U/Kuk0XXUucLu8uUdUJ6/Sk1KK1CeHnBXZ2+aguYBIhYD5hUFrehgA3WtOIeYAFHB601aRzOI7R7kxIq42uvH1FdJAROFLLzmsaO1DEccit/SoRuQHqKulDUl1HFanR28Qjthxg4FOqw6/uQB6CotvFdTRyt3dyr4i0ZNZ0ox4HnouYyfX0PtXjCGTTL9o5AVXcVYHsele/W3+rFcH8TPDYkjbVLVemBMo9ezD+VY1oO3Oj1ssxSi/YVHo9vU5aG4lsrqG9sm2sh3Ajp7g+1eu6FqMWrafFdQ8Bhhl7q3cGvD9IusE2034E11XhDWToOq7JyfsU5CyD+6f7w/z0qaU1GXkzrx+FdeGnxR2812PYIUxVgDFMjIKgg5BGQR6U+vXirI+SbuwoooqhBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV8xfGZNnj7XP9p7dv/IKj/wBlr6dr5o+OSlPiFfDtJbW8g/J1/wDZa5sV8B6uTv8A2j5f5HnCrzmpKMUV5x9UlYKWkFRySheBQO5KzBRzVeSYngVEWLHJNAUmqSJchMk05VJNSLHUyIBTbJGotShacFp22i4yMrTSKmK1Gy0gK8sYYVQljKtxWoahljDCmS1cfpGu3OnEJnfB3Q9voa6yx161uwMPsbup4NcJJEQelRbfTiplTTOaph4ydz1FLlW6ODUnmj1FeYRXV1D/AKuaQD0zkVZXV79Rjzv0H+FZ+yZzvCvoz0UyD1pvmj1rzttW1Bus5H0AFQSXd3J9+4lPtuNL2LEsJLqz0S4vreAZllRPqQKx7zxNaRZEAMre3A/OuMKljlmJPfNKFFWqKW5rHCxWrNa78RXtxkRkRIey9fzrKZnkYs7FiepPNKFqRVrVRS2OmNOMdkRBBS7BUpWkxQVYZ5Yo2FTuUkEdKlCinBaAsaOm+ILq1ZVlPmqv97r+de0aI0c9rG64JZQf0rwGWM5yK9H+H2uEwLaysRJDgDPcdhUWUXdHnYuikuaJ6ekP8QGK1LGE5Vl6iqNlILhAV5PcV0mmWxEYJHNdEI32PIrOyNCBN0PPpSiIHip7eI9McVaS3x1rpjTORyK9vDhKWeBJonjlUNG4Ksp5BGORV1YwBikKVXsyVNngnjnw/JoWqZiyYXy0T+o7g+4qvZzC9tRn/WL1r2rxXoUWu6RJbNgTL80Tn+Fv8D0rwSVJtI1N45kKFWKup6g56V5lak6MvJn1uBxf1uld/HHf/M9d+G/iA3Vv/Zd43+kQjMRP8aen1H8vpXeV4FDcSW1xBf2T4kRgykevv7V7ToOqw6zpkV3CQNww690buDXbhKvMuSW6PGzXCezl7eC0lv5P/gmpRRRXYeOFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXzh+0DHs+IMLf8APTTYj+Ikl/xr6Pr5/wD2jotnibRJ+0tnKn/fLqf/AGeufEr92ellLtiV8zyfFJilqOaQKPevNWp9cyOaXHA61WJJOTQSSc0+NcmtErECxqTVhEApUUAVIBSuAgWnAUoFLikMcKWminUAFIRmlooAhZcUwirBGaaVp3EVXQGqzxVoMtRMlAmjPKkUbatPHURXFVcmxCFpdtShadtoCxCFNKEqUIaeENFwsQhcU4Kam8sDrRgClcqwwJ60jKAalyKY4zRcLDOKUDJ4pKs2sQYl3O1F5J6/l70CbsSWOnXN/eW9rZQma6uJBFDGOrsf5DHJPYV9P6R8OdJ0/wAJR6T5aG6C7nvAo8xpepbPp2x6cVk/B7wONFtE1nVIGXV7iMrHG/8Ay7RHHy47McZPp07c+oV20aK5feW58zmONdWfJTeiPNdH0u40q/a0vseaOVYfdkX+8v8Ah1H5V29lCCoIFT6hYwX8QS4UkqdyMpwyH1U9jTrOF4I9kj78dGxgke9VClyO3Q86VRy3LCKFFOoorczCiiigArzL4reGvOjOrWy5IAWcD9G/pXptQzQpPC8Uqho3BVlPQgisq1JVY8rOnCYmWFqqpH5+aPnHR7oqxtpvoM12fgjWRoermG4bFpckKxPRW7N9OcVzXjbQpdB1iRFyY874m/vL/j2pLWYXtoG/jA5ryIuVOXmj6+pCnXp94TR9D0Vx/wAO9cOo6Z9kuGzdWoAOerJ2P9K7CvZpzU4qSPja9GVCo6ct0FFFFWYhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXiv7SlsTZ+HrsDhJpYT/AMCQN/7Tr2qvPfjpYLefD27mxlrKWO5HsA21j/3yzVnWV4M6sFPkxEJeZ8zZ+XNVJGLMTVrBClT1HBqqR8xry0faS2GqMmrMS8VCg5qzGKbYiRRTgKFpaQwxRSilAoATFOxSgCloAbiilNJQAUUUUAJimsop9FAEDKPSomUVZYVA1MQzaKXApaKADAopM0UABpjU8000AIBRilAqRUyCxOFHJJ6AUCEiiBO5yFVeSTwAK9x+DngA+ZFr2t2uxEw1jbyjnP8Az2cdj/dHbr1xil8Jfhs93Jba54hi2WikSW1m68yntI47L3C9+p44PvNdlCj9qR4GZZhe9Kk/VhRRRXWeEFFFFABRRRQAUUUUAFFFFAHM+OdCGuaLIkaBruEF4T3Pqv4/zxXhNrI+n3xRwVQnBB7GvpyvHPix4dFtdjUbZcQ3LHcAOFkx/Xr9c15+Mpf8vY/M9/JsUtcNPrt/kZem38mlalBf2pyFPzKOjr3Fe32V1FeWsVxbsGikUMpHpXzzo1yJoDBJ95ema9F+GmteTO2j3LfKxLwE9j/Ev9fzrPC1eWXK9n+ZvmuF9rT9ovij+X/APSaKKK9Q+ZCiiigAooooAKKKKACiiigAooooAKKKKACqeqWMGpabdWN2u62uYmhkHqrDB/nVyigE7O6Pi3U9Pn0rUrvT7z/j4tZWgkPTJU8N9CMH8azpR81e2/tAeGPLv7bxBaxHZcAW10V6K4/1bH65KE/7orxeVT+IryqkOSTR9pg66xFFT6kKcGrMdVuhqaJqk6SwOlKKaOlSKKQwC0tLSUALS0lFAC0mKM0ZoAMUhpc0GgBKKTFGKAEbpVdutTt0qE9aaENoJpSabQAUZpM0lADqQClRS3AFaekaVd6nfx2Wm20l3eScrEgycepPRR7nii1yZSUVdlBI+Nz8DoPUnsAK9s+GHwtDJDq3im3IOQ8FhIOno0o7nvt7d+eB0fw3+Gdt4d2ahrJivNYIBXAzFbeyZ5Lf7R59Md/S67aWHtrI+ex2Zud6dHbv/kFFFFdR4oUUUUAFFFFABRRRQAUUUUAFFFFABWfrWmw6tps1ncD5JFxnuD2NaFFJpNWZUZODUouzR80atZz6Lq8sUq7JInKsOx9x7Y5rZhuGUwXtq+2WNgysOxrtfiz4f+0266pbplkASbHp2b/PtXmeh3Jjka2lPB6ZrxalN0puDPtKGIWKoqst9mvzPoDw7qkesaTBdx4BYYdR/Cw6itWvJ/h9qo0zWWs52xb3eAMnhX7H8en5V6xXqYer7SF3ufLY/DfVqzitnqvT/gBRRRW5xBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFDWdMtdY0u60/UIxLa3KGORfY/17/Wvk/xpoNz4c16402+bfLGAyS4wJoz0cfyOOhz2xX1/XH/EbwXaeMtI8mRhBqEOWtbnGTGxHII7qeMj8eorGtS9otNz0Mvxn1ap73wvc+TWHNCHBqxqdjd6XqNxp+pQNb3tu22SJux7EHuCOQR1FV684+sTUldbFqNgamFUY3INWo5AaQyWigEUUDEpaKSgBaSiigApM0E00sKAH0hIFRlwKjZyaAHu1Rk00tTSaYhxam5pKfGjSSpGil5HOFRASzH0AHU/SgTdhvJqVYwF3yMEX1NeieFPhL4h1cxy6gi6TaHBLXA3Ske0YPH/AAIj6V7F4V+HHh/w5KlxDbtd3y4xc3RDsp9VGML9QM+9bQw8pb6Hm4jNKNLSLu/L/M8d8GfDDWfEEaXFyp0rT2wfNmQ+a49UTt9Wx6gGvevC3hjSvDFj9m0i2EecGSVvmklPqzd/5Dtit2iuynSjDY8DE42riPienYKKKK1OQKKKKACiiigAooooAKKKKACiiigAooooAKKKKAIbiCO4gkgmUNFIpVlPQgivnbxZpU2h6zLEf+WbZVv7y9jX0fXC/FPQ11DRzfRr+/tR82OpTPP5dfzrkxlLnhzLdHrZPivY1vZy+GWnz6HmsEwu7RZEOHXnI6g17N4O1f8AtjRIpnOZ0/dy/wC8O/49a8E0ac2100Dn5T0ru/BGq/2Tr6xSNi1u8RtnoG/hP64/GuPDVeSd3sz18ywvtqTit46r9T16iiivXPkgooooAKKKKACiiigAooooAKKKKACiiigAooooA4v4jeBLDxnpu2TFvqcI/wBGvFXLIf7rf3lPp+I5r5k8R6BqnhrUfsWt2ht5jny3HMcoHdG7/TqO4r7PrK8Q6FpviHT3sdZs4ru2bna45U+qnqD7jmsKtFT1W56OCzCeG916x/rY+MCKcrEV6t4w+C+q6a0lx4al/tO06i3lYLOg9jwr/ofrXlVzFLa3T213DLb3KHDQzIUdT7qRXDKEobo+koYmlXV6bJkmqZZQao4oBIqToNDcKNwqiGNLvNFguXC4pjSCq280m6iwXJmkphaoiwAySAPU1JZQz383lafb3F5L/cto2kP5KDQJySV2IWpM12+ifCvxfqpUtpqWER/5aXkgTj/dGW/MCu50T4EpuD67rcjr/wA8rKMRj8XbJP5CtY0Zy6HHVzDD095X9NTw13VBl2Cj1JxXSaF4K8Sa55bado9yYX6TzL5MePXc2Mj6A19K+HvAPhrw+UfTtJg+0L0nmHmy59dzZI/DFdVW8cL/ADM8ytnT2pR+88P8NfA5Rtl8S6kZD1NvZZVfoXIyfwAr1bw/4a0bw/CI9H0+3tuMF1XLt9XPzH8TW1RXRGnGGyPKrYqrX/iSCiiirOcKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKjkjWWNo5AGRhhge4qSigD528baJLo2uSwoDsDboj/eQnj/Ct3QtPfULSNiuXHWvQPHehrqlrDcKoMkBweOSp6/407wro62sAyOK81YW1Rx6H0ksz5sPGf2lozd0mSR7CHz/9aFAY+p9au01FCjA4p1eilZWPnZNNtoKKKKZIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZWu6BpWv2wg1mwtr2MdBLGCV9weo/CtWihq402ndHlmofBHwvcbjZSajYE9BFPvUfhIGrnbv4CvuJsvEmF7CazDH8w4/lXutFZOjB9Drhj8RDabPnp/gRrIPya5p7D1Nu6n/0I0+L4D6q3+u8QWKf7lqzf+zCvoKil9Xp9jT+1MT/N+CPDrX4CICDeeI5n9RDaKn6lmrctPgf4ZiA+03OqXR7751QH/vlRXqtFNUYLoZyzDEy3mzjNM+GPg7TiGh0G1lcfxXO6c/8Aj5NdZa20FrCsVrDHDEOiRqFA/AVPRWiio7I5p1Jz1k7hRRRTICiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBrqHUqwyCMEUyGIRJtXpUtFA79AooooEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A tamponade device is passed through the parenchymal tract and inflated. The end of the device is brought through the abdominal wall via a separate stab wound. Prior to deflation of the balloon, hepatic arteriography with embolization can be performed, if needed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_16_36096=[""].join("\n");
var outline_f35_16_36096=null;
var title_f35_16_36097="Anterior uveitis in a patient with IBD";
var content_f35_16_36097=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75384%7ERHEUM%2F76962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75384%7ERHEUM%2F76962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anterior uveitis in a patient with inflammatory bowel disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 233px; height: 177px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anterior uveitis in a patient with inflammatory bowel disease is characterized by injection of the conjunctiva and opacity in the anterior chamber.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the American Gastroenterological Association&copy;. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner-Fenwick, Inc at 1-800-432-8433.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diffuse episcleritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 214px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADWAVYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDzDX9fub+4YK2I6xGj8/gn5vWn20LPx1NSyQlOV4IrwlaCtE+8UL6FON9mYn+8OlOlt2eHzk6ipJ1EsBKKBIOppuk3IaXyZOp7VpfTmRna0lGXXYt6fEt3GDnDitS0snMbhzkdqz5YGsrgTxf6r+IV2Xh+KLVNnknr1rCWusdmVKfKrT0aPP7uKbTtTjlT7ua7q1uXlNtcZzng1N4t8PLAjAgFgMg1H4G0e7v7aTewAQ8Ke9acrqLzRwVKkIO99GdjfwW7WURtyN7LzWj4F0PSRHcfbITJdNyrE9K5e4umtpjDKhBTitHQ9Rfz/kyvvU87TtYiVLmp7mP4ttSdQSGPjMmB+ddb4e0y306CRi+bhl6n6Vi6tCbm+En8QOQa0g7RxqWJz3rOLsbTg5JK5zmradJeapDJKSY4n3Y9ea3Jrma/CK2AIhgCrmE27sDJqlhklJCjmk+xtHXXqdD4ZkNrL50jfMn3adrWpXN9ceZLJmse0mYMdxIpZnZpdq/jScrLQmNH3+Zk1zK867c9KoedcbigbgVcT5WBXk96ZHHid2I4qldxNVaOhmSRXCEyK31rU0e5JJMgyAMYp1/LbiBQmc981VsZY1lxkDNRZbGrbnC7RptukY7Cc9qQzOIyrHk0qXiQK3Cnd3NMhInDHp6Voo6GGu/Q2rS+dLARhsEVuaVdboiJ5OMcHFce5wg54qw+oztGsa7RgYGBTRhOjzbC6pcN9saGGQsmadFI+FXdjHeqVkqvKzyt82easShkDMD8orRaDlG3uj5Gbeyu26rul6vLazoIZDEqn9KxjcFVLHoarrMS5YYxRzLcl0nJWZteKbqS+VxHLvjY5/GuKe2dJB5yBlByDXRx/NjNRXcaSDB61LalqVT/AHa5UZNpd2zzlLiNQhOM46V0/wDZVhZ26Jf4ubeRdyMO1cvJp+JDtUFW9a6V7lX0BLbH72JcCrpyd3czrw25TgvE2jvqWrxJp06xIgHQVU1fQ/EFlCjkwXNuPQYNa9nqFxp2pfajbrMo4ZDT/Enir7ba/wCi2bp229hVwmne6LqRnFxjF6Hm2uR3LKrnTWGByQawTrFpaMFubN1b3r1LQrjWL2C4it9Njm3oQu8j5fevO/ENnewXWdZslZkPGyt6cU43aOadacZcsH95a/4TDS4bDFnaATepWsWfxe8w3zRZftxxXR6HLp95ats0+FGQdHAyawtVW31K48sWsdsE4+QdatU4btGDq1b2i0Yl1rkl46tdnKqeEFdDpHi/7OgSC35HoKRfCKNbLNbbpMfe3DAqJlt7BxEUXzD0AonGm1axdB1k23Kxd1Lx5fmExxJtB9qwtPuNX166MSSnrWsmkG8dd+1dx4Ga7jwvo1jo8gZ2jViO5qG4QVorUvlqzl70tDynxf4fuNGa3Ny+5pRmiu2+MktnNFpzQSq75OcdhRXVRlJwTZ42LjFVXylW2V4UY47U0SZJ8xcUxJpYSBKMoe9aVqYJwOQc9q8iTtq0fZQjbVMz1EZlXYwweopt5o7CZZ7YYcdcV0MekWchBOVb2NSyaTPER9nl3KOgJqIz1vFkVZqS5JINNsje2uGQ5xhhVzwvYXGma0pjJ8gnkHtUVmNWtiSkOV74rZ0W6mkuP3sez1JFVF8j9TjqtzjaT2Oi19Y7yYYAIxWPFcnSLiHZ8ilgCRVi8uZBMNqfuvUVFcxpdRggBqTm07oyjTTios6vxNo0SW1veqFdZk3Zp3hOXSIrW4+2qolA+QYrn7W6uDbpBPIzovCgnpSvbopyp5NKU9boI0W6fJNj2lVriRgBjcdtRXDttJbpSwx5YhecVPPHm2OcZHNZJtnckotECMwjG489qtx/MoCjOetU4Z0nKrj514NaMLxxJxwRTaexUlboW7aGJrebeQrIPlBHWs6NHLMe3rVi5uotgx1rJN4+WAbAp2SQqUJSuyxdXXkDavJqul/Imc81Slm3Pyc5pm2ZvuIzD2FTzPZHZGlFL3iee4eRsseKrSTEHctTjTdRkA/0Ztp6Ui6TegOZEAVeuTStLexpGdJacyGpd70wxNXre9EcYBYg1Qm0+a2h8yTYqHkEmo4rS5nZVhAkYjOAapSewnGnJXT0NQ3jn+P5SelWlfcgYS4J7ViS2l9bOBPA4B6YFAmYH51ZfwpqViXSi9Ys6u1icBXQb8+lWVk/dSCUkH0NctbatJbKAkmCOlTyasZUO8gsfStOZM5ZYedy3M4M4QNkDtU0CqVbmsVbgbuvJrSs33R8kZpXHUp2RbCykgJ34FWLy1msmRbkbXK7sH0qGG5VRjPTpUV9dyzTB5pDIQMAk9qajpc52pOVkSRYkkA7d6siMq7MoyKo2O/Oe561eMgUdeaqMjOrFp2Mi5sme4LxjA9PWoZ0WGM/ugc9Riuht08xdy81BeW25SSK0tbYz9pfRlDw5qUPmMsBWGRAdwPGRXO+KptP84yTspbP3eua2JtMiZ/MwRJ0yvFZ19oFrcxncjF/7xPStE7xsyFFRnzI5N9Jvb3UrK7sNNzYhhuVRjf61seJ7W4mlP2DQFg2rjkVZtm1nS7cW1jdp5YOVDDkVSv/ABDrT6gF1K5SBDgFgK1U1axzypyUuZHPtp+tpaMl1KttCTkp0NTpZafNFHBawGSUjDStzg12H9hJc2n2m6uGnZuV+bgis5podJuI45oSsB/jVc1nOdnyo1ppNXZDp3g2GMg3ckgzypDdKi1Lw/FHIuySWTnGN+a3rvxPpRiWJbhdzcD2qextvKtmu7jBhfhXzxUpS6l06ij70jz74kaPbQaRYNGmH8zBP/AaKk+INzNe+THbRs0KOTuA6nFFdVObUbHn16SnNyKc1lNEcqu+P0pEto2wQGjeujt4ywAxkntWxY6duTMkIP4V5EavNofQ1HyLU5G3tdQYqtu6vk4FaH2TWrO4AdUYYz1rqxaJGR5SBfpTpYpIWDtl17iq5ujRy87vdPQXSNeFvpb293anz2/iC5qBLmGU/KCPqKWGVWuMhcKexFXHjiYEqoB+lRKetmKNJR1XUdtVoQB0quuE+VBU0ecYFSJGoOcVDdzWKsMhifOcVYVcDcanjZTgcU+QJ8uBxVR1E3qRW0IxnoM025lREIY5pJJQgI3YFZ1yzuRhSQxxnFU7RNYQcnqJGVRmcYGacJnkOEyTmrWnaejn9+ec/dp0VpdefPHZIoy2Q57Cs3Usza8dddu4kekX91g7Qin1NaVv4XA+adtx64Bqja6jd2Nz9nvpMEH5SeARXS2+t2L/ACpcIWxzzWseR6s48RUxMNI7eRlX2l2tuitHGFYHnPOa0NMihDKoQYxzx3qS8uLa6t2KMr47j1rHFwgWNlk2Ofet4xUdUcvNOpHlle5vXdwInI3cKOgrlL66ubu5ENupy5OQeKsXGtWaQyfv1aUda5yDU5GuGliZjKfuqBWblfVnVhcNKN3y/edTHpsHlBNSy8h6AdBUsV1pNojGQ7AnG5OK51dO1O6Xz5nfeevOMCnxeG7i4O6ME+xOQTWbct0dKpU9qlT7jf8A7WsbgE/aG2j7u4dao3mrWAtwjQljnqF5+taem6JA8CGWEeYvB44Fb0Gi24gGYYzJ2JAq4xclqzllWoUnon95x0kGky2LHjzCMjB5rDuLWAxD7Pu808YruNZ0yO1R5fJSPaOuOK5HQYbi3vZL+SLzLfJ+U9venyWeux00a3NByjJ/N/gVJdKuYIRI/BxkiovNljT5Q31FemwW0F5aQ3QAKSjOGrL1axhVgsEar/e44roWGjNXizlWaST5ZxucOl03UtzVyC4VwPmyfek1nTZTzbx4B/i9axJBcWR/eqSR6VnKhOK01OuGLo1N3ZncW0iLB8p5NRStnBz9a5ax1dWYKZMH0Nay3QkI5qY+ZMqVndM6W1kVIjtp8soKDcRzWXBMAoGeKY7lmAB4qk2cbppyNBggUng1TA35K9DUdwxiUZPFNsJid3OFJqlPoHs2lcz7iBlud23IFcz4mNuC73SFoyOe9eisiOvAFUbrSrecHzY1ZT1BFHJrcSqLqeTWGsT6eQsF4WtW+6rnpXW6X4hs2njOobDGOckZFS6r4L069UgxmIdsGs1/hlbPYOYZ5Cf97gVtJRdtTBy5FsaPieTwPq1mVs42/tNjwsQwKydP8E+I7vQpY01Bkj3fu4mftiufuPBmp6OFezeOWTd8uDzU1xP47trQAPiN+AVNdCdtmcUo6aHN682v+HmFpeSoQGOCDmin/wDCMa1rLtPfT7mz/E3eiq5qa3DkrPVHeaVdQWrqzzq7e9dRBrMBg2RyIM1ysEGnS5YWspA9BWpYabZzICsDpk9DXhKCTuj26rT3N2GZGUEOpPtViRPMQc1nx2UcJHlAj2rQh4QAnmk53IULalJrcGUBeMUjJKoIWtCJFaT3qd7YNz3rJJyN/aKOjM+zjmOA351JLFL5m3171pxxBYgeBVS6nVG+U5aulQtHUzVRylohgUQrljUL3paRY0HXjNVriWRycjkc4qtG0mQ2MAHNZ8yT5UdMaV1zM6e20lHUPK25uuKbqEKALsUKIjnj1qO1v5I4wXOFAqu0sjOqbgxmfNOortaHPT57tyZqzWZniWSBsOo7UljdPaoy3ERD+o6Vo6XubcZAFA4+tWriBJIWBANONN/EjklXSfJLVHOa1po1SNZ5k2qPukGoLPSLWFmjYDA5zV1LmSS1kh4PlNj8K5/VtSlM2y2H1I7VpCMG22dMHWkvZp2SKt/qq6ZdXES87jhcdKyptRVwrSz4HoKvhLaQfMvnTHkk9qptYNLHPKtsWC9OKalyq0dj0qcKe81qW7TTIHia4ZJGVhwcdatr4emW1W4gZkbOc45FN8N3EtvbZkxJGv8ACe1dPpfiCzlk8q4jMIbgHsanmT0ZjXqVoSfIrpGMEvI1jji1EPuHzBuNtSQa7c6YwiuNjoeA6GrF9pbJdte2q+bAeqilNra3sBlt4gHj6xHrWc3JdNBQlSklza3/ADNrTL21nCyWs+JjyysetbsV4hRVJPmDk+lca2iyXMK3GmOsUyjlR/WpobbWZrfCTJvGQR3rSm2/hOKtRpy15vvL3iLVRd4skZS8jAEA9BWsmmWp0aNUP78YDKOmKy9I8MoYZJ5pS9wR1PY0+3uZYoyskvKnAz3rsijkqcvLyUnsZGtQ3VksbWBfMRyI8/LUul6414JLbUY0iuSM8HqKlN5cXVw8WEV/X1rA8R6ZeLKLqIjzFH3geatKz5oDcozXs6tr9GaOoXkhV4YwHVe9c9eTCbcnl/N3J7VVs9cdA0Fwp80cMfWlv3KSpLDwG+8D3rb2icdDlnTdOXLJHMarZSreeZHlc+lLaane2hUSDeB1zW3IDO6tsG3p9KcLOORTuALVhKHM9TSONlSVkyS18QwOyq77T/tcVqJfo+CjBhXKX+lIq8VkNeXmmsCjb4xzg0p0P5TehmEZaVEd/c3kkoUAfL61csnGOelcvpetWOpWoCz+XdD/AJZPwT9K04Lto+CK55RlF6noxlCrH3DdFwwPDcVegnV4/mrl2uJZW/dAAe9WYJp4gFYEitIOxjOhdG9cbXRsYzWHcahc2NvIIBknqp71eiuSBkjNRXFsLiNj0zVyXNqjnUUtJbHNjW7XUWMe8QTIuWVzjn2qjp+p3umO63EZvLHPUHJWpNb0FJHMiALMvQjjd7VhQXHkSNb/AGlrOQjG2T7rfSla+24SirWZev8AV44ZTJpTB45Dlkz900VzGoeGdYE7T2UysJTk7TxRWqhfqjL2jjo4s9RbTXhUvaMFPdT0qW1a5ix5sGfdasLKztgDCVbTBUCvHctTud2rMiUhskjFTRIzDPanpb5NWUVVXbQo3YOVthkMO07l61O52DJPNHKxkgc1ga1rAtIgGYeYeAtdCioIIQlVlaJdu78qCCwz6VkNM7Shi2BVWCYz5aRskjNKWy6qoyTUuV0dcaSg7Elzcu06hWBHSnGbIKE4YU94443TAG7uKspBCAWlxz61Cg27op1YqKViompvJH5TEAjitHT2L3queVjHA96yWtA9y4ixnqMVbsZZLeZklDDcfvGrjKz94VWMXF+zO30q5DIRIAMHj3q5d3SRRs2eADXJvqCRQFkkG5axb3X7i9PlRthBwWrsdlG6PIhg51Z36BLq0zSTCB/mkY59qS1jkcFERnZjy2O9VdHNoYpWmYmXdjB6Zrq/DzK1n8iABTywHNc0IX0Z6+ImqCfKisvh+KKJDJIBKeW9q1Ioo4bURW6GQEHJxWheWds1uJYzuY85JqSM7LZSVUAjjFaz00PIeIlNXbucJc6beWwkkgysJOSAO1OuIHntYZYYjheM11V9cxJAYkmXzGGQvvVjRdLiW1USZzJ8zA9jXG0ublR6KxjUOea1uYem6pe2kBjjiLxjqpqO4njnHmW3+jzt1J4FdW2lCPfLbnBAxgjg1zF3YTpcMrQtlssoTpQ02rIKVWnOTktGX9Jv5LW3cywMV/ikXoa6rTY42iiljK5POT71h2VpLDpIjk+ZH6+1WNJ1WGK2FpOm1lJCP61tTjZHDiffu4F29upYJ2jtigZuoJrmpvtAkZzImwHJA9al113DtcxsQBwSKqxXMLAHcdpHIPrW0Xd2IjHkhzIgvL+VCsilZGH3lXrWbf6pqEpwtuwiPHNXL5oopfNiBJ/iHpWRd3ru4ZSCuecdRWiTXUylKL1UblFo4LmZzcx+W2asPGHKrGcqB3odROwMg47nvT4Y1iOCenStIJnHXq36jWjWIdDjrVSabbypx7ir80gKe9ZMrYdgB8p5rdaHDfmGvPv4Zsj3qle2YuY28pS2ByBRPkPuBx6Gs2+1KSzVnSTDDuKiTu7HRTTSuYl5am3cOhKOvIPQin2njGezkEd2omj7t3qudeXU7wRXSoRtOWHB4rmNWWP7SfssheJumeorsWG5o+8ZrHShL3HZnrmieKtLvF/16xv/AHXODXUx6hGIwSQ6EcMtfMzFkbIJBHoa6PRPGF7YBIpm8yHPc8iuWphHH4T06OZwqO1XTzPd1vY5VKowya0reVQigkV5zpOvWmoKDBKu/wBM10djqZjBWUjHTJrmd1oehOClG8dTX1ApIxwo965LX9Gtb9fnXEi9GHUV06TC4GVZKz70YJ2jkdapLqZL+VnAm/1fQn8qSTdbkYj3UVo6vvkl2upKg5HFFdMMU4K1l9yf5on6tP7L0PRI0K9RzVy1Q5561Gqnbz1qzaxsp3t0rwoQudU5FoIQmSMVWcgHINPubvCkBhiuX17WEtkdYZAZscDNbaIdGjKo7IvaprIt1ZFYGT0rlLxxfybp+W7VnRzSSkvISXbkk1I7FI2YHkChpyPXpUFRem47T5ZY7h4lJIXkVsw3gLAOuCO5rmtJlbLkH5mPWrF5NIsiYPNNU9Ll14c9XlaN64uB9sjfd+HtVy5kSZUYn5a5IXDmRt2c4x9KuJdP5AXJPpWkIW1OerReluh19iLaBhLuG7HrU11dQiWOUMpHQ1xP2iQY3Mee1WlDSwMVY8c4rdwTRxOg1K8mXfENyspVIcKT1IrIhOxHCS8DqfU02eVnZUJG7GK34dKtBoyyt9/jOfWueq9fdPQpctCEVLqauhaV9pgGyMBOpc9zXV28MdjDtVDyPmIqvp0CppsJtz5bbelMs5bq6lljeQLs4+tTzNK1jxK83Wk3fRF9LdHjUo5UD1qrMbm3coTvizxite0VFjAdTwMGoZE3MyowCjkA0TWljmpz95nO6SI21mQyhUXH8Xauxto45WwrjI5JFYUlnBIrOIB5vqO9TWSXKNHIEVVUAbT3rns46HTVare8nY25nIcxo4PvUNnu+1ys6bsDGfamtcIpZhFiQkZA6VaQS24bzo8GQAqa0i767HK4uKsUTcJAZYZcxgnK571zeoIwspXCttySPb3rq79kuYGRkBbGM+9ZF/BcNZeWE2kDGR3FVZs2o1VHcrpLbPpUaJIrKQNwJ6VQurSMxlLcKSRlWz0qvJpiFY5F3BSMNg8ZpphntEZZYyVA+V1NbU076oms4r4JFVmmthmVPMBOGJ7Vl36xz3mLUYDLnj1q9O7s3LExsOvfNUViaORpFyMdzW6V9DinO2vUkRSgUsDkcGlkcMKfNOGQAYxVOUgtwcV0QSR5tSTkV55HRvl6ehqBMzzRx5Cl2C59M1PKFx1rD1O8S2BO8AjpzVunJ7CjNLc63xf4OvNJh3RSrc4jEjLF8xAP0rx7xA95s+aKRIjxllIzX0t+zLPBq51g3hFxLtC4k5+XNen+Jfh/oerm2SXToDArEugXrXRCMIP3lqc1StUtZao/PKaN4yOoOOtQnCYLHJJ5FfX3x6+HnhnQvCjXunaZDbsqldyDv2r4+kBGM10aNXREJXbT6Fie3aBhvBIcZUjmqh68irdteeTEVK7mz8pPaq0rGRyzdTSla2habH21zLbSiSCRkYdwa63R/F8+4R3jcdN1cXRWM6cZ7nVQxVSg/denY9nsdZEgDQzD8DWhHqgkTDMN2a8Usr6e1bMTke2a6XTNfDnEzBGrllQtsevRx0KnxaM9FFwjMd4DDtRXPWt8GTIcGisHBncqitue1xxqE3P1qreXiopCnFN1SaRZNqDj2rltd1MQxukfMuOvpXnXeyOmhQ52mytrGuvFI8UDAt61y++SeZpJGJY9SaTl2LE5PWmo21iPWi1j6CjTjBWiXgwVB64pk85aEj14pMBgAD2qKSQL8vHStE0TGGpcs7cCIeUQT3Ip80W2RdxqHRp1RMe/NaM8ayPuzxT3RjUbhU1KdptaV/NHfirUDp80RHAPBrPJdZCy9AanklZdskYOD1pxd0KrDXQuW0UbTMH5x0p3mYZwmAMVFaRNcTB0yKbcWU7XGE+VT15rSMrbnLJJvVmc7HzjLkkqamGtTbFjzlFP3au3lkILYhRyRya5poyJD2waxklc9HD8taN30PQ9J168eBo2YblHCk4rM/tm/F+7JKQqt8xBrHjldirIRuxgmtW0s3NrmIKWJy2e9Zz7mP1elTbbS1O3t/E0kFqreZHIpHU9aqnxI884dNgx1B4zWDp+kSEl5Yfk7DqBWr/Zi3kIQJHgcZxj9aHNyR5zw+HpyZq6ZrwkuPLL4wcnHNbb6qt0RFbSBB3LcZrgXtG0y4jlsE2zocOD/EKllur4N9oliTygeQBzUXbHLBU5NSgejRPMibfkOcEmrFxrDsVWYDaowCK4yC/hkhjaC5IlxyGPArTgkjmgVix92J4Jq0n1POqUFF3kbE0khkDmIshGRT5pf3QcPz6Gi0dDEpaQjsfpVK/kFwHij+bByCK1S6nFJ3duxFNJbxW7RyjYDndntmsK7u2yUDbouxHpXSXTQR2RFzD5jFerc1yO1EMjodqf3fSt4t7GDs7srOFMwVZCF68025CpGQrcnsaa4RSZA2c+tULifLE10xVkcdSV2PMgIweMVVmkK55prvkH3qncMRkZpPQmCuRXdyyIea4XXrp5brG7I9K3tZuikTZPauIaZpJyzHnNdWFb1bM8UlGyW59I/skzMNW1NBDlWjGXx05r6au9x2InBJ614D+yRb7dO1W4OPmIX9a+hD1H6VVTWTOOK908d/aklRPh26ufvOMV8MzCvr39rvW4E0ez0tJh5xO90Hp2r5BlrePwpCj8TZEakKqI8sTu9KYOoqSdgcYpmhHtO3OOKbTi7FdpPAptSxijrUoHpUQ61ZiQEc1LLiWbTUp7ZSoJI96KiAV+MdKKhxR0xrTSsmfUniS5jsrV5cgyHhRXmGoXDSSOzHO7k1q63dzzufNbdgcCubd8sd3rXhLU+8wdD2cbt3YiyhG29jUsUW8FgeKz52O7I4q1ZPv+UHk03E9HZXRcjkCgq3VaZEqSyNkZBpi2zSSZLY55FacNssaYx8p71nsKU1DYoRKI5GCDAxVlludq5baDU0VmrsyknjkHNX4Y0lh2H7w6GkpGdWtHcxxM6TeW65LccVs2FspjxL8pHQUxLUGRSR86mrskLyMNo6dxVX6I5K1ZPbQhiuEtVKsD14xUkF1FPlRwc9TUyWCiNnd8svIrOFq0842LtI6EUXaRzpU6jbuSahKTBg8k9BWIVSKYErvz1rWuoJY0/eHBxgYqjp/l5f7RkOegxUrud9BqENNizY6PPdWkk8A6HIA60kUl7ESsEZZl4NbOi362EjwnOxuee1WVMU2o4hyofr2zUuVxSrSUnzq66Gl4USOOxSWW+ZruVtr27KcKPXNaMqPp0hidRLBLyMdQayIbWYzlPL+VPm4Na1tc+fcEE/vEG0I1NPmR49bWbmtU9/0Ks0DRyxGVw6n7pHarzaaJLYsJkAPr1pqII7qMMm7/AGc9DWlf6f5yRtHhWYc4NQo31B17WV7GGvhrdGsxQkk9jjIrdSyKaYoZdqA4296n0yZ2jIkI3RDaOatXOTHGHdSrcgit4w03OSviakpWl0IJ1Kwp5YHAxj1rOiY2zlz8zf3R2q3czsGEYww9aquqqzbz83WtFHVWOOVRpO42S4a4Hlu2FHPIrEveHOwcDj61fupNgbYysTxgjpWJNIwY/NhvSuqPY4n3RDfyIYfLxismTco4OR7067Z/OI35/ComLHGT+FW5GXL5iSMQPmqhdy4U4q3MxAweayr87UJJxUSlc0pQszlPEd0+8ovINc2JMNV/XpS1ycGshmGRivSpK0UcFd3mz6e/ZW8TLpUV7aXaEW0zZWTHQ5r6Z0/U7TUmcWkocp19q+FvhF8R7Pwm01tq1l9ptZejLwVNe1/D74veGLOXUb25uWhiYfJCRk1c4RautziUqinZrQ8m/aYW6tfHc8F3KZCQHXPYHpXjDnJrv/jV4yi8beNJ9UtlKwbFjQH0FeenrVXubU42QClJptFTc0CiiikA5Rk1aiXsKqoMmtK2UVMnY0grj44Qq8jrRWisAKDiiuZ1DsVJ20PR9UuFLnHpWO8YfLAGtG6R5AHC81TkLKpGMeoryoan6AlyxsjIujh8U61YxTI5HAovUQTfI273pwUlAFHFaM6IK61NyJlaVWGMEVZG7GwnHPSsa2ldCit0FajSEkP3Fc8omc42ZdUiHbkZ9cVOq5lVkU7DWVLcEMGxkelaGl6nGE2ONpz3o5Tkqwko8yVzUMeVGAVPrUhLQRhV5Jqs148zhIFyvc1et/LRgZTmTtVxXU82pdJc33FKeSXhVQjPBz2q9psGFfOCR3qxfCMpvBUcc0Wl5AUIC8+1NL3tTGVRuHuorahYloCzHJ6j2rHv9IuBbpOo3EHggV0k1yj2zBhgVPok0bgxynKD1pVI22NsPialJX7GXpFgl1IGvNnI24U/rVnUtFktU8y0fdt6g+lF8qWd8ZEBWPHG3pnNboeO4tElUlgV6CsUrourXnGSmn7rOV07WblZCqrk9CSOlalpKGl3XYCF+VlU9KpXMUNrOrRoW3vgqOtSXUSmFvLDMTyFNJG1RQk7xVrmhZX6efIHDu4OEIHWrqasXbyZ4JI4l4Z/SqmmedIkcjAQlPurtrZtLizeKWO7flz8xPAppnJUUU/huSM9s1soiD+m4d6a7RW6qWJPbbuziobfTrR1fZdsQD8oDcCnGOGDKsQ7HvnOa0iru7OafKtE2xkgYsrKSoPQelQXl0643KDj+IVLv+YLOSq9sVn38ylnWP7oHWtk7HLNcztYhnKyxmRiVz+FZM+5kbvjofWprq5Zo/J4IPf0qtKZViOCMAdPWuiDucdSPKjKlciQ5FN3cZIOaJJCznKHNKrAoCPyqZyu9CYq26K8z46Cs3UTviIx2rUkKkkCqF4AY2HtUwVpaluScdDzPXDi7ZfSsotzWz4ii2XLNWIa9iDTWh5U01LUXNBP0puaSqJFJzSUUUXAKKKKQBRRTkG5gKAJYEya1LWE5z2qC3t84wK2LWBlXkHFZVJWR0U4pk0TbUwRRTXPNFYcrepvzpaI9Et5A0fPT0qndQhi5wapNNJBznp2pn2ppXA3da8+LSWp966Ur3iZcv7u4IxxmpRNsG0CtMxQEv58e4MuAQehrEcvC2yVSPrVOJrTqpuzLscwZQOhqWCdwxUnIqjEyM3XBqdU+YEfnWTRvzJo14SpUEnJqZ415IXrWbE5Dhc8VqRvvUqcfnWTuc1SXKye1822KiEkq3PNbVtdRNzKuGrN0wh42jY/MvQ1Yhj2EhsMvrVxdnqediHGd09zoYhBfW/OMjjioEVUZkZVBHQgVgs8llckwMdh5xmln1J57qOP7qnhquT+85Y4WV/dehuX7JsChe1YMN7Pb37pEu/d2rQvbtfs4jQbgB1FVNBvo4Y5SyqZc8bqiSfU6KCtTbtc2Vvm+ytFcQMCR1IzWfY6lfW0RihXcnbdV95jIwM6HBHBHSqU8kokP2aFimNvSsbtbDpKLTi47/cXNInCyyXM3zyk/N321tWN9A1wjCMHrksK5+zlEURBTbJ/F71v6M1tIGJH7wDpiqjqc+Jsm20XYnLSs8aiMHu3Q0+OKK7bZLH8q9Soqu7IJlyM46rnpR/aLhj5KiNTxWenUzUZNe6WvsEDsFV9qHsvbFOubaMxhQG9sVJFcb4SrrlvYYzUT3eF2lMY9a2hYwm5mLfW8pdV8xio6Vl3QkCFGV/l9O9a91fbpCgQEHuDWVfXkkn7oRMpXoTTVm9GaR57aooIXzyPwzTZseWSS28/lRKGUlsEH3qGW7Jj4Q/TFdMdDgrpy1RXZyDzkfhUcjMFOAPrUc8zHGEbJ9RSPI3ljIxWkEm0cVS6TuV2dtp9arOWKndVh5AFO0c0yL5iS/QVvKnJrRGNOpGL1OJ8S25YscVyR4OK9Q120EsJYLxivO9RtTDIcA4rppe7HlZjVfO+ZFGiiitTEKKKKACiilAzQAAZNXLWLkEim28PcitO3iB2jFJstIuWEa7hWywVUxjNZsEJTmrDyFUNZOSejL5XuincybXO3rRVS4Y7z3orRRRPMzrJpgfvcg1CH546dqrxnPB5qVR+deLax+ok0UhEmHyR2NGs3E13MjyYPloEBAxwKaOFwalt8OjK/T1q4u+hjUST5jKyRzU0M0gOFpkiiOUoelIG2txTcQUjQgmZztkwKuJKdn3sN2rFSbD5NX450bbnINZSgE5Jm3aiRVWRGO5uoqa6uZlwEJU981Wt7nCYOD9KnN0jJtkHzHgZrJnKk+a7VzTsWSW1zKNz+poW0CAOQC2eKZps3loscydehrRnTC7gOnNNK6OWU3CdujEkDWkJJQYcd6rW+m+dZu2xlcnIIp93dJeRoi53p6VYtNRKS+VKjDA6inMUXOMbpajILi4hjCTIXxxz2rc04xNFt3DJ5NZ73EMg+6xY+1QIybyXDDngdMVhs9RSXtFtY0WkWB5I5VwP4Wx1pkJmtY3mjAdW/Oo5LsrCR8rJ23dazrXUE+0OrElT0B6ZpvsVTouSbt6mjAZpElluZGiYjKAd6t2cFwCGVlkAG7k07S/s8khZZFeU9QT0rZGmMSFik5PJxUcjCpXUW4vQom9dEJfqR91arvd+ZhSjI/bPetP7DFakiTcxPJrMu5AXxbx8A/xVa8zKKhL4URpYkZJO5icjmqGouVibEmJV4C1aM+yQOzE7RWcQJ3eRfvMeAa1VlsQ1L4pbEfmMbRTIdzdyR3qFiSMkAGrX2c+Xgvgd8VE6FQSGDexrqje2p5Vezd0Z9ySRnj6CqjZkGK0GUknI/CmJGhl+bgmtabscNbUpfZQVJPBFRC3djhR8tbEtsGQBSc0sUflrgiur2tonHyXZk3UAEBDDtXG6vp6vvJHWu51EqAcmsSSMThhjFccJy5rndyrlPMLu1aFzgHFViK7XUdN68ZrCuNPPWu6NaLOaWHla5jUVo/YD706OxOea050ZOlJbmekbMelXIrbGK07ewJHIq7Fp7HFT7WOxfspJXRQtrfn7vFakEKgDirkVntTGKqyfuc85yaxqNt2RrStbUexJG3GBVeVh070SzZA25qq02OT1qoRa3FKzegMqgndRVSWbLUVrcnlR0QbZ061LE3OTRHb7+pqytjleGrx7o/RHJ2E4I96lj2KmPWoHtJB0Y0wxTr74qouJnLmYzUIv4l5xVLdkVbdpcEFDVMqynlGAq00TqhA2DzTklIPFIpXoQacsSt0anYXMy9b35QjNXhc+a6MuOKwijKemafHIyEYJrOUEy4vU7O0aRwDuA9KvvdTRod20rj1rjI9TmjXaBQ19cTJgscfWsvZtEui5y1Og0vUY4b12lxhjj6VrX08MzRyLIFA6muHTPGRk1ajuTwGQqO9KUWzWeHi58yO0XUWMZVYsgdGHenxK82VZwqnk+tYttq8JiEew8DHFWLc7VaUThGJztJ7Vm4u+pyOnyJ6WNNtqT+VHjkdWNLJpkctoQjDzVOc1g3N80s4JIG3uO9XLa9YgDeV9cdTUSibRp1IJNMu2kht7hJgAoX5SB1rsNI1gtJjcjADjnmuJhmkJcCIkHo1MRPLkb94VkPcGpTsOth41r8252+q3ha5XJwzfwis1o/PZnuHYZ6AVk2srQuJCxnl+vSpnu5TlvKIz2FWnrc5vYOC5Yk86IN2NzDGM1Re3ZGBVyF7GmC/eHcrxH/gVMeUuDI2WX0FWkmJwnH0LCSbYsHJ5xmom3LKG/gNVhcRxsGXJ9jUsjiXOWwp5rqhseTiaTTuMmn2yHZzUaBS+9j81MuSoUHO7HYd6qvM8wAxsX9a0WjPOlG68jWW5UOEz83pVhSrrlqzLSNE+br7mp2uUQketU7yVjlsovQpX+15WGeazJCFOwVfutjSFgc59KhSNGak4uKKjJNmTdIAhJrLMAk7VuanGOApqtBbE1m48sbnXSqc0rPYx5LQBhxip1sEwDnmtKeCNRlnGfSoRJGo561VKTauGItzJIiS1wMYqQIsfBNNNyuDziqFxeqG65NTGnOTKc4xRfmnVVIB5rAuJssSelPuLvcKzpph3Nd1OLS1OGUVfQfLcHpVd5wBzUEswPCjJqS0sJ7p/ukCtW0txQhKbtFEJMkxOxScUV22i6KiRHcMn6UVi6vY9COB0956lmGE4yeDVqHjr2qMx3cQ52SY9BUUd2fN2yRshzz6V5Fmz672ie5d/i9aYQd/TirsMO8BlYEU82/GO9ZuVik4lRIgx+YVI9pEVxip1THB60/aQOnFCkwZnSaNHIuVrPl0iSJvkNdRahghPJzSlcg5HNaqq0Ytu+pxU0EydVP5VWLEH5lNd/HbxyIQyjNVJtKhY52itI1riuk+xyCsGxmrUcS9jWvLokRPy5B9qrvoUwyY3PFO6ZoqlupUj2o4Lg1ZE6A8YP1qtLY3kPP3hVR55VOJIj+VLluU5X1L80aswZDtb2qSK5KZjmGT0BrJ89v8AaHtS+ex61XL0L5k9zoYQ6JuGD7VbhmIG7HPtXLpdyLwHNWF1B1GBg+9ZypspWZ10GqNtESp14zV+C0hmBMsmWPoa4q1v2iy2M1aXVXPKEg/Ws5UiZU3f3NDrphDbW5RSQ/rnrVe2uJdgKMF5+81c+LqWZQ7yYH1qJLv5yCSw9zUqI/YNppu50NwyzSDe5LD7x7VC8xQFVxtHesqOf5i2evamG6y5B6GrSIdLoaLyMVOCKak5xsfJHSs15xkDJ/Op454wRW8XY4q9DQ0gEjGAOT3NU5ZPLc5PBomnR027iCO9UpnUAEncR3NdMWtj5+th3e7Ly3mUKqpx6mmt5zLwrN9BWLNqDD5dwAHStbTNTv4mjngO5gMDEZYCtKcLvU460eVaBslWUI0b726DFWo9Kv5ptiIQfes64vdXm1hrh1uHYn7whbH8q34NSu5ABcwX5IGF8uJgf5V0xpwe7OGcqi2RlahpF9E+yVVVh6mqF1HcWUIeVcITjNS+KhrCEXL2eoqg/jdD/hXI3uvXM6CO4d3C9A1ROnF6I0pzkrM6x7eyn0/z0uwJh1RjXOrerGzbgHNYE9+zdCR+NVTcyHgE0o0klsaObe7ubMl3lyc4FUp7ld3BqkiTSn5VY/hWla6DcTgFsqD7U24x3NIU6lXSKKD3JP3RRDbzXTgKrHPtXX6Z4VUnL5Y+ldNZaLHAP9WB+FZyrpbHXTy97zZxGn6BtIaXk+mK7HSdMiIxgDFaosYxxtGarbGtptwzs9q5nW5tWepTwyiuWGg9oFgYgdKKUypKeDRWTrK51Qoaaj9fsJNKv47YyK+4ZyBVVIA4+YKfwoorlexdKcnFNsv2+mRKA4OD7VObcKAM5oorMbk7kLxDnPY0xIxvA7UUUI3i3YsLHtJCnimOBRRRIUdxMBQMZzUwiGOTzRRSiExJIwOnWpbVxLEflxjiiitE2ZtXjchuoFC9KpvaxP1Rfyooocncum9CBtMt5eqAfhVKbRIQSc0UU1JmsZu9im+kxYyDiov7JUniQiiitOZnQkmI2lkdJTUcli8Y4kBooo5mXFIgYyR8bsioTO4aiitI6kTk1sSC8bHf8KDcnIPNFFXZEc7FM7HPWlF0V7E0UU0iJO61JGvm29KgluXbpxiiirRw1YIzriVnJPSun8LfEfU/DNuILW0sZ0HOZo9xoorog2eNiqMJOzR08fx+1yPGNJ0nj/phT5v2g/EkqFYrDTIye4h6UUVrzM876tSbtYwNU+Jvi7XbaS3utQQQyDBVVrjRor3Um6WfJPXiiisZ1Z9z0aOCoJaRLtv4WhJ+eUmtS38M2sQGcN9aKKyc5PdnXGjTjsjqNJ8PWm0fIv5Vdu9LhtgCoGPTFFFD2M6bbqWCKFIpFZBjNTXDcpwOtFFc/M7nVyq42RBmqtzLHGmGQmiinCKd7mdSbilYw73UraEj9w+T6NiiiitlRg1sc312utFL8j//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Monocular attack of diffuse episcleritis in a patient with relapsing polychondritis. There is diffuse injection of the episcleral vessels, but the underlying sclera is normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of M Reza Dana, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_16_36097=[""].join("\n");
var outline_f35_16_36097=null;
var title_f35_16_36098="CT NPH calculation of Evans ratio";
var content_f35_16_36098=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F56382&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F56382&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT NPH calculation of Evans ratio",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Evans ratio is the ratio of&nbsp; the maximal diameter of the frontal horns of the lateral ventricles (at the slice where the frontal horns are largest) to the maximum width of the cranial cavity measured at the inner tables of the skull at the same level. The modified Evan's ratio is 0.375 in this patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_16_36098=[""].join("\n");
var outline_f35_16_36098=null;
var title_f35_16_36099="Urea and hydrocortisone: Patient drug information";
var content_f35_16_36099=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Urea and hydrocortisone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/31/8691?source=see_link\">",
"     see \"Urea and hydrocortisone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F232505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Carmol-HC&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F232506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ti-U-Lac&reg; H;",
"     </li>",
"     <li>",
"      Uremol&reg; HC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin rashes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to urea, hydrocortisone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697759",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care when a large part of the skin is involved or where there are open wounds.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696250",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use. Do not wash your hands after use if putting this on your hand.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12148 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.97.94.19-4FC0FD0E7D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_16_36099=[""].join("\n");
var outline_f35_16_36099=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232505\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232506\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015307\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015306\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015311\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015312\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015314\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015309\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015310\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015315\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015316\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?8/31/8691?source=related_link\">",
"      Urea and hydrocortisone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_16_36100="Neutropenic fever sepsis algorithm";
var content_f35_16_36100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Time-dependent algorithm for the initial assessment and management of cancer patients with neutropenic fever and suspected sepsis syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 774px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CVAD: central venous access device; Na: sodium; K: potassium; Cl: chloride; TCO",
"     <sub>",
"      2",
"     </sub>",
"     : total carbon dioxide; SIRS: systemic inflammatory response syndrome; LRT: lower respiratory tract; URT: upper respiratory tract; GI: gastrointestinal tract; GU: genitourinary tract; O",
"     <sub>",
"      2",
"     </sub>",
"     : oxygen; IV: intravenous; MASCC: Multinational Association for Supportive Care in Cancer; PO: per os (by mouth).",
"     <br/>",
"     * The Northern Ireland Cancer Network states that neutropenic sepsis is a \"time-dependent\" condition, the successful management of which is dependent upon the early recognition of the likelihood that the cancer patient's problem represents a neutropenic fever/sepsis syndrome",
"     <sup>",
"      [1]",
"     </sup>",
"     . Since more than 70 percent of cancer treatment-related syndromes, including neutropenic fever, manifest within four to six weeks of systemic treatment",
"     <sup>",
"      [2]",
"     </sup>",
"     , Northern Ireland Cancer Network has recommended a history of chemotherapy within the past six weeks as a sensitive discriminator to detect patients with neutropenic fever/sepsis syndromes by triage services in healthcare facilities",
"     <sup>",
"      [1]",
"     </sup>",
"     .",
"     <br/>",
"     &Delta; SIRS (systemic inflammatory response syndrome) is defined by the presence of two or more of the following criteria: body temperature &gt;38&deg;C or &lt;36&deg;C; heart rate &gt;90 beats/min; respiratory rate &gt;20/min; Pa CO",
"     <sub>",
"      2",
"     </sub>",
"     &lt;32 mmHg; or an alteration in the total leukocyte count to &gt;12,000 cells/mL or &lt;4000 cells/mL; or the presence of &gt;10 percent band neutrophils in the leukocyte differential",
"     <sup>",
"      [3]",
"     </sup>",
"     .",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Hypoperfusion is defined by hypotension (systolic blood pressure &lt;90 mmHg, mean arterial pressure &lt;70 mmHg, systolic blood pressure decrease of &gt;40 mmHg, or &lt;2 standard deviations below the mean for age), an elevated serum lactate &gt;4 mmol/L, or oliguria (urine output &lt;0.5 mL/kg/hr).",
"     <br/>",
"     &sect; Goal-directed therapy for resuscitation includes the following: a) central venous pressure 8 to 12 mmHg; b) mean arterial pressure &ge;65 mmHg; c) urine output &ge;0.5 mL/kg/hr; and d) central venous (superior vena cava) or mixed venous oxygen saturation &ge;70 percent",
"     <sup>",
"      [4,5]",
"     </sup>",
"     .",
"     <br/>",
"     &yen; Patients at low risk for serious complications are defined as those who are expected to be neutropenic (absolute neutrophil count [ANC] &lt;500 cells/microL) for &le;7 days and those with no comorbidities or evidence of significant hepatic or renal dysfunction. High-risk patients are defined as those who are expected to be neutropenic (ANC &lt;500 cells/microL) for &gt;7 days; patients with neutropenic fever who have ongoing comorbidities or evidence of significant hepatic or renal dysfunction are also considered to be high-risk, regardless of the duration of neutropenia. The Multinational Association for Supportive Care in Cancer (MASCC) risk index can also be used for determining risk. A MASCC score of &ge;21 predicts a low risk for medical complications of neutropenic fever syndromes that would require hospitalization and/or prolonged length of hospitalization. A score of &lt;21 predicts patients at high risk for such complications",
"     <sup>",
"      [6]",
"     </sup>",
"     . See the text for more details regarding the definitions of low- and high-risk patients based upon clinical criteria and the MASCC risk score.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Bell MS, Scullen P, McParlan D, et al. Neutropenic Sepsis Guideline. In Edition Northern Ireland Cancer Network 2010; 1-11.",
"       </li>",
"       <li>",
"        McKenzie H, Hayes L, White K, et al. Chemotherapy outpatients' unplanned presentations to hospital: a retrospective study. Support Care Cancer 2011; 19:963-969.",
"       </li>",
"       <li>",
"        Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003; 29:530.",
"       </li>",
"       <li>",
"        Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327.",
"       </li>",
"       <li>",
"        Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-873.",
"       </li>",
"       <li>",
"        Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000; 18:3038-3051.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_16_36100=[""].join("\n");
var outline_f35_16_36100=null;
var title_f35_16_36101="Clinical presentation and diagnosis of prostate cancer";
var content_f35_16_36101=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical presentation and diagnosis of prostate cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/16/36101/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/16/36101/contributors\">",
"     Philip W Kantoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/16/36101/contributors\">",
"     Mary-Ellen Taplin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/16/36101/contributors\">",
"     Joseph A Smith, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/16/36101/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/16/36101/contributors\">",
"     Nicholas Vogelzang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/16/36101/contributors\">",
"     W Robert Lee, MD, MS, MEd",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/16/36101/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/16/36101/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/16/36101/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/16/36101/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate cancer is the second most common cancer in men worldwide, with an estimated 900,000 cases and 258,000 deaths in 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36101/abstract/1\">",
"     1",
"    </a>",
"    ]. In the United States there will be an estimated 239,000 cases and 29,700 deaths in 2013 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36101/abstract/2\">",
"     2",
"    </a>",
"    ]. The clinical behavior of prostate cancer ranges from a microscopic, well-differentiated tumor that may never be clinically significant to an aggressive, high grade cancer that ultimately causes metastases, morbidity, and death.",
"   </p>",
"   <p>",
"    The frequency of a diagnosis of prostate cancer has increased, due largely to the widespread use of serum prostate specific antigen (PSA) screening. Following the introduction of PSA testing, the incidence or prostate cancer peaked in 1992, declined between 1992 and 1995, and has risen since then at a rate of about 1 percent per year. The reasons for this increasing incidence are not known; both genetic and environmental factors have been implicated. The incidence is higher in blacks than in whites in the United States (",
"    <a class=\"graphic graphic_figure graphicRef62493 \" href=\"mobipreview.htm?43/37/44637\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31562?source=see_link\">",
"     \"Risk factors for prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=see_link\">",
"     \"Screening for prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An overview of the clinical presentation and initial diagnosis of men with prostate cancer is presented here. The staging system used for prostate cancer, the initial staging evaluation, and management approaches based upon risk are presented separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23527?source=see_link&amp;anchor=H686719695#H686719695\">",
"       \"Initial staging and evaluation of men with newly diagnosed prostate cancer\", section on 'Introduction'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9704?source=see_link\">",
"       \"Prostate cancer: Risk stratification, other prognostic factors, and predictive tools\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23527?source=see_link&amp;anchor=H686719695#H686719695\">",
"       \"Initial staging and evaluation of men with newly diagnosed prostate cancer\", section on 'Introduction'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9704?source=see_link\">",
"       \"Prostate cancer: Risk stratification, other prognostic factors, and predictive tools\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/36/16969?source=see_link\">",
"       \"Initial approach to low-risk clinically localized prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/26/21930?source=see_link\">",
"       \"Initial management of regionally localized intermediate and high risk prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost 80 percent of men currently diagnosed with prostate cancer undergo a biopsy because of a suspicious serum prostate specific antigen (PSA). However, digital rectal examination retains an important role for early detection as 20 percent of cases have a prostate nodule that prompts the biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74636032\">",
"    <span class=\"h2\">",
"     PSA screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;PSA is a protein made solely by prostate cells so the antigen is highly specific for the prostate. However, it is not prostate cancer specific and other prostate conditions such as benign prostatic hyperplasia (BPH) or prostatitis can affect PSA levels. The lack of specificity for prostate cancer has led to considerable controversy about the role of routine PSA testing. The controversy is compounded by the knowledge that not all cancers detected by routine screening require treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/2/41001?source=see_link&amp;anchor=H9#H9\">",
"     \"Measurement of prostate specific antigen\", section on 'Causes of an elevated serum PSA'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=see_link&amp;anchor=H2#H2\">",
"     \"Screening for prostate cancer\", section on 'Prostate specific antigen (PSA)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The fact that PSA screening detects more cancers is not debated. The incidence of a prostate cancer diagnosis increased substantially after the advent of PSA testing in the late 1980&rsquo;s.",
"   </p>",
"   <p>",
"    Originally, reference ranges were established as cut points for a &ldquo;normal&rdquo; PSA. More recent knowledge shows that PSA levels correlate with a continuum of increasing risk with no level below which a man can be declared to not have prostate cancer nor is there a level above which the PSA level definitively indicates prostate cancer. PSA levels generally increase with age and prostate size so the norm for a man less than age 50 years is less than 1",
"    <span class=\"nowrap\">",
"     ng/ml",
"    </span>",
"    while it is over 3",
"    <span class=\"nowrap\">",
"     ng/ml",
"    </span>",
"    for men over the age of 60 years. &nbsp;",
"   </p>",
"   <p>",
"    Multiple methods are used to increase the accuracy of PSA testing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age related reference range &ndash; PSA levels generally increase as men age so that a single value must be benchmarked against the norm for a specific age group.",
"     </li>",
"     <li>",
"      PSA density &ndash; PSA levels increase with increasing prostate size as the benign cells make PSA. PSA density simply calculates the ratio between PSA levels and prostate volume measured by transrectal ultrasound (TRUS). An estimate of PSA density can also be made based upon digital rectal examination (DRE) findings although DRE is known to be unreliable for estimating prostate size.",
"     </li>",
"     <li>",
"      Fractionated PSA &ndash; PSA can be measured in two serum components, either conjugated or free. The percentage of free PSA relative to the total PSA can be informative as a high ratio (&gt;30 percent) is considered favorable while a low ratio (&lt;10 percent) is more commonly associated with prostate cancer.",
"     </li>",
"     <li>",
"      PSA velocity &ndash; Changes in PSA over time, sometimes termed PSA velocity, can be highly informative. Although some increase with age is expected, a substantial change is worrisome. A change of",
"      <span class=\"nowrap\">",
"       &gt;0.35ng/ml",
"      </span>",
"      may prompt a biopsy if the PSA value is between 2.5 and 4",
"      <span class=\"nowrap\">",
"       ng/ml",
"      </span>",
"      while a greater than",
"      <span class=\"nowrap\">",
"       0.75ng/ml",
"      </span>",
"      change within a year may prompt investigation with a PSA over",
"      <span class=\"nowrap\">",
"       4.0ng/ml.",
"      </span>",
"      <br/>",
"      <br/>",
"      Generally, PSA should be repeated before a biopsy is recommended since almost a third of patients will have a decrease to baseline levels if PSA is repeated a month or so later. Giving antibiotics to asymptomatic men with no evidence of a urinary tract infection or prostatitis is not helpful.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H638867441\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Considerable controversy remains about PSA screening. Although more cancers are found through PSA screening, many men undergo a biopsy which may prove to be negative or are subjected to treatment and its side effects for a cancer that may not be life threatening. Targeting screening to the most optimal population (those with at least 10 years of life expectancy) and a straightforward discussion of the merits of treatment for a cancer that is detected temper some of the concerns surrounding PSA screening.",
"   </p>",
"   <p>",
"    The issues surrounding PSA screening for prostate cancer are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=see_link\">",
"     \"Screening for prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74636051\">",
"    <span class=\"h2\">",
"     Digital rectal examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;On digital rectal examination, asymmetric areas of induration or frank nodules are suggestive of prostate cancer. In contrast, symmetric enlargement and firmness of the prostate are more frequent in men with benign prostatic hyperplasia (BPH). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36696?source=see_link\">",
"     \"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A prostate biopsy is indicated in men with a digital rectal examination that is suspicious for cancer, regardless of the serum PSA. All men with significant asymmetry, induration, or palpable nodularity of the prostate gland require further diagnostic studies to rule out prostate cancer, particularly if they are over the age of 45 or have other risk factors for the disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31562?source=see_link\">",
"     \"Risk factors for prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Digital rectal examination can detect tumors in the posterior and lateral aspects of the prostate gland. Tumors not detected by digital rectal examination include the 25 to 35 percent that occur in other parts of the gland, and small, T1, cancers that are not palpable (",
"    <a class=\"graphic graphic_table graphicRef75565 \" href=\"mobipreview.htm?40/19/41277\">",
"     table 1",
"    </a>",
"    ) (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23527?source=see_link&amp;anchor=H686719702#H686719702\">",
"     \"Initial staging and evaluation of men with newly diagnosed prostate cancer\", section on 'Staging system'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The serum PSA level should be measured prior to biopsy in men with an abnormal digital rectal examination for prognostic purposes. Although serum PSA concentrations may rise slightly during the first several hours after a rectal examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36101/abstract/3\">",
"     3",
"    </a>",
"    ], the rise is small enough that the blood sample for PSA testing can be obtained at any time prior to biopsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/2/41001?source=see_link&amp;anchor=H9#H9\">",
"     \"Measurement of prostate specific antigen\", section on 'Causes of an elevated serum PSA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transrectal ultrasonography (TRUS) is often used to evaluate abnormalities detected by digital rectal examination and to guide sites for prostate biopsy. However, prostate biopsy is recommended regardless of the results, since TRUS misses a substantial number of tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36101/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Cancers typically appear hypoechoic, but some may be hyperechoic or isoechoic, leading to false negative studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74636058\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most men with early stage prostate cancer have no symptoms attributable to the cancer.",
"   </p>",
"   <p>",
"    Urinary frequency, urgency, nocturia, and hesitancy are seen commonly but are usually related to a concomitant benign prostate enlargement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36696?source=see_link\">",
"     \"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hematuria and hematospermia are uncommon presentations of prostate cancer but their presence in older men should prompt consideration of prostate cancer in the differential diagnosis. These symptoms are also present in men with benign prostatic hyperplasia (BPH) and are more likely to be caused by BPH than cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36696?source=see_link\">",
"     \"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bone pain may be the presenting symptom in men with metastatic disease but an initial diagnosis when bone metastases are present has become unusual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36101/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/41/41622?source=see_link&amp;anchor=H19253279#H19253279\">",
"     \"Bone metastases in advanced prostate cancer: Clinical manifestations and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23527?source=see_link&amp;anchor=H686719814#H686719814\">",
"     \"Initial staging and evaluation of men with newly diagnosed prostate cancer\", section on 'Evaluation for distant metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men with abnormal prostate exams (nodules, induration, or asymmetry) should be referred to a urologist for a prostate biopsy, with a the histologic diagnosis based upon tissue obtained from the biopsy. A prostate biopsy may also be indicated based upon abnormal PSA values. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=see_link&amp;anchor=H37#H37\">",
"     \"Screening for prostate cancer\", section on 'Referrals for biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Biopsy typically is performed with transrectal ultrasound (TRUS) guidance although perineal biopsy and MRI targeted biopsies are sometimes used. TRUS may image prostate cancer as a hypoechoic area but the test is used to direct prostate biopsy rather than as a diagnostic modality.",
"   </p>",
"   <p>",
"    If a biopsy is to be performed based upon the finding of an elevated serum PSA, confirmation of the elevated serum PSA is advisable prior to proceeding to prostate biopsy. The measurement of serum PSA is also important for prognostic purposes. Although serum PSA concentrations may rise slightly during the first several hours after a rectal examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36101/abstract/3\">",
"     3",
"    </a>",
"    ], the rise is small enough that the blood sample for PSA testing can be obtained at any time prior to biopsy.",
"   </p>",
"   <p>",
"    The technique involved in prostate biopsy, including preparation, complications, and the extent of sampling (6 core, 12 core, saturation) are discussed separately, as is pathologic interpretation of the prostate biopsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/20/14666?source=see_link\">",
"     \"Prostate biopsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/52/24394?source=see_link\">",
"     \"Interpretation of prostate biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A negative biopsy does not exclude the diagnosis of prostate cancer. Biopsy is a sampling technique with a substantial potential for misdiagnosis. Repeat biopsy may be indicated if the PSA level increases further. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/20/14666?source=see_link&amp;anchor=H2924776#H2924776\">",
"     \"Prostate biopsy\", section on 'Need for repeat biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/3/2099?source=see_link\">",
"       \"Patient information: Prostate cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/55/38770?source=see_link\">",
"       \"Patient information: Prostate cancer screening (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/39/40565?source=see_link\">",
"       \"Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/41/42643?source=see_link\">",
"       \"Patient information: Treatment for advanced prostate cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74636381\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients who undergo prostate biopsy do so because of a PSA determination despite the controversy surrounding PSA screening. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the risk for having a biopsy positive for prostate cancer increases as the PSA level rises, there are no absolute numbers used as a threshold to determine a need for biopsy. (See",
"      <a class=\"local\" href=\"#H74636032\">",
"       'PSA screening'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=see_link&amp;anchor=H2#H2\">",
"       \"Screening for prostate cancer\", section on 'Prostate specific antigen (PSA)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patient age, prostate volume, digital rectal examination findings, and family history must all be considered. A PSA level substantially above normal for a certain age may be an indication for biopsy.",
"     </li>",
"     <li>",
"      A change from prior values (more than",
"      <span class=\"nowrap\">",
"       0.35ng/ml/year",
"      </span>",
"      for a PSA of &lt;4.0 or",
"      <span class=\"nowrap\">",
"       0.75ng/ml",
"      </span>",
"      if the PSA is &gt;4.0) should be considered suspicious.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An abnormal digital rectal exam, especially asymmetry, nodularity, or induration, should prompt a biopsy regardless of the serum PSA level. (See",
"      <a class=\"local\" href=\"#H74636051\">",
"       'Digital rectal examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms are an unusual presentation for men with prostate cancer and may be difficult to differentiate from symptoms due to benign prostate disease. (See",
"      <a class=\"local\" href=\"#H74636058\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of prostate cancer requires tissue. This is usually obtained by biopsy with guidance of transrectal ultrasound, which should be preceded by measurement of serum PSA. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/20/14666?source=see_link\">",
"       \"Prostate biopsy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/52/24394?source=see_link\">",
"       \"Interpretation of prostate biopsy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36101/abstract/1\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36101/abstract/2\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36101/abstract/3\">",
"      Crawford ED, Schutz MJ, Clejan S, et al. The effect of digital rectal examination on prostate-specific antigen levels. JAMA 1992; 267:2227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36101/abstract/4\">",
"      Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36101/abstract/5\">",
"      Stamey TA. Making the most out of six systematic sextant biopsies. Urology 1995; 45:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36101/abstract/6\">",
"      Collin SM, Metcalfe C, Donovan JL, et al. Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. Eur J Cancer 2009; 45:3254.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6939 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-76F9A528C7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_16_36101=[""].join("\n");
var outline_f35_16_36101=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H74636381\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H74636032\">",
"      PSA screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H638867441\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H74636051\">",
"      Digital rectal examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H74636058\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H74636381\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/6939\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6939|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/37/44637\" title=\"figure 1\">",
"      Prostate cancer by race",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6939|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/19/41277\" title=\"table 1\">",
"      TNM staging prostate CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/41/41622?source=related_link\">",
"      Bone metastases in advanced prostate cancer: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36696?source=related_link\">",
"      Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/36/16969?source=related_link\">",
"      Initial approach to low-risk clinically localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/26/21930?source=related_link\">",
"      Initial management of regionally localized intermediate and high risk prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23527?source=related_link\">",
"      Initial staging and evaluation of men with newly diagnosed prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/52/24394?source=related_link\">",
"      Interpretation of prostate biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/2/41001?source=related_link\">",
"      Measurement of prostate specific antigen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/3/2099?source=related_link\">",
"      Patient information: Prostate cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/55/38770?source=related_link\">",
"      Patient information: Prostate cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/39/40565?source=related_link\">",
"      Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/41/42643?source=related_link\">",
"      Patient information: Treatment for advanced prostate cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/20/14666?source=related_link\">",
"      Prostate biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9704?source=related_link\">",
"      Prostate cancer: Risk stratification, other prognostic factors, and predictive tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31562?source=related_link\">",
"      Risk factors for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=related_link\">",
"      Screening for prostate cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_16_36102="Treatment of exogenous endophthalmitis due to Candida species";
var content_f35_16_36102=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of exogenous endophthalmitis due to Candida species",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/16/36102/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/16/36102/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/16/36102/contributors\">",
"     Marlene L Durand, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/16/36102/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/16/36102/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/16/36102/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/16/36102/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/16/36102/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/16/36102/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H866067736\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida species are a common cause of fungal endophthalmitis. This infection arises in two discrete ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The exogenous form follows trauma, eye surgery, or progression of fungal keratitis (corneal infection). Fungi are directly inoculated into the aqueous",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vitreous.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The endogenous form follows candidemia, with hematogenous seeding of the eye. Fungi usually first seed the highly vascular choroid, then infection typically progresses through the retina into the vitreous. The aqueous is sometimes involved as well. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39112?source=see_link\">",
"       \"Treatment of endogenous endophthalmitis due to Candida species\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of exogenous endophthalmitis caused by Candida species will be reviewed here. The epidemiology, pathogenesis, clinical manifestations, and diagnosis of fungal endophthalmitis are discussed separately. The treatment of endogenous endophthalmitis caused by Candida species and endophthalmitis due to molds are also presented separately. Bacterial endophthalmitis, Fusarium keratitis, as well as candidemia and other types of Candida infection are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13849?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39112?source=see_link\">",
"     \"Treatment of endogenous endophthalmitis due to Candida species\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/18/24873?source=see_link\">",
"     \"Bacterial endophthalmitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/5/42071?source=see_link\">",
"     \"Overview of Candida infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/42/3753?source=see_link\">",
"     \"Treatment and prevention of Fusarium infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H866067796\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;endophthalmitis&rdquo; refers to infection within the eye involving the vitreous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aqueous (",
"    <a class=\"graphic graphic_figure graphicRef57690 \" href=\"mobipreview.htm?41/35/42549\">",
"     figure 1",
"    </a>",
"    ). Exogenous endophthalmitis signifies that the infection was introduced into the eye from the &ldquo;outside,&rdquo; either by trauma, eye surgery, or extension of corneal infection (keratitis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H866068119\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;No controlled trials of treatment regimens for exogenous Candida endophthalmitis have been performed. The evidence comes from case reports and small observational studies.",
"   </p>",
"   <p>",
"    The choice of therapy must take into account the site and stage of infection, the pharmacology of the available antifungal agents, and existing anecdotal clinical experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36102/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The approach to therapy may involve a combination of the following modalities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Systemic antifungal therapy",
"     </li>",
"     <li>",
"      Intravitreal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intracameral antifungal therapy",
"     </li>",
"     <li>",
"      Surgical removal of the vitreous (vitrectomy) and any foreign material (eg, artificial intraocular lens [IOL] implant)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H728946907\">",
"    <span class=\"h2\">",
"     Intraocular therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cases in which the aqueous is primarily involved (eg, acute Candida endophthalmitis after corneal transplantation), either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    may be injected intracamerally (into the anterior chamber) (",
"    <a class=\"graphic graphic_figure graphicRef57690 \" href=\"mobipreview.htm?41/35/42549\">",
"     figure 1",
"    </a>",
"    ). Intracameral injection of amphotericin B deoxycholate has been used for many years for fungal endophthalmitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36102/abstract/4\">",
"     4",
"    </a>",
"    ], and appears to be effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36102/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The usual dose of amphotericin B deoxycholate is 5 mcg in 0.1 mL sterile water. There may be transient increase in eye pain, hypopyon, or intra-aqueous inflammation in some eyes after amphotericin B injection, but this resolves by 24 to 48 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36102/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Several studies have reported effective use of intracameral voriconazole at doses ranging from 12.5 mcg to 100 mcg per 0.1 mL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36102/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Intracameral doses of 100 mcg of voriconazole have been used repeatedly in some eyes without any apparent toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36102/abstract/8\">",
"     8",
"    </a>",
"    ], but we prefer a dose of 50 mcg due to the limited experience with intracameral voriconazole and because this dose produces sufficiently high levels in the aqueous to treat Candida species.",
"   </p>",
"   <p>",
"    Once the infection is known to be due to Candida spp, we prefer to use intracameral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    rather than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate, given the potential toxicity of the latter agent. However, in cases in which rapid improvement does not occur with voriconazole, we favor switching to amphotericin B deoxycholate. Efficacy studies comparing intracameral administration of these two agents have not been performed.",
"   </p>",
"   <p>",
"    Intracameral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    has been shown to have a half-life of only 22 minutes in an experimental rabbit model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36102/abstract/10\">",
"     10",
"    </a>",
"    ], so topical voriconazole 1 percent solution can be used to prolong the drug level in the aqueous. Application of 1 percent voriconazole ophthalmic solution (eyedrops) every 2 hours for 24 hours prior to scheduled eye surgery produced high levels in the aqueous in one study of 13 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36102/abstract/11\">",
"     11",
"    </a>",
"    ]. In cases of exogenous Candida endophthalmitis resulting from Candida keratitis, the keratitis should also be treated with antifungal eyedrops. Topical voriconazole eyedrops (1 percent) are preferred in these cases since topical voriconazole penetrates the cornea and achieves good levels in the aqueous, whereas topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    does not.",
"   </p>",
"   <p>",
"    It is important to note that intracameral injections of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate do",
"    <strong>",
"     not",
"    </strong>",
"    produce significant levels in the vitreous, so intravitreal injections of voriconazole or amphotericin B deoxycholate should also be given in any case of exogenous endophthalmitis if vitreous involvement cannot be excluded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36102/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapy should include vitrectomy and intravitreal injection of an antifungal agent when the vitreous shows severe involvement. Vitrectomy entails the use of a vitrector, an instrument inserted into the vitreous that simultaneously cuts and aspirates much of the 4 mL of gel-like vitreous into a canister (",
"    <a class=\"graphic graphic_figure graphicRef59512 \" href=\"mobipreview.htm?30/11/30899\">",
"     figure 2",
"    </a>",
"    ). Intravitreal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate (5 to 10 mcg in 0.1 mL sterile water) has been used most commonly. Since most Candida species are susceptible to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    and since voriconazole is well tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36102/abstract/13\">",
"     13",
"    </a>",
"    ], intravitreal voriconazole can be used as an alternative to amphotericin B. The usual dosing for intravitreal voriconazole is 100 mcg in 0.1 mL sterile water.",
"   </p>",
"   <p>",
"    When infection has resulted from cataract surgery with IOL implantation, it is often necessary to remove the IOL. An IOL is an artificial lens placed during cataract surgery. Antifungal drugs can suppress but cannot always cure the infection without removal of the IOL. This is likely related to the development of a biofilm, which some Candida species readily form on the implant. When antifungal agents are stopped in cases in which the IOL is left in place, relapse is a possibility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36102/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If endophthalmitis has followed corneal transplantation with an infected donor cornea, repeat transplantation, along with intracameral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate, is usually indicated at the onset of endophthalmitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61418186\">",
"    <span class=\"h2\">",
"     Systemic antifungal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to intraocular therapy, we recommend systemic azole therapy, based on the efficacy of systemic azoles in treating endogenous Candida endophthalmitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39112?source=see_link\">",
"     \"Treatment of endogenous endophthalmitis due to Candida species\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    For",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    -susceptible strains, oral fluconazole (400 to 800 mg daily) should be given. Fluconazole achieves concentrations in the vitreous in humans that are approximately 70 percent of that in the plasma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36102/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Fluconazole has shown efficacy in a rabbit model of exogenous Candida endophthalmitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36102/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the rare case of Candida krusei or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    -resistant C. glabrata exogenous endophthalmitis, fluconazole should",
"    <strong>",
"     not",
"    </strong>",
"    be used.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    is a reasonable alternative agent in this situation since it has activity against C. krusei and some fluconazole-resistant C. glabrata, and it achieves adequate levels in the eye [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36102/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Because C. glabrata isolates can demonstrate cross-resistance to both fluconazole and voriconazole, susceptibility testing should be performed, and the response to therapy should be monitored closely. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\", section on 'C. glabrata and C. krusei'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We generally do not recommend systemic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    for exogenous Candida endophthalmitis because it achieves poor levels in the aqueous and the vitreous [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36102/abstract/20\">",
"     20",
"    </a>",
"    ] and has known systemic toxicities. The value of systemic echinocandins for treating exogenous Candida endophthalmitis is unknown, but it is unlikely that they would be effective because of the poor intraocular concentrations achieved with these agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H866068368\">",
"    <span class=\"h2\">",
"     Approach to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of Candida endophthalmitis varies depending on whether it is of exogenous or endogenous origin and on the degree of vitreous involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1214565769\">",
"    <span class=\"h3\">",
"     Exogenous endophthalmitis with vitritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with exogenous Candida endophthalmitis with vitritis, we suggest the following treatment course:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vitrectomy (when the vitreous is heavily involved)",
"      <strong>",
"       and",
"      </strong>",
"     </li>",
"     <li>",
"      Intravitreal injection of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate (5 to 10 mcg in 0.1 mL sterile water) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (100 mcg in 0.1 mL sterile water)",
"      <strong>",
"       and",
"      </strong>",
"     </li>",
"     <li>",
"      Systemic therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (400 to 800 mg [6 to 12",
"      <span class=\"nowrap\">",
"       mg/kg]",
"      </span>",
"      orally daily) for Candida species that are susceptible to fluconazole.",
"     </li>",
"     <li>",
"      Most patients infected with a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      -resistant species can be treated with systemic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      , as discussed below:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For C. krusei, which is inherently resistant to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      and susceptible to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      , voriconazole should be used.",
"     </li>",
"     <li>",
"      For C. glabrata isolates that are",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      -resistant,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      should be used if the isolate is shown to be susceptible. It is important to note that cross-resistance between fluconazole and voriconazole is common among C. glabrata isolates, and patients infected with this species should be followed carefully for their response to treatment.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       Voriconazole",
"      </a>",
"      dosing is 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously every 12 hours for two doses, then 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously every 12 hours. In patients who present acutely, the IV formulation is recommended initially prior to switching to oral therapy. Oral therapy at a dose of at least 200 mg orally twice daily can be used following an initial response to the IV formulation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link&amp;anchor=H19#H19\">",
"       \"Treatment of candidemia and invasive candidiasis in adults\", section on 'C. glabrata and C. krusei'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with a subacute presentation who are being managed as outpatients, the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      loading dose can be given orally (400 mg twice a day for two doses), followed by an oral maintenance dose of at least 200 mg twice daily.",
"     </li>",
"     <li>",
"      It is important to measure serum concentrations of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      approximately one week after initiating therapy to ensure that adequate concentrations have been achieved to allow success and to avoid high levels that have been associated with adverse events. Although debate remains over the optimal target concentration, available data suggest a therapeutic range between 1 and 5.5",
"      <span class=\"nowrap\">",
"       mg/L.",
"      </span>",
"      In patients with concentrations that are too high or too low, the serum concentration should be rechecked four to five days after adjusting the dose. Once appropriate levels have been achieved, it is not necessary to recheck them unless there is a change in clinical status or concern for drug-drug interactions. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36938?source=see_link&amp;anchor=H28#H28\">",
"       \"Pharmacology of azoles\", section on 'Voriconazole'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who have an IOL who fail to improve after the therapeutic regimen described above (vitrectomy, intravitreal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    injection, and systemic azole therapy), the IOL will likely need to be removed and repeat intravitreal injections of amphotericin B deoxycholate (5 mcg in 0.1 mL) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    (100 mg in 0.1 mL) given. Voriconazole cannot be used, however, if the organism is resistant to this agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1214565777\">",
"    <span class=\"h3\">",
"     Exogenous endophthalmitis with primarily aqueous involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cases of exogenous Candida endophthalmitis in which the aqueous is the major site of intraocular infection (eg, from contiguous spread of fungal keratitis), intracameral (into the anterior chamber) injection of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    (50 mcg in 0.05 mL of sterile water) plus frequent topical voriconazole eyedrops (1 percent) hourly should be administered. Intracameral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate (5 mcg in 0.05 mL sterile water) and topical amphotericin B deoxycholate eyedrops (0.15 percent in sterile water) hourly may be given instead of intracameral voriconazole for voriconazole-resistant strains of Candida. However, amphotericin B deoxycholate eye drops can be very irritating to the eye. Even in cases in which only the aqueous appears to be involved clinically, intravitreal injection of amphotericin B deoxycholate (5 or 10 mcg in 0.1 mL sterile water) or voriconazole (100 mcg in 0.1 mL sterile water) should be considered. Such cases may have occult infection of the vitreous. Systemic voriconazole or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    should be given for susceptible strains, even for cases in which only the aqueous is involved.",
"   </p>",
"   <p>",
"    The management of endogenous endophthalmitis caused by Candida species and endophthalmitis caused by molds are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39112?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of endogenous endophthalmitis due to Candida species\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H728947070\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of antifungal therapy for Candida endophthalmitis is a minimum of four to six weeks, depending upon the stabilization or improvement of lesions as determined by serial ophthalmic examinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36102/abstract/21\">",
"     21",
"    </a>",
"    ]. Many patients will require several months of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148502501\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reports on the outcome of therapy for exogenous Candida endophthalmitis vary from vision restored to normal to light perception only. There are too few cases reported to have a firm idea of outcomes, although one series of 15 patients reported visual acuities of at least",
"    <span class=\"nowrap\">",
"     20/60",
"    </span>",
"    in one-half of the patients, most of whom did not have the implant removed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36102/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H866068501\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Candida species are a common cause of fungal endophthalmitis, but most cases are endogenous, meaning they develop from hematogenous seeding of the eye during candidemia. Exogenous Candida endophthalmitis, in which Candida is inoculated into the aqueous",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vitreous from outside the body, is less common (",
"      <a class=\"graphic graphic_figure graphicRef57690 \" href=\"mobipreview.htm?41/35/42549\">",
"       figure 1",
"      </a>",
"      ). Exogenous Candida endophthalmitis occurs most commonly after eye surgery (eg, cataract surgery, corneal transplantation) or penetrating eye trauma, but may also occur as an extension of Candida keratitis (corneal infection). (See",
"      <a class=\"local\" href=\"#H866067736\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with exogenous Candida endophthalmitis require aggressive multimodality therapy to control infection and preserve vision. We use the following approach:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with exogenous Candida endophthalmitis with vitreous involvement, we recommend vitrectomy for heavy vitritis, along with intravitreal injection of an antifungal agent (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ); either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate (5 to 10 mcg in 0.1 mL sterile water) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (100 mcg in 0.1 mL sterile water) may be used. Antifungal injections alone may be considered for light vitreous involvement.",
"     </li>",
"     <li>",
"      For patients with exogenous Candida ocular infection with primarily aqueous involvement, we recommend intracameral injection of an antifungal agent (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ); either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate (5 mcg in 0.05 mL sterile water) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (50 mcg in 0.05 mL of sterile water) may be used. In addition, in patients with exogenous Candida endophthalmitis resulting from Candida keratitis, we also recommend administration of voriconazole eyedrops (1 percent) (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with exogenous Candida endophthalmitis, we also recommend systemic azole therapy targeted to the susceptibility of the pathogen (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ); many patients can receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      , but some require",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      All foreign bodies (eg, intraocular lenses placed during prior cataract surgery) should be surgically removed if primary treatment fails. (See",
"      <a class=\"local\" href=\"#H866068368\">",
"       'Approach to treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of endogenous endophthalmitis caused by Candida species and endophthalmitis caused by molds is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39112?source=see_link\">",
"       \"Treatment of endogenous endophthalmitis due to Candida species\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36102/abstract/1\">",
"      Barza M. Treatment options for candidal endophthalmitis [editoria; comment]. Clin Infect Dis 1998; 27:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36102/abstract/2\">",
"      Riddell J 4th, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin Infect Dis 2011; 52:648.",
"     </a>",
"    </li>",
"    <li>",
"     Durand ML. Endophthalmitis. In: Principles and Practice of Infectious Diseases, 7th edition, Mandell GL, Bennett JE, Dolin R.  (Eds), Churchill Livingstone Elsevier, Philadelphia 2010. Vol 1, p.1553.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36102/abstract/4\">",
"      Pflugfelder SC, Flynn HW Jr, Zwickey TA, et al. Exogenous fungal endophthalmitis. Ophthalmology 1988; 95:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36102/abstract/5\">",
"      Kuriakose T, Kothari M, Paul P, et al. Intracameral amphotericin B injection in the management of deep keratomycosis. Cornea 2002; 21:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36102/abstract/6\">",
"      Yoon KC, Jeong IY, Im SK, et al. Therapeutic effect of intracameral amphotericin B injection in the treatment of fungal keratitis. Cornea 2007; 26:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36102/abstract/7\">",
"      Wykoff CC, Flynn HW Jr, Miller D, et al. Exogenous fungal endophthalmitis: microbiology and clinical outcomes. Ophthalmology 2008; 115:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36102/abstract/8\">",
"      Shen YC, Wang CY, Tsai HY, Lee HN. Intracameral voriconazole injection in the treatment of fungal endophthalmitis resulting from keratitis. Am J Ophthalmol 2010; 149:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36102/abstract/9\">",
"      Lin RC, Sanduja N, Hariprasad SM. Successful treatment of postoperative fungal endophthalmitis using intravitreal and intracameral voriconazole. J Ocul Pharmacol Ther 2008; 24:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36102/abstract/10\">",
"      Shen YC, Wang MY, Wang CY, et al. Pharmacokinetics of intracameral voriconazole injection. Antimicrob Agents Chemother 2009; 53:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36102/abstract/11\">",
"      Vemulakonda GA, Hariprasad SM, Mieler WF, et al. Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans. Arch Ophthalmol 2008; 126:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36102/abstract/12\">",
"      Goyal J, Fernandes M, Shah SG. Intracameral voriconazole injection in the treatment of fungal endophthalmitis resulting from keratitis. Am J Ophthalmol 2010; 150:939; author reply 939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36102/abstract/13\">",
"      Kernt M, Neubauer AS, De Kaspar HM, Kampik A. Intravitreal voriconazole: in vitro safety-profile for fungal endophthalmitis. Retina 2009; 29:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36102/abstract/14\">",
"      Kauffman CA, Bradley SF, Vine AK. Candida endophthalmitis associated with intraocular lens implantation: efficacy of fluconazole therapy. Mycoses 1993; 36:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36102/abstract/15\">",
"      Tod M, Lortholary O, Padoin C, Chaine G. Intravenous penetration of fluconazole during endophthalmitis. Clin Microbiol Infect 1997; 3:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36102/abstract/16\">",
"      Urbak SF, Degn T. Fluconazole in the management of fungal ocular infections. Ophthalmologica 1994; 208:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36102/abstract/17\">",
"      Park SS, D'Amico DJ, Paton B, Baker AS. Treatment of exogenous Candida endophthalmitis in rabbits with oral fluconazole. Antimicrob Agents Chemother 1995; 39:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36102/abstract/18\">",
"      Kim JE, Perkins SL, Harris GJ. Voriconazole treatment of fungal scleritis and epibulbar abscess resulting from scleral buckle infection. Arch Ophthalmol 2003; 121:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36102/abstract/19\">",
"      Breit SM, Hariprasad SM, Mieler WF, et al. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 2005; 139:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36102/abstract/20\">",
"      GREEN WR, BENNETT JE, GOOS RD. OCULAR PENETRATION OF AMPHOTERICIN B: A REPORT OF LABORATORY STUDIES AND A CASE REPORT OF POSTSURGICAL CEPHALOSPORIUM ENDOPHTHALMITIS. Arch Ophthalmol 1965; 73:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36102/abstract/21\">",
"      Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36102/abstract/22\">",
"      Stern WH, Tamura E, Jacobs RA, et al. Epidemic postsurgical Candida parapsilosis endophthalmitis. Clinical findings and management of 15 consecutive cases. Ophthalmology 1985; 92:1701.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16220 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-150152D66E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_16_36102=[""].join("\n");
var outline_f35_16_36102=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H866068501\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H866067736\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H866067796\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H866068119\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H728946907\">",
"      Intraocular therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61418186\">",
"      Systemic antifungal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H866068368\">",
"      Approach to treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1214565769\">",
"      - Exogenous endophthalmitis with vitritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1214565777\">",
"      - Exogenous endophthalmitis with primarily aqueous involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H728947070\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H148502501\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H866068501\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/16220\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16220|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/35/42549\" title=\"figure 1\">",
"      Eye anatomy in cross section",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/11/30899\" title=\"figure 2\">",
"      Vitreous aspirate vitrectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/18/24873?source=related_link\">",
"      Bacterial endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13849?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/5/42071?source=related_link\">",
"      Overview of Candida infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/42/3753?source=related_link\">",
"      Treatment and prevention of Fusarium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=related_link\">",
"      Treatment of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39112?source=related_link\">",
"      Treatment of endogenous endophthalmitis due to Candida species",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_16_36103="Desipramine: Pediatric drug information";
var content_f35_16_36103=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Desipramine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=see_link\">",
"    see \"Desipramine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/24/27013?source=see_link\">",
"    see \"Desipramine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F157638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Norpramin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F157639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dom-Desipramine;",
"     </li>",
"     <li>",
"      Novo-Desipramine;",
"     </li>",
"     <li>",
"      Nu-Desipramine;",
"     </li>",
"     <li>",
"      PMS-Desipramine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1052016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidepressant, Tricyclic (Secondary Amine)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1052010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=see_link\">",
"      see \"Desipramine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Depression:",
"     <b>",
"      Note:",
"     </b>",
"     Not FDA approved for use in pediatric patients; controlled clinical trials have not shown tricyclic antidepressants to be superior to placebo for the treatment of depression in children and adolescents (Dopheide, 2006; Wagner, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-12 years: 1-3 mg/kg/day in divided doses; monitor carefully with doses &gt;3 mg/kg/day; maximum dose: 5 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents: Initial: 25-50 mg/day; gradually increase to 100 mg/day in single or divided doses; maximum dose: 150 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Initial: 75 mg/day in divided doses; increase gradually to 150-200 mg/day in divided or single dose; maximum dose: 300 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F157615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Norpramin&reg;: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg [contains soybean oil]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F157600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088665.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088665.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1052021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food to decrease GI upset",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1052020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of depression (FDA approved in adults); has also been used as an analgesic in chronic pain; treatment of peripheral neuropathies",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F157663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Desipramine may be confused with clomiPRAMINE, dalfampridine, diphenhydrAMINE, disopyramide, imipramine, nortriptyline",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Norpramin&reg; may be confused with clomiPRAMINE, imipramine, Normodyne&reg;, Norpace&reg;, nortriptyline, Tenormin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (SIADH: Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Norpramin: Brand name for desipramine [U.S., Canada], but also the brand name for enalapril/hydrochlorothiazide [Portugal]; omeprazole [Spain]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F157660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, edema, flushing, heart block, hyper-/hypotension, MI, palpitation, stroke, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, ataxia, confusion, delusions, disorientation, dizziness, drowsiness, EEG alterations, exacerbation of psychosis, extrapyramidal symptoms, fatigue, fever, hallucinations, headache, hypomania, incoordination, insomnia, neuroleptic malignant syndrome, nightmares, restlessness, seizure, suicidal thinking and behavior",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, itching, petechiae, photosensitivity, skin rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast enlargement, galactorrhea, gynecomastia, hyper-/hypoglycemia, impotence, libido changes, SIADH",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, anorexia, black tongue, constipation, diarrhea, epigastric distress, nausea, parotid edema, paralytic ileus, stomatitis, sublingual adenitis, unpleasant taste, vomiting, weight gain/loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Micturition delayed, nocturia, painful ejaculation, polyuria, testicular edema, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, eosinophilia, purpura, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, cholestatic jaundice, hepatitis, liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Falling, numbness, paresthesia of extremities, peripheral neuropathy, tingling, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, disturbances of accommodation, intraocular pressure increased, mydriasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, diaphoresis (excessive), withdrawal symptoms",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1052025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to desipramine (cross-sensitivity with other tricyclic antidepressants may occur) or any component; use of MAO inhibitors within 14 days (potentially fatal reactions may occur); use in patients during the acute recovery phase following MI; narrow-angle glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1052009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with extreme caution in the following patients: Patients with cardiovascular disease (due to the possibility of conduction defects, arrhythmias, tachycardias, strokes, and acute MI); patients who have a family history of sudden death, dysrhythmias, or conduction abnormalities; patients with thyroid disease or taking thyroid medications (due to the possibility of cardiovascular toxicity and arrhythmias); patients with a history of seizure disorders (desipramine may lower the seizure threshold; in some patients, seizures may precede cardiac dysrhythmias and death); patients with a history of urinary retention or  glaucoma (due to the anticholinergic effects of the medication). Desipramine causes less sedation and fewer anticholinergic adverse effects than amitriptyline or imipramine; it should be noted that overdose of desipramine has resulted in a higher death rate compared to other tricyclic antidepressants.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1052008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clinical worsening of depression or suicidal ideation and behavior may occur in children and adults with major depressive disorder",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . In clinical trials, antidepressants increased the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (18-24 years of age) with major depressive disorder and other psychiatric disorders. This risk must be considered before prescribing antidepressants for any clinical use. Short-term studies did",
"     <b>",
"      not",
"     </b>",
"     show an increased risk of suicidality with antidepressant use in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients of all ages who are treated with antidepressants for any indication require appropriate monitoring and close observation for clinical worsening of depression, suicidality, and unusual changes in behavior, especially during the first few months after antidepressant initiation or when the dose is adjusted. Family members and caregivers should be instructed to closely observe the patient (ie, daily) and communicate condition with healthcare provider. Patients should also be monitored for associated behaviors (eg, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania) which may increase the risk for worsening depression or suicidality. Worsening depression or emergence of suicidality (or associated behaviors listed above) that is abrupt in onset, severe, or not part of the presenting symptoms, may require discontinuation or modification of drug therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Do not discontinue abruptly in patients receiving high doses chronically (withdrawal symptoms may occur). To reduce risk of intentional overdose, write prescriptions for the smallest quantity consistent with good patient care. Screen individuals for bipolar disorder prior to treatment (using antidepressants alone may induce manic episodes in patients with this condition). Hypertensive episodes have been reported during surgery in patients receiving desipramine (discontinue desipramine use as soon as possible prior to elective surgery).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The American Heart Association recommends that all children diagnosed with ADHD who may be candidates for medication, such as desipramine, should have a thorough cardiovascular assessment prior to initiation of therapy. These recommendations are based upon reports of serious cardiovascular adverse events (including sudden death) in patients (both children and adults) taking usual doses of stimulant medications. Most of these patients were found to have underlying structural heart disease (eg, hypertrophic obstructive cardiomyopathy). Asymptomatic ECG changes and minor increases in diastolic blood pressure and heart rate have been noted in children receiving &gt;3.5 mg/kg/day; four cases of sudden death have been reported in children 5-14 years of age; an association between desipramine and sudden death was not shown to be significant in one retrospective study. Pretreatment cardiovascular  assessment should include a combination of thorough medical history, family history, and physical examination. An ECG is not mandatory but should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F157649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2A6 (moderate), CYP2B6 (moderate), CYP2D6 (moderate), CYP2E1 (weak), CYP3A4 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F157609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Tricyclic Antidepressants may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Tricyclic Antidepressants may enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: Tricyclic Antidepressants may diminish the antihypertensive effect of Alpha2-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Tricyclic Antidepressants may enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Tricyclic Antidepressants may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Desipramine. Management: Consider lower doses of desipramine in patients treated with boceprevir and monitor for symptoms of desipramine toxicity (including dizziness, hypotension and syncope), due to a possible increase in desipramine concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inhibitors (Moderate) may decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DULoxetine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Tricyclic Antidepressants may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neurotoxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Tricyclic Antidepressants may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with tricyclic antidepressants for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: May increase the serum concentration of Desipramine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of CYP2D6 Inhibitors (Moderate).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Tricyclic Antidepressants may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure and/or loss of consciousness may be increased in patients with significant sodium phosphate induced fluid/electrolyte abnormalities.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Tricyclic Antidepressants. The risk of serotonin syndrome may theoretically be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Cyclic Antidepressants may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terbinafine (Systemic): May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Tricyclic Antidepressants may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: Tricyclic Antidepressants may increase the serum concentration of Yohimbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1052028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May increase riboflavin dietary requirements",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10912704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies are inconclusive.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1052015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate, ECG, mental status, weight. Monitor patient periodically for symptom resolution;  monitor for worsening of depression, suicidality, and associated behaviors (especially at the beginning of therapy or when doses are increased or decreased)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      ADHD:",
"     </b>",
"     Evaluate patients for cardiac disease prior to initiation of therapy for ADHD with thorough medical history, family history, and physical exam; consider ECG; perform ECG and echocardiogram if findings suggest cardiac disease; promptly conduct cardiac evaluation in patients who develop chest pain, unexplained syncope, or any other symptom of cardiac disease during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Long-term use:",
"     </b>",
"     Also monitor CBC with differential, liver enzymes, serum concentrations",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1052019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Plasma concentrations do not always correlate with clinical effectiveness.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Timing of serum samples: Draw trough just before next dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic: 50-300 ng/mL (SI: 188-1125 nmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Possible toxicity: &gt;300 ng/mL (SI: &gt;1070 nmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Toxic: &gt;1000 ng/mL (SI: &gt;3750 nmol/L)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1052007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases the synaptic concentration of serotonin and/or norepinephrine in the CNS by inhibition of their reuptake by the presynaptic neuronal membrane",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1052023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antidepressant effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Occasionally seen in 2-5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: After more than 2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1052024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapidly and well absorbed from the GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 21 L/kg; distributes into breast milk (concentrations approximately equal to maternal plasma)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 12-57 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 70% in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1052014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/24/27013?source=see_link\">",
"      see \"Desipramine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Before starting treatment notify physician if you have any of the following: Cardiovascular disease; family history of sudden death, cardiac dysrhythmias, or cardiac disturbances; thyroid disease or are taking thyroid medication; history of seizure disorder; urinary retention; or glaucoma. Read the patient Medication Guide that you receive with each prescription and refill of desipramine. An increased risk of suicidal thinking and behavior has been reported with the use of antidepressants in children, adolescents, and young adults (18-24 years of age). Notify physician if you feel more depressed, have thoughts of suicide, or become more agitated or irritable. May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth; avoid alcohol and the herbal medicine St John's wort; limit caffeine; may discolor urine to blue-green color; do not discontinue medication abruptly; may increase appetite. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD; available at: file://americanheart.mediaroon.com/index.php?s=43&amp;item=422.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Biederman J, Thisted RA, Greenhill LL, et al, &ldquo;Estimation of the Association Between Desipramine and the Risk for Sudden Death in 5-14 Year-Old Children,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1995, 56(3):87-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/16/36103/abstract-text/7883735/pubmed\" id=\"7883735\" target=\"_blank\">",
"        7883735",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dopheide JA, \"Recognizing and Treating Depression in Children and Adolescents,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2006, 63(3):233-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/16/36103/abstract-text/16434782 /pubmed\" id=\"16434782 \" target=\"_blank\">",
"        16434782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levy HB, Harper CR, and Weinberg WA, &ldquo;A Practical Approach to Children Failing in School,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1992, 39(4):895-928.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/16/36103/abstract-text/1635811/pubmed\" id=\"1635811\" target=\"_blank\">",
"        1635811",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vetter VL, Elia J, Erickson C, et al, \"Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2008, 117(18):2407-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/16/36103/abstract-text/18427125/pubmed\" id=\"18427125\" target=\"_blank\">",
"        18427125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagner KD, \"Pharmacotherapy for Major Depression in Children and Adolescents,\"",
"      <i>",
"       Prog Neuropsychopharmacol Biol Psychiatry",
"      </i>",
"      , 2005, 29(5):819-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/16/36103/abstract-text/15908090/pubmed\" id=\"15908090\" target=\"_blank\">",
"        15908090",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13210 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-201.211.0.116-A318AF7B5E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_16_36103=[""].join("\n");
var outline_f35_16_36103=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708682\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157638\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157639\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052016\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052010\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157615\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157600\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874425\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052021\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052020\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157663\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157660\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052025\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052009\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052008\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157649\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157609\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052028\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10912704\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052015\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052019\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052007\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052023\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052024\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052014\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13210\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13210|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=related_link\">",
"      Desipramine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/24/27013?source=related_link\">",
"      Desipramine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_16_36104="Munchausen syndrome by proxy (medical child abuse)";
var content_f35_16_36104=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Munchausen syndrome by proxy (medical child abuse)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/16/36104/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/16/36104/contributors\">",
"     Erin E Endom, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/16/36104/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/16/36104/contributors\">",
"     Daniel M Lindberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/16/36104/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/16/36104/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/16/36104/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/16/36104/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Named for Baron von Munchausen, who told fanciful tales about his travels and exploits, Munchausen syndrome is the fabrication or induction of illness in the self in order to get attention; it results in needless medical investigation and treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Munchausen syndrome by proxy (also known as factitious disorder by proxy, Meadow syndrome, proxy factitia, and erroneously as Polle syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/3\">",
"     3",
"    </a>",
"    ]) was first described in 1977 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/4\">",
"     4",
"    </a>",
"    ] and consists of fabricating or inducing illness in a child in order to get attention.",
"   </p>",
"   <p>",
"    Munchausen syndrome is a psychiatric illness. In contrast, Munchausen syndrome by proxy is a psychiatric illness and an insidious form of child abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. The American Professional Society on the Abuse of Children (APSAC) multidisciplinary task force on Munchausen by proxy (MBP) describes two components: the adult perpetrator (who is diagnosed with factitious disorder by proxy), and the child victim, who suffers from pediatric condition (illness, impairment, or symptom) falsification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, clinical features, evaluation, and management of MBP will be reviewed here. Munchausen syndrome and other forms of child abuse and neglect are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/21/7512?source=see_link\">",
"     \"Factitious disorder and Munchausen syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/62/18408?source=see_link\">",
"     \"Child neglect and emotional abuse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/54/26473?source=see_link\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Munchausen by proxy (MBP) is a relatively rare form of child abuse which poses a significant danger of morbidity or mortality to the affected child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/8\">",
"     8",
"    </a>",
"    ]. In the largest prospective series of cases, the annual incidence of MBP, nonaccidental poisoning, and nonaccidental suffocation in the United Kingdom and Ireland was determined to be",
"    <span class=\"nowrap\">",
"     0.5/100,000",
"    </span>",
"    in children younger than 16 years and",
"    <span class=\"nowrap\">",
"     2.8/100,000",
"    </span>",
"    in children younger than one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/10\">",
"     10",
"    </a>",
"    ]. A similar annual incidence (2.0 per 100,000 in children younger than 16 years) was determined in New Zealand by surveying pediatricians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the prospective study described above, 128 cases of MBP were detected in two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/10\">",
"     10",
"    </a>",
"    ]. Most of the affected children (77 percent) were younger than five years (median age 20 months). Hospitalization was required in 95 percent of cases; length of stay was between 7 and 30 nights in 41 percent, and &gt;30 nights in 23 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/10\">",
"     10",
"    </a>",
"    ]. Mortality rates of 9 to 10 percent have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. Death is often caused by poisoning or suffocation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/10\">",
"     10",
"    </a>",
"    ]. The perpetrator was the mother in 85 percent of cases, the father in 5 percent, another adult in 1 percent, and uncertain in 9 percent.",
"   </p>",
"   <p>",
"    Perpetrators of MBP may have a personal history of abnormal illness behavior including factitious or somatoform disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. In one literature review of 117 cases of MBP, 24 percent had Munchausen syndrome or features of Munchausen syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/12\">",
"     12",
"    </a>",
"    ]. In another study, 34 out of 47 mothers who underwent detailed psychopathologic evaluation had a history of factitious or somatoform disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5450?source=see_link&amp;anchor=H2#H2\">",
"     \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\", section on 'Terminology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common presentations include bleeding, seizures, depressed central nervous system, and apnea (",
"    <a class=\"graphic graphic_table graphicRef59264 \" href=\"mobipreview.htm?15/56/16267\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/12\">",
"     12",
"    </a>",
"    ]. In the review of 117 cases described above, 25 percent of cases involved simulation of illness only, 50 percent involved induction only, and 25 percent involved both simulation and induction of illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/12\">",
"     12",
"    </a>",
"    ]. In this series of cases, at least 70 percent of illness simulation or induction took place in the hospital [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/12\">",
"     12",
"    </a>",
"    ]. Comorbid conditions include failure to thrive, nonaccidental injury, inappropriate administration of medications, and child neglect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/15\">",
"     15",
"    </a>",
"    ]. Multiple children in the family may be abused, either simultaneously or sequentially; this is known as multiple-child MBP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terminology used to describe MBP is confusing and somewhat controversial. Some authors argue that MBP is neither a syndrome nor a \"diagnosis\" in the traditional sense, but rather an observational description with implications regarding cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/17\">",
"     17",
"    </a>",
"    ]. Others suggest that the term should be applied to the behavior rather than the perpetrator, deferring the description of the perpetrator's mental health and personality to",
"    <span class=\"nowrap\">",
"     psychiatrists/psychologists",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/6,13\">",
"     6,13",
"    </a>",
"    ]. Still others argue that the term MBP should be abandoned altogether and replaced with a factual description of what happened to the child (eg, &ldquo;medical child abuse&rdquo;) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In caring for children in whom fabrication or induction of symptoms is suspected, preoccupation with terminology should not get in the way of accurately describing what happened to the child (eg, induced apnea, factitious epilepsy, parental exaggeration of asthma symptoms) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/6,13,17,18\">",
"     6,13,17,18",
"    </a>",
"    ]. The evaluation should focus on whether the child has been abused, the manner in which the child was abused, and whether the child or his or her siblings are at risk for harm in the future [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Definitions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author who originally described MBP defines it by the following criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An illness is fabricated (faked or induced) by the parent or primary caregiver.",
"     </li>",
"     <li>",
"      The child is presented to doctors, usually persistently; the perpetrator (initially) denies causing the child's illness.",
"     </li>",
"     <li>",
"      The illness subsides when the child is separated from the perpetrator.",
"     </li>",
"     <li>",
"      The perpetrator is considered to be acting out of a need to assume the sick role by proxy or as another form of attention seeking behavior.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The American Psychiatric Association (APA) uses the term factitious disorder by proxy and applies it to the perpetrator rather than the abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/5\">",
"     5",
"    </a>",
"    ]. The APA's research criteria for the disorder include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intentional production or feigning of physical or psychological signs or symptoms in another person who is under the individual's care.",
"     </li>",
"     <li>",
"      The motivation for the perpetrator's behavior is to assume the sick role by proxy.",
"     </li>",
"     <li>",
"      External incentives for the behavior (such as economic gain) are absent.",
"     </li>",
"     <li>",
"      The behavior is not better accounted for by another mental disorder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In both sets of criteria, the perpetrator's behavior is motivated by the need to assume the sick role. This criterion was essential to the original case description [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/4,12\">",
"     4,12",
"    </a>",
"    ] and has the advantage of preventing the term from being used inappropriately to describe some other forms of child abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/6,13\">",
"     6,13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)&nbsp;",
"   </p>",
"   <p>",
"    However, the criterion also has the disadvantage that motive is difficult to ascertain, particularly at the time the abuse is detected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/13,17\">",
"     13,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;MBP should be considered if the following features are present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The reported history varies from what is observed (eg, descriptions of severe illness in the presence of a normal appearing child) or does not make sense.",
"     </li>",
"     <li>",
"      The illness is unexplained, unusual, or prolonged and does not respond to treatment as expected.",
"     </li>",
"     <li>",
"      The problem seems to originate only in the presence of the suspected perpetrator.",
"     </li>",
"     <li>",
"      The problem resolves or improves when the child is separated from the suspected perpetrator.",
"     </li>",
"     <li>",
"      The problem recurs when the suspected perpetrator is told that the child is improving or is soon to be released from the hospital or treatment program.",
"     </li>",
"     <li>",
"      Family members have unexplained symptoms, illness, or death.",
"     </li>",
"     <li>",
"      The suspected perpetrator behaves in a manner that appears to be consistent with exaggeration, fabrication, or induction of physical, psychological, or behavioral problems in the child.",
"     </li>",
"     <li>",
"      The alleged perpetrator does not seem to be as worried by the child's illness as the health professionals who are caring for the child.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The history in cases of MBP is one of frequent recurrent illnesses without a clear etiology. The presenting signs and symptoms encompass an enormous spectrum, limited only by the imagination of the abuser. The most common presentations involve bleeding from various sites, seizures, central nervous system depression, and apnea (",
"    <a class=\"graphic graphic_table graphicRef59264 \" href=\"mobipreview.htm?15/56/16267\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/12\">",
"     12",
"    </a>",
"    ]. When seizures or apnea are involved, the abuser is typically the only one to witness the",
"    <strong>",
"     onset",
"    </strong>",
"    of events, although other witnesses may observe the ongoing crisis, induced by the abuser. The findings occur when the perpetrator is present and resolve when the perpetrator and child are separated.",
"   </p>",
"   <p>",
"    Illnesses are unexplained, recurrent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prolonged, and if the child has a specific diagnosis, it may be extremely rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/22\">",
"     22",
"    </a>",
"    ]. Multiple physicians or emergency departments may have been involved in evaluation or management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/22\">",
"     22",
"    </a>",
"    ]. Children undergo repeated procedures including venipuncture, lumbar punctures, and surgical procedures in order to evaluate and treat reported illnesses; thus, medical personnel become unwitting co-abusers by extension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Associated features",
"    </span>",
"    &nbsp;&mdash;&nbsp;During hospitalizations, the perpetrator (usually the mother) is at the child's bedside almost constantly, and may insist that she is the only one for whom the child will take medicines or eat. She is characteristically compliant, overtly concerned with caring for the child, and becomes familiar with medical terminology. She often forms close emotional bonds with the hospital staff [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/12,16\">",
"     12,16",
"    </a>",
"    ] and may be anxious to impress them with her aptitude in caring for her child and her degree of medical knowledge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/22\">",
"     22",
"    </a>",
"    ]. This constellation of characteristics has been described as \"a masquerade of good mothering\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/22\">",
"     22",
"    </a>",
"    ]. The perpetrator in cases of MBP may receive sympathy; praise for her medical knowledge and devotion to the sick child; financial aid; or relief from the responsibilities of marriage and parenting during hospital stays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/23\">",
"     23",
"    </a>",
"    ]. Although these secondary gains may be viewed as \"external incentives\" they are not the primary motivator for the perpetrator's behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/8,13\">",
"     8,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Typical characteristics of the perpetrators have been described (",
"    <a class=\"graphic graphic_table graphicRef52225 \" href=\"mobipreview.htm?4/57/5020\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/5,12,14\">",
"     5,12,14",
"    </a>",
"    ]. These characteristics were originally put forth to help medical workers consider the diagnosis, not as diagnostic criteria, nor as a \"profile\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/19,24\">",
"     19,24",
"    </a>",
"    ]. They are neither sensitive nor specific and have low predictive value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/18,25\">",
"     18,25",
"    </a>",
"    ]. They should never be used in isolation as proof (or disproof) of the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Fabricated illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fabrication of symptoms results in unnecessary medical evaluation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment. Examples of illness fabrication include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reporting symptoms that have not occurred (eg, seizures, apnea, or syncope)",
"     </li>",
"     <li>",
"      Simulation of symptoms (eg, addition of blood to urine or stool samples to simulate hematuria or hematochezia, warming a thermometer to simulate fever)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Induced illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inducement of illness may directly result in permanent damage or death. Examples of illness inducement include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The administration of medications such as ipecac to induce vomiting, phenolphthalein or other stool softeners for diarrhea, and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/4/21578?source=see_link\">",
"       warfarin",
"      </a>",
"      or rodenticides to simulate a bleeding diathesis are well documented [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/12,16\">",
"       12,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Seizures or apnea can be produced by suffocation, carotid sinus pressure, or poisoning with tricyclic antidepressants, hydrocarbons, or other agents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/12,23\">",
"       12,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Coma can be produced by a variety of drugs, including insulin,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/38/2662?source=see_link\">",
"       chloral hydrate",
"      </a>",
"      , barbiturates, tricyclic antidepressants, and hydrocarbons, as well as suffocation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rashes can be simulated by painting on the skin, applying caustics, or with various drugs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Salt poisoning is usually inflicted by the addition of table salt to breast milk, formula, or other fluids and presents with symptoms of severe hypernatremia (serum sodium can exceed 200",
"      <span class=\"nowrap\">",
"       meq/L),",
"      </span>",
"      including seizures, coma, hemorrhagic encephalopathy, and death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/12,16,26,27\">",
"       12,16,26,27",
"      </a>",
"      ]. In children who are able to drink, salt poisoning is accompanied by acute weight gain because of increased thirst and stimulation of antidiuretic hormone&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/27\">",
"       27",
"      </a>",
"      ]. This is in contrast to children with hypernatremic dehydration, who typically have acute weight loss.",
"     </li>",
"     <li>",
"      Bacteriological abuse consists of injection of saliva, feces, or other contaminated material into skin or intravenous lines to induce recurrent infection (frequently with multiple organisms identified on culture, characteristic of their site of origin), and may masquerade as a poorly defined immunodeficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/12,28\">",
"       12,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Factitious psychiatric disorders, including attention-deficit hyperactivity disorder, bipolar disorder, and",
"      <span class=\"nowrap\">",
"       anorexia/polydipsia,",
"      </span>",
"      have been reported, with the parent describing, coaching, or inducing on cue the appropriate symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/29,30\">",
"       29,30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;MBP is a diagnosis that must be carefully considered among the other diagnostic possibilities, which include an undiagnosed general medical or psychiatric condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/5\">",
"     5",
"    </a>",
"    ] and forms of child maltreatment in which the behavior of the perpetrator is motivated by factors other than the need to assume the sick role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/6,12,17\">",
"     6,12,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unrecognized physical abuse (eg, deliberate poisoning or smothering) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/54/26473?source=see_link\">",
"       \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Failure to thrive or child neglect (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/62/18408?source=see_link\">",
"       \"Child neglect and emotional abuse\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/12/14538?source=see_link&amp;anchor=H11#H11\">",
"       \"Etiology and evaluation of failure to thrive (undernutrition) in children younger than two years\", section on 'Etiology'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mothers with delusional disorder; these mothers have convinced themselves that their child is ill and cannot be dissuaded from the belief by appropriate investigation and careful explanation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/31\">",
"       31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      An enmeshed relationship in which repetitive induced or fabricated illnesses results in missed school and the failure of the child to develop independence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/32\">",
"       32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hysteria by proxy in which the parent enforces the belief that the child has an unusual illness, allergy, or incapacitating postviral syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/33\">",
"       33",
"      </a>",
"      ]; in some cases, the parent believes that they too have the illness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/34\">",
"       34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Mothering to death, in which mothers, without the involvement of doctors, treat their child as disabled or ill [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. The children may be confined to a bed or wheelchair, or encased in bandages until they die or are permanently disabled. These parents seek to evade medical and social services and appear to have a need to adopt a perpetual",
"      <span class=\"nowrap\">",
"       mothering/nursing",
"      </span>",
"      role for themselves, rather than a sick role.",
"     </li>",
"     <li>",
"      Other forms of pediatric condition falsification (eg, parents who falsely report abuse of their children for the primary purpose of obtaining custody or harming their spouse or partner)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the above conditions, a number of situations that exist along the spectrum of health seeking behaviors must be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/6,13,37-39\">",
"     6,13,37-39",
"    </a>",
"    ]. The spectrum ranges from child neglect to MBP as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Classic neglect (child's symptoms ignored)",
"     </li>",
"     <li>",
"      Child's health is jeopardized through carelessness",
"     </li>",
"     <li>",
"      Marked non-compliance",
"     </li>",
"     <li>",
"      Parent is rather lackadaisical about symptoms or treatment",
"     </li>",
"     <li>",
"      Parent responds appropriately to child's symptoms",
"     </li>",
"     <li>",
"      Parent becomes anxious about trivial symptoms",
"     </li>",
"     <li>",
"      Parent exaggerates child's symptoms",
"     </li>",
"     <li>",
"      Parent invents symptoms",
"     </li>",
"     <li>",
"      Classic MBP (child's symptoms procured)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a general rule, there is good agreement between parents and health care professionals regarding the need to consult other health professionals for the middle three behaviors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/37\">",
"     37",
"    </a>",
"    ]. On the other hand, there may be little to no agreement between parents and health care professionals for the six behaviors at the two ends of the spectrum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the suspected MBP can be difficult. It requires a high index of suspicion and a coordinated approach by all members of the medical team (",
"    <a class=\"graphic graphic_table graphicRef65683 \" href=\"mobipreview.htm?13/62/14315\">",
"     table 3",
"    </a>",
"    ). Whenever possible, a multidisciplinary child protection team that includes a child abuse specialist or pediatrician with similar expertise should be consulted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/40\">",
"     40",
"    </a>",
"    ]. All professionals caring for the child should be educated regarding the nature of the syndrome, danger signals, and the need to protect the child. The primary concern must be the health and safety of the child and his or her siblings. The interactions between patient and parent should be monitored closely by an experienced medical professional to prevent further harm to the child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/20\">",
"     20",
"    </a>",
"    ]. The child's and family's medical history should be reviewed, including neutral sources (not just the statements of the immediate family members), with attention to any unusual illnesses or deaths in the siblings or parents, and the condition of the child when outside the care of the suspected perpetrator [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/20,24\">",
"     20,24",
"    </a>",
"    ]. Any reported witnesses to the child's illness (babysitters, relatives, physicians and nurses who have previously treated the child) should be interviewed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/12,20\">",
"     12,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although laboratory testing must be performed as necessary to confirm the diagnosis, or exclude other diagnostic considerations, unnecessary medical procedures should be avoided whenever possible. Blood, urine, and stool samples, potentially contaminated intravenous fluids or lines, and other materials should be retained for future analysis, with care taken to establish a chain of evidence for law enforcement purposes (this includes proper sealing, labeling, and storing of specimens to ensure that they cannot be tampered with) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/12,16,20\">",
"     12,16,20",
"    </a>",
"    ]. Analysis of these materials may include drug assays, toxicology screening, blood group typing, testing of stools for phenolphthalein or other laxatives, analysis of blood, urine, intravenous fluid, or milk for added substances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hospitalization may lead to a cessation of symptoms, only to have them recur when the patient is discharged. Symptom induction in the hospital occurs in 70 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/12\">",
"     12",
"    </a>",
"    ] and occurs when the patient is alone with the parent, their interactions unwitnessed. A search of the parent's luggage may reveal medications used to induce illness. Searching a parent's luggage poses both ethical and legal problems; the invasion of the parent's privacy must be weighed against the information to be obtained by the search which may not be verifiable any other way, and which directly affects the safety and well-being of the child.",
"   </p>",
"   <p>",
"    Unfortunately, little has been published regarding this issue. In a 1980 review of laxative abuse as a manifestation of Munchausen syndrome in adults, the authors recommended that a search be conducted while the patient is away from the room unexpectedly, and that it be conducted in the presence of another person to defend against a possible claim of theft. It was also suggested that if medication was found the amount should be verified and a repeat count made a few days later to determine if the patient was actually using the medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/41\">",
"     41",
"    </a>",
"    ]. Such actions should be undertaken only after consultation with a multidisciplinary team, including representatives of the medical and nursing staff, social services, hospital risk management, and security services.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Video surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Video surveillance may reveal deliberate harmful actions by the parent (suffocation or administration of medications or contaminants). Video surveillance in cases of suspected MBP is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/25,42-46\">",
"     25,42-46",
"    </a>",
"    ]. It is considered by some to be an invasion of privacy, unethical, and a form of entrapment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/45\">",
"     45",
"    </a>",
"    ]. Others argue that the need to protect the child overrides these concerns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/25,46\">",
"     25,46",
"    </a>",
"    ]. Proponents of surveillance argue that without it, cases of MBP will go undetected (due to the reluctance of physicians to make the diagnosis, the tendency of patients to switch physicians once the diagnosis is suspected, and the difficulty in proving inducement or fabrication of illness without monitoring) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/25\">",
"     25",
"    </a>",
"    ]. The use of video surveillance can either support or exclude abuse due to MBP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/25\">",
"     25",
"    </a>",
"    ]. As an example, one study reviewed the use of covert video surveillance in the evaluation of 41 cases of suspected MBP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/25\">",
"     25",
"    </a>",
"    ]. A diagnosis of MBP was made in 23 cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/25\">",
"     25",
"    </a>",
"    ]. Video surveillance was required to make the diagnosis in 13 cases (56 percent), supportive of the diagnosis in five cases, and ruled out the diagnosis in four cases.",
"   </p>",
"   <p>",
"    Initiation of covert video surveillance should be preceded by the following steps:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment of the case by a multidisciplinary team, including representatives of the medical and nursing staff, social services, hospital risk management, and security services, with the conclusion that either MBP is likely and surveillance is necessary to protect the child, or MBP is unlikely but no other explanation of the child's symptoms can be determined.",
"     </li>",
"     <li>",
"      The parents must consent to video monitoring. In the series described above, such consent was included in the routine admission forms, and a sign at the entrance to the hospital informed visitors that the facility was monitored by hidden cameras.",
"     </li>",
"     <li>",
"      Local children's protective services should be notified that monitoring is taking place.",
"     </li>",
"     <li>",
"      The video feed should be monitored continuously by security officers or other personnel who have been trained in the manifestations of MBP and the monitoring of caretakers for unusual or dangerous actions.",
"     </li>",
"     <li>",
"      All healthcare workers on the floor should be aware of the monitoring. When notified by the security officer of an unusual or dangerous action on the part of the caretaker, the floor nurse should be ready to enter the room immediately, assess the situation, and intervene if necessary [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is extremely difficult to prove that the caregiver is fabricating or inducing illness. Confirmation of abuse due to MBP syndrome requires proof that the suspected perpetrator has deliberately exaggerated, fabricated, or induced the signs or symptoms in the child, and a rationale that the behavior is consistent with MBP maltreatment rather than something else [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evidence for exaggeration, fabrication, or induction is often circumstantial or obtained fortuitously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/25\">",
"     25",
"    </a>",
"    ]. Careful history must be documented. Clear evidence of fabrication or inducement of disease can be provided by video surveillance (eg, parent is seen injecting a substance into an IV line); laboratory (eg, a positive drug assay), or a reliable witness (eg, a nurse who observes the parent smothering the child) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of confirmed cases of MBP requires the involvement of law enforcement and children's protective, and social services when Munchausen by proxy is suspected or confirmed.",
"   </p>",
"   <p>",
"    The disclosure of the diagnosis to the family should be done in a straightforward and supportive manner, with the emphasis on helping both the child and the parent or caregiver rather than eliciting a confession. Measures must be in place to prevent the caregiver from fleeing with the child during or after the conference. Psychiatric evaluation by a therapist familiar with MBP should be readily available for both the child (if age appropriate) and parents. There is a risk of maternal suicide attempt following disclosure of suspicion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/12,16\">",
"     12,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The child and siblings should almost always be removed from the home, and ongoing court-ordered supervision of the case should be requested, as well as court-ordered review of the medical records and examination of the siblings, and court-ordered psychiatric evaluation and treatment for the child and family [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/12\">",
"     12",
"    </a>",
"    ]. If supervised visits are permitted, the supervisor should be a medically experienced person who is in constant attendance and the provision of food, drink, or medicine by the family should be prohibited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although it appears that at least some children who have undergone MBP abuse may be safely returned to their homes with parental therapy and close monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/47\">",
"     47",
"    </a>",
"    ], most children require permanent removal from the abusive environment because of the high risk of further abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/48-50\">",
"     48-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The consequences of Munchausen syndrome include repeated, needless, painful medical evaluation and therapy, including prolonged hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/10\">",
"     10",
"    </a>",
"    ]. Permanent damage or death may result from illness induction (eg, poisoning) or from medical interventions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. Other sequelae include chronic invalidism with prolonged or recurrent school absence; chronic fears related to bodily integrity; or a disturbed self-image [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/12,16,22\">",
"     12,16,22",
"    </a>",
"    ]. Munchausen syndrome in adulthood continues the pattern of behavior established by the parent during childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36104/abstract/16,51\">",
"     16,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5956623\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Munchausen by proxy (medical child abuse) is a relatively rare form of child abuse marked by fabrication of illness by the parent or primary caregiver that results in persistent medical evaluation. The illness does not occur when the child and the caregiver are separated. The perpetrator is most commonly the mother who denies causing the child&rsquo;s illness. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several clinical features are typically present in cases of Munchausen by proxy, including a discrepant history; an illness that is unexplained, unusual, prolonged, and is recalcitrant to treatment; the problem only originates in the presence of the perpetrator and resolves when the child and perpetrator are separated; the perpetrator seems less concerned about the child&rsquo;s illness than the clinicians who are providing care. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presenting signs and symptoms of Munchausen by proxy vary significantly. The most common presentations involve bleeding from various sites, seizures, central nervous system depression, and apnea (",
"      <a class=\"graphic graphic_table graphicRef59264 \" href=\"mobipreview.htm?15/56/16267\">",
"       table 1",
"      </a>",
"      ). When seizures or apnea are involved, the abuser is typically the only one to witness the",
"      <strong>",
"       onset",
"      </strong>",
"      of events, although other witnesses may observe the ongoing crisis, induced by the abuser. Children undergo repeated procedures including venipuncture, lumbar punctures, and surgical procedures in order to evaluate and treat reported illnesses; thus, medical personnel become unwitting co-abusers by extension. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although individual behaviors may vary, perpetrators of Munchausen by proxy commonly display several characteristics as listed in the table (",
"      <a class=\"graphic graphic_table graphicRef52225 \" href=\"mobipreview.htm?4/57/5020\">",
"       table 2",
"      </a>",
"      ). The perpetrator may fabricate symptoms which results in unnecessary medical evaluation and treatment or may induce illness with direct harm to the child, including death. &nbsp;(See",
"      <a class=\"local\" href=\"#H6\">",
"       'Associated features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Fabricated illness'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Induced illness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other diagnoses with features similar to Munchausen by proxy include physical child abuse, child neglect, and mental illness in the caregiver. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Establishing the diagnosis of Munchausen by proxy requires a multidisciplinary approach that includes the medical care team (physicians, nurses, social workers), hospital security, and hospital risk management (",
"      <a class=\"graphic graphic_table graphicRef65683 \" href=\"mobipreview.htm?13/62/14315\">",
"       table 3",
"      </a>",
"      ). Whenever possible, a multidisciplinary child protection team that includes a child abuse specialist or pediatrician with similar expertise should be consulted. Although laboratory studies may be necessary to exclude medical illness, unnecessary procedures should be avoided. Hospitalization is typically necessary. Clear evidence may include covert video surveillance of the caregiver inducing illness, laboratory studies, or a witnessed event. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of Munchausen by proxy must first ensure the safety of the child and requires the involvement of law enforcement and children's protective, and social services when suspected or confirmed.",
"     </li>",
"     <li>",
"      The disclosure of the diagnosis of Munchausen by proxy to the family should be done in a straightforward and supportive manner, with the emphasis on helping both the child and the parent or caregiver rather than eliciting a confession. Measures must be in place to prevent the caregiver from fleeing with the child during or after the conference. Psychiatric evaluation by a therapist familiar with Munchausen by proxy should be readily available for both the child (if age appropriate) and parents. In almost all instances, the child and siblings should be removed from the home and placed in state-supervised custody pending court-ordered review of the case.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/1\">",
"      Meadow R. Munchausen syndrome by proxy abuse perpetrated by men. Arch Dis Child 1998; 78:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/2\">",
"      ASHER R. Munchausen's syndrome. Lancet 1951; 1:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/3\">",
"      Meadow R, Lennert T. Munchausen by proxy or Polle syndrome: which term is correct? Pediatrics 1984; 74:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/4\">",
"      Meadow R. Munchausen syndrome by proxy. The hinterland of child abuse. Lancet 1977; 2:343.",
"     </a>",
"    </li>",
"    <li>",
"     Factitious disorder by proxy. In: Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text Revision, American Psychiatric Association, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/6\">",
"      Meadow R. What is, and what is not, 'Munchausen syndrome by proxy'? Arch Dis Child 1995; 72:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/7\">",
"      Stirling J Jr, American Academy of Pediatrics Committee on Child Abuse and Neglect. Beyond Munchausen syndrome by proxy: identification and treatment of child abuse in a medical setting. Pediatrics 2007; 119:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/8\">",
"      Ayoub CC, Alexander R, Beck D, et al. Position paper: definitional issues in Munchausen by proxy. Child Maltreat 2002; 7:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/9\">",
"      Schreier H. Munchausen by proxy defined. Pediatrics 2002; 110:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/10\">",
"      McClure RJ, Davis PM, Meadow SR, Sibert JR. Epidemiology of Munchausen syndrome by proxy, non-accidental poisoning, and non-accidental suffocation. Arch Dis Child 1996; 75:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/11\">",
"      Denny SJ, Grant CC, Pinnock R. Epidemiology of Munchausen syndrome by proxy in New Zealand. J Paediatr Child Health 2001; 37:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/12\">",
"      Rosenberg DA. Web of deceit: a literature review of Munchausen syndrome by proxy. Child Abuse Negl 1987; 11:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/13\">",
"      Meadow R. Different interpretations of Munchausen Syndrome by Proxy. Child Abuse Negl 2002; 26:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/14\">",
"      Bools C, Neale B, Meadow R. Munchausen syndrome by proxy: a study of psychopathology. Child Abuse Negl 1994; 18:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/15\">",
"      Bools CN, Neale BA, Meadow SR. Co-morbidity associated with fabricated illness (Munchausen syndrome by proxy). Arch Dis Child 1992; 67:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/16\">",
"      Souid AK, Keith DV, Cunningham AS. Munchausen syndrome by proxy. Clin Pediatr (Phila) 1998; 37:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/17\">",
"      Fisher GC, Mitchell I. Is Munchausen syndrome by proxy really a syndrome? Arch Dis Child 1995; 72:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/18\">",
"      Morley CJ. Practical concerns about the diagnosis of Munchausen syndrome by proxy. Arch Dis Child 1995; 72:528.",
"     </a>",
"    </li>",
"    <li>",
"     Lasher LJ. MBP overview and definitions. www.mbpexpert.com/definition.html (Accessed on November 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/20\">",
"      Meadow R. Management of Munchausen syndrome by proxy. Arch Dis Child 1985; 60:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/21\">",
"      Schreier HA, Libow JA. Munchausen by proxy syndrome: a modern pediatric challenge. J Pediatr 1994; 125:S110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/22\">",
"      Meadow R. Munchausen syndrome by proxy. Arch Dis Child 1982; 57:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/23\">",
"      Mullins ME, Cristofani CB, Warden CR, Cleary JF. Amitriptyline-associated seizures in a toddler with Munchausen-by-proxy. Pediatr Emerg Care 1999; 15:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/24\">",
"      Schreier H. On the importance of motivation in Munchausen by Proxy: the case of Kathy Bush. Child Abuse Negl 2002; 26:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/25\">",
"      Hall DE, Eubanks L, Meyyazhagan LS, et al. Evaluation of covert video surveillance in the diagnosis of munchausen syndrome by proxy: lessons from 41 cases. Pediatrics 2000; 105:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/26\">",
"      Meadow R. Non-accidental salt poisoning. Arch Dis Child 1993; 68:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/27\">",
"      Coulthard MG, Haycock GB. Distinguishing between salt poisoning and hypernatraemic dehydration in children. BMJ 2003; 326:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/28\">",
"      Kohl S, Pickering LK, Dupree E. Child abuse presenting as immunodeficiency disease. J Pediatr 1978; 93:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/29\">",
"      Schreier HA. Factitious disorder by proxy in which the presenting problem is behavioral or psychiatric. J Am Acad Child Adolesc Psychiatry 2000; 39:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/30\">",
"      Moszkowicz M, Bj&oslash;rnholm KI. Factitious illness by proxy presenting as anorexia and polydipsia by proxy. Acta Paediatr 1998; 87:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/31\">",
"      Woollcott P Jr, Aceto T Jr, Rutt C, et al. Doctor shopping with the child as proxy patient: a variant of child abuse. J Pediatr 1982; 101:297.",
"     </a>",
"    </li>",
"    <li>",
"     Waller D, Eisenberg L. School refusal i nchildhood: a psychiatric-pedatric perspective. In: Out of School, Hersov L, Berg I.  (Eds), Wiley, Chinchester 1980. p.209.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/33\">",
"      Wessely S, Wardle CJ. Mass sociogenic illness by proxy: parentally reported epidemic in an elementary school. Br J Psychiatry 1990; 157:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/34\">",
"      Warner JO, Hathaway MJ. Allergic form of Meadow's syndrome (Munchausen by proxy). Arch Dis Child 1984; 59:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/35\">",
"      Meadow R. Mothering to death. Arch Dis Child 1999; 80:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/36\">",
"      Rahman F, Young D, Whyte J. Mothering to death. Arch Dis Child 1999; 81:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/37\">",
"      Eminson DM, Postlethwaite RJ. Factitious illness: recognition and management. Arch Dis Child 1992; 67:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/38\">",
"      Libow JA, Schreier HA. Three forms of factitious illness in children: when is it Munchausen syndrome by proxy? Am J Orthopsychiatry 1986; 56:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/39\">",
"      Masterson J, Dunworth R, Williams N. Extreme illness exaggeration in pediatric patients: a variant of Munchausen's by Proxy? Am J Orthopsychiatry 1988; 58:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/40\">",
"      Brown P, Tierney C. Munchausen syndrome by proxy. Pediatr Rev 2009; 30:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/41\">",
"      Oster JR, Materson BJ, Rogers AI. Laxative abuse syndrome. Am J Gastroenterol 1980; 74:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/42\">",
"      Byard RW, Burnell RH. Covert video surveillance in Munchausen syndrome by proxy. Ethical compromise or essential technique? Med J Aust 1994; 160:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/43\">",
"      Spying on mothers. Lancet 1994; 343:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/44\">",
"      Foreman DM, Farsides C. Ethical use of covert videoing techniques in detecting Munchausen syndrome by proxy. BMJ 1993; 307:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/45\">",
"      Morley C. Concerns about using and interpreting covert video surveillance. BMJ 1998; 316:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/46\">",
"      Southall DP, Plunkett MC, Banks MW, et al. Covert video recordings of life-threatening child abuse: lessons for child protection. Pediatrics 1997; 100:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/47\">",
"      Berg B, Jones DP. Outcome of psychiatric intervention in factitious illness by proxy (Munchausen's syndrome by proxy). Arch Dis Child 1999; 81:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/48\">",
"      Davis P, McClure RJ, Rolfe K, et al. Procedures, placement, and risks of further abuse after Munchausen syndrome by proxy, non-accidental poisoning, and non-accidental suffocation. Arch Dis Child 1998; 78:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/49\">",
"      McGuire TL, Feldman KW. Psychologic morbidity of children subjected to Munchausen syndrome by proxy. Pediatrics 1989; 83:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/50\">",
"      Bools CN, Neale BA, Meadow SR. Follow up of victims of fabricated illness (Munchausen syndrome by proxy). Arch Dis Child 1993; 69:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36104/abstract/51\">",
"      Meadow R. ABC of child abuse. Munchausen syndrome by proxy. BMJ 1989; 299:248.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6608 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-EF0CD76C64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_16_36104=[""].join("\n");
var outline_f35_16_36104=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5956623\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Definitions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Associated features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Fabricated illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Induced illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Video surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5956623\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6608\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6608|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/56/16267\" title=\"table 1\">",
"      Presenting complaints Munchausen by proxy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/57/5020\" title=\"table 2\">",
"      Perpetrator characteristics Munchausen by proxy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/62/14315\" title=\"table 3\">",
"      Diagnosis Munchausen by proxy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/62/18408?source=related_link\">",
"      Child neglect and emotional abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/12/14538?source=related_link\">",
"      Etiology and evaluation of failure to thrive (undernutrition) in children younger than two years",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/21/7512?source=related_link\">",
"      Factitious disorder and Munchausen syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5450?source=related_link\">",
"      Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_16_36105="Overview of the routine management of the healthy newborn infant";
var content_f35_16_36105=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the routine management of the healthy newborn infant",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/16/36105/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/16/36105/contributors\">",
"     Tiffany M McKee-Garrett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/16/36105/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/16/36105/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/16/36105/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/16/36105/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/16/36105/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;After birth, most newborn infants require only routine care to make a successful transition to extrauterine life.",
"   </p>",
"   <p>",
"    The major components of routine care for the term (gestational age &ge;37 weeks) and late preterm (gestational age between 34 to 36",
"    <span class=\"nowrap\">",
"     6/7",
"    </span>",
"    weeks) neonate are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Delivery room and transitional care, including early bonding",
"     </li>",
"     <li>",
"      Newborn assessment including a comprehensive review of the maternal history and a complete physical examination",
"     </li>",
"     <li>",
"      Prophylaxis care to prevent serious disorders",
"     </li>",
"     <li>",
"      Family education",
"     </li>",
"     <li>",
"      Discharge evaluation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The routine management of the healthy newborn will be reviewed here. The assessment of the newborn is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/21/24922?source=see_link\">",
"     \"Assessment of the newborn infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, issues specific to the late preterm infant are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/11/22713?source=see_link\">",
"     \"Late preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DELIVERY ROOM CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;After delivery, immediate neonatal care includes drying the infant, clearing the airway of secretions, and providing warmth. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26346?source=see_link&amp;anchor=H8#H8\">",
"     \"Neonatal resuscitation in the delivery room\", section on 'Initial steps'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During this initial care, a delivery room assessment of the neonate's clinical status is quickly performed by addressing these questions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is the infant full-term?",
"     </li>",
"     <li>",
"      Is the infant breathing or crying?",
"     </li>",
"     <li>",
"      Does the infant have good muscle tone?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If yes is the answer to all the questions, the infant does not require further intervention and should be given to the mother. Healthy term or late preterm infants should remain with the mother to promote infant-maternal bonding by skin-to-skin contact and early initiation of breastfeeding.",
"   </p>",
"   <p>",
"    If the answer to any of the questions is no, then the infant requires further evaluation and intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]. The following interventions may be required and are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26346?source=see_link\">",
"     \"Neonatal resuscitation in the delivery room\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oxygen administration",
"     </li>",
"     <li>",
"      Positive pressure ventilation",
"     </li>",
"     <li>",
"      Chest compressions",
"     </li>",
"     <li>",
"      Use of resuscitative medications (eg, epinephrine)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Apgar score",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation is generally based upon the assignment of an Apgar score at one and five minutes of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/1\">",
"     1",
"    </a>",
"    ]. The following signs are given values of 0, 1, or 2 and added to compute the Apgar score. Scores may be determined using the Apgar score calculator (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?13/24/13697?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Heart rate",
"     </li>",
"     <li>",
"      Respiratory effort",
"     </li>",
"     <li>",
"      Muscle tone",
"     </li>",
"     <li>",
"      Reflex irritability",
"     </li>",
"     <li>",
"      Color",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    About 90 percent of all neonates have Apgar scores of 7 to 10, and generally require no further intervention. They usually have all of the following characteristics and can be admitted to the level 1 newborn nursery for routine care:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Term or late preterm gestation",
"     </li>",
"     <li>",
"      Spontaneous breathing or crying",
"     </li>",
"     <li>",
"      Good muscle tone",
"     </li>",
"     <li>",
"      Pink color",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infants with lower scores may require further evaluation and intervention including one percent of all neonates who require extensive resuscitative measures at birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/3\">",
"     3",
"    </a>",
"    ]. The care of these infants is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26346?source=see_link\">",
"     \"Neonatal resuscitation in the delivery room\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Transitional period",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transitional period between intrauterine and extrauterine life is during the first four to six hours of life after delivery. Physiological changes that occur during the transitional period include decreased pulmonary vascular resistance with increased blood flow to the lungs, lung expansion with clearance of alveolar fluid and improved oxygenation, and closure of the ductus arteriosus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/19/8502?source=see_link\">",
"     \"Physiologic transition from intrauterine to extrauterine life\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During this period of time, the clinical status of the infant should be assessed every 30 to 60 minutes to ensure further interventions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    evaluations beyond routine care are no longer required for successful transition to extrauterine life. The following clinical parameters are monitored beginning in the delivery room and continuing in either the nursery or mother's room:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Temperature &mdash; The normal axillary temperature should be between 36.5 to 37.5&ordm;C (97.7 to 99.5&ordm;F) for an infant in an open crib [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/1\">",
"       1",
"      </a>",
"      ]. Initial hyperthermia may be reflective of maternal fever or the intrauterine environment. Persistent hyperthermia or hypothermia may be indicative of sepsis. Hypothermia may contribute to metabolic disorders such as hypoglycemia or acidosis.",
"     </li>",
"     <li>",
"      Respiratory rate &mdash; The normal respiratory rate is 40 to 60 breaths per minute, which should be counted over a full minute. Tachypnea may be a sign of respiratory or cardiac disease. Apnea may be secondary to exposure to maternal medications (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/29/34262?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      and anesthesia), a sign of neurologic impairment, or sepsis.",
"     </li>",
"     <li>",
"      Heart rate &mdash; The normal heart rate is 120 to 160 beats per minute but may decrease to 85 to 90 per minute in some term infants during sleep. Heart rates that are too high or low may be indicative of underlying cardiac disease.",
"     </li>",
"     <li>",
"      Color &mdash; Central cyanosis (lips, tongue, and central trunk) may be indicative of respiratory or cardiac disease.",
"     </li>",
"     <li>",
"      Tone &mdash; Hypotonia may be secondary to exposure to maternal medications or fever [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/5\">",
"       5",
"      </a>",
"      ], be indicative of an underlying syndrome (Down syndrome), sepsis, or neurologic impairment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2442?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of neonatal encephalopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Respiratory disease and suspected cardiac disease in the newborn are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31511?source=see_link\">",
"     \"Overview of neonatal respiratory distress: Disorders of transition\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33482?source=see_link\">",
"     \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ROUTINE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A newborn should have a thorough evaluation performed within 24 hours of birth to identify any abnormality that would alter the normal newborn course or identify a medical condition that should be addressed (eg, anomalies, birth injuries, jaundice, cardiopulmonary disorders, or increased risk of sepsis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/3\">",
"     3",
"    </a>",
"    ]. The assessment of the newborn infant including review of the maternal, family, and prenatal history and a complete examination is discussed in detail separately. The assessment and management for neonatal sepsis are also presented. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/21/24922?source=see_link\">",
"     \"Assessment of the newborn infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the assessment of the newborn, the following routine procedures and ongoing evaluations are performed after birth to prevent serious disorders.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prophylactic eye care to prevent neonatal gonococcal ophthalmia",
"     </li>",
"     <li>",
"      Administration of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/21/15701?source=see_link\">",
"       vitamin K1",
"      </a>",
"      to prevent Vitamin K deficient bleeding (VKDB)",
"     </li>",
"     <li>",
"      Hepatitis B vaccination",
"     </li>",
"     <li>",
"      Umbilical cord care to prevent infection",
"     </li>",
"     <li>",
"      Monitoring for hyperbilirubinemia and hypoglycemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the United States, universal newborn screening for hearing loss, metabolic and genetic disorders, and congenitally acquired infectious disorders are routinely performed in all neonates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Eye care",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the neonate, the risk of contracting gonococcal conjunctivitis is markedly reduced by prophylactic administration of ophthalmic antibiotic agents shortly after birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/6\">",
"     6",
"    </a>",
"    ]. Ocular prophylaxis is safe, easy to administer, and an inexpensive method to prevent sight-threatening gonococcal ophthalmia. In the United States, the majority of states require prophylaxis against gonococcal ophthalmia neonatorum.(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/34/39462?source=see_link&amp;anchor=H6#H6\">",
"     \"Gonococcal infection in the newborn\", section on 'Ophthalmia neonatorum'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following are regimens recommended by the American Academy of Pediatrics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/6\">",
"     6",
"    </a>",
"    ] and the Centers for Disease Control and Prevention (CDC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      0.5 percent",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/11/38064?source=see_link\">",
"       erythromycin",
"      </a>",
"      ointment (1 cm ribbon in each eye)",
"     </li>",
"     <li>",
"      1 percent",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/38/28262?source=see_link\">",
"       tetracycline",
"      </a>",
"      ointment (1 cm ribbon in each eye)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/11/38064?source=see_link\">",
"     Erythromycin",
"    </a>",
"    ophthalmic ointment causes less chemical conjunctivitis than does",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/46/20194?source=see_link\">",
"     silver nitrate",
"    </a>",
"    solution. However, silver nitrate is more effective as a prophylaxis for penicillinase-producing Neisseria gonorrhoeae than erythromycin and should be used in areas where that organism is prevalent. One percent silver nitrate solution and 1 percent",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/38/28262?source=see_link\">",
"     tetracycline",
"    </a>",
"    are not commercially available in the United States.",
"   </p>",
"   <p>",
"    Povidone-iodine solution (2.5 percent) also may prevent ocular gonococcal infection with less toxicity and at lower cost than other agents, although further confirmatory studies are needed. This preparation also is",
"    <strong>",
"     not",
"    </strong>",
"    commercially available in the United States.",
"   </p>",
"   <p>",
"    In 2009, there was a shortage of 0.5 percent",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    ophthalmic ointment in the United States. As of December 2009, according to the Food and Drug Administration, erythromycin ophthalmic ointment is available in sufficient quantities to meet the historical demand for this product [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/8\">",
"     8",
"    </a>",
"    ]. However, it remains important for institutions to limit their orders to meet their immediate clinical needs until increased production rates produce sufficient amounts to restore inventory supplies.",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    ophthalmic ointment is not available, the Centers of Disease Control (CDC) recommends the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If 0.5 percent",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/11/38064?source=see_link\">",
"       erythromycin",
"      </a>",
"      ophthalmic ointment is not available, an acceptable alternative is 1 percent",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/15/35056?source=see_link\">",
"       azithromycin",
"      </a>",
"      ophthalmic solution (AzaSite). The recommended dose is 1 to 2 drops placed in the conjunctival sac of each eye, taking care to not touch the applicator tip to the infant. Because this is a solution, it is important to assure that the drops are placed properly, and a two person administration approach should be considered.",
"     </li>",
"     <li>",
"      If neither 0.5 percent",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/11/38064?source=see_link\">",
"       erythromycin",
"      </a>",
"      ophthalmic ointment or 1 percent",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/15/35056?source=see_link\">",
"       azithromycin",
"      </a>",
"      ophthalmic solution is available, other alternatives include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      0.3 percent",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"       gentamicin",
"      </a>",
"      ophthalmic ointment (Gentak)",
"     </li>",
"     <li>",
"      0.3 percent",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/39/22129?source=see_link\">",
"       tobramycin",
"      </a>",
"      ophthalmic ointment (Tobrex)",
"     </li>",
"     <li>",
"      If none of these are available, a fluoroquinolone ophthalmic ointment (0.3 percent",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/15/38128?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      ophthalmic ointment) can be used, but this is a less suitable alternative given data on possible gonococcal antimicrobial resistance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, there have been adverse reports associated with 0.3 percent",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    ophthalmic ointment of lid swelling and dermatitis, appearing a few days after ointment application [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/10\">",
"     10",
"    </a>",
"    ]. Most cases have been mild and have not required additional treatment. Some cases were much more severe with eyelid discharge, blistering, erythema, and swelling, which have prompted some clinicians to suggest that gentamicin ophthalmic ointment not be used as an alternative for neonatal ocular prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/11\">",
"     11",
"    </a>",
"    ]. If gentamicin ointment is used, excess ointment from the eyelids should be removed by delivery room staff to prevent and reduce the severity of this complication.",
"   </p>",
"   <p>",
"    Since there are no efficacy data for any of the above suggested alternatives, providers should be alert to the possibility of failure of prophylaxis. At the first postnatal visit within 48 to 72 hours after discharge, the infant should be examined closely for ophthalmia neonatorum. Infants with ophthalmia neonatorum should be tested for Neisseria gonorrhoeae infection and should be reported to the local health department and CDC as a prophylaxis failure.",
"   </p>",
"   <p>",
"    The CDC has also recommended that hospitals:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Routinely review their supply of 0.5 percent",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/11/38064?source=see_link\">",
"       erythromycin",
"      </a>",
"      ophthalmic ointment.",
"     </li>",
"     <li>",
"      Reserve 0.5 percent",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/11/38064?source=see_link\">",
"       erythromycin",
"      </a>",
"      ophthalmic ointment for only neonatal prophylaxis.",
"     </li>",
"     <li>",
"      If there are severely low supplies (ie, depletion within the week), contact their wholesale distributor or call Bausch and Lomb customer service, 1-800-323-0000.",
"     </li>",
"     <li>",
"      If supplies are not available, contact the FDA drug shortage email account (",
"      <a class=\"external\" href=\"mailto:drugshortages@fda.hhs.gov\">",
"       drugshortages@fda.hhs.gov",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ocular infections in newborns caused by Chlamydia trachomatis are common in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/6\">",
"     6",
"    </a>",
"    ]. The agents used for gonococcal prophylaxis are not effective in preventing neonatal chlamydial conjunctivitis. Povidone-iodine appears to be significantly more effective against C. trachomatis than",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/46/20194?source=see_link\">",
"     silver nitrate",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;After wiping each eyelid with sterile cotton gauze, the prophylactic agent is placed in each of the lower conjunctival sacs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/6\">",
"     6",
"    </a>",
"    ]. The agent should be spread by gentle massage of the eyelids, and excess solution or ointment can be wiped away after one minute. The eyes should",
"    <strong>",
"     not",
"    </strong>",
"    be irrigated after the application because doing so may reduce efficacy.",
"   </p>",
"   <p>",
"    Eye prophylaxis should be performed shortly after birth within the first hour of life in all infants, regardless of whether they are delivered vaginally or by cesarean section. &nbsp;If prophylaxis is delayed, a monitoring system should be established to ensure that all infants receive prophylaxis. The efficacy of longer delays is not known.",
"   </p>",
"   <p>",
"    The principal side effect is chemical (noninfectious) conjunctivitis. This condition typically appears within the first 24 hours of age and resolves by 48 hours. It is most often seen after application of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/46/20194?source=see_link\">",
"     silver nitrate",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Vitamin K",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/21/15701?source=see_link\">",
"     vitamin K1",
"    </a>",
"    is given to newborns shortly after birth to prevent vitamin K deficient bleeding (VKDB), previously referred to as hemorrhagic disease of the newborn. In a systematic review of trials that compared either oral or intramuscular administration of vitamin K to placebo, vitamin K1 oxide improved biochemical indices of coagulation status during the first week after birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/12\">",
"     12",
"    </a>",
"    ]. In the single trial of intramuscular vitamin K, vitamin K compared to placebo was more effective in preventing VKDB. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15960?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of vitamin K\", section on 'Prevention of vitamin K deficient bleeding in newborns'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/21/15701?source=see_link\">",
"     Vitamin K1",
"    </a>",
"    can be given either orally or intramuscularly. However, currently used oral regimens are less effective than a single intramuscular dose of vitamin K in preventing late-onset VKDB (defined as bleeding disorder due to vitamin K deficiency in infants between two weeks and two months of age) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. This was illustrated in a review of surveillance data from four countries that used oral vitamin K prophylaxis in a variety of different regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/16\">",
"     16",
"    </a>",
"    ]. The rate of late-onset VKDB was 1.2 to 1.8 per 100,000 births for oral prophylaxis versus no reported cases of late VKDB in infants who received vitamin K intramuscularly.",
"   </p>",
"   <p>",
"    Several small studies suggested that intramuscular preparations of vitamin K may increase the risk of childhood cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], however, subsequent studies have failed to show an association between vitamin K and childhood cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics (AAP) concluded that intramuscular prophylaxis of vitamin K is superior to oral administration because it prevents both early (within the first week of life) and late VKDB, and the risk of cancer from intramuscular vitamin K is unproven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/23\">",
"     23",
"    </a>",
"    ]. Based upon these conclusions, the AAP recommends vitamin K1 be given to all newborns as a single intramuscular dose of 0.5 to 1 mg. An oral suspension of vitamin K is not available in the United States.",
"   </p>",
"   <p>",
"    Oral prophylaxis with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/21/15701?source=see_link\">",
"     vitamin K1",
"    </a>",
"    (2 mg per dose) is generally given at the first feeding and then at one, four, and eight weeks. Small daily oral doses of vitamin K may approach the efficacy level of parenteral administration, but further studies are needed for confirmation. In some countries, oral administration of vitamin K has been advocated because it is easier to administer and is less costly. Efforts continue to develop an oral regimen that is equally effective as the single intramuscular dose of vitamin K.",
"   </p>",
"   <p>",
"    Infants who are premature, receiving antibiotics, or have liver disease or diarrhea, should receive intramuscular prophylaxis because they may have decreased absorption of the oral preparation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Preterm infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above AAP recommendation to administer intramuscular vitamin K to newborns is based upon evidence obtained in full term infants. The optimal dosing in preterm infants is unknown. In one small controlled trial of infants less than 32 weeks gestation, intramuscular prophylaxis of 0.2 mg provided adequate vitamin K supplementation as demonstrated by normal undercarboxylated prothrombin concentrations and no evidence of clinical bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/24\">",
"     24",
"    </a>",
"    ]. A larger intramuscular dose of 0.5 mg resulted in higher vitamin K1 and vitamin K1 2,3-epoxide concentrations, suggesting that an excess of vitamin K1 was administered. Further studies with a larger number of patients are required to determine whether the lower intramuscular vitamin K dose of 0.2 mg is sufficient in preterm infants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Umbilical cord",
"    </span>",
"    &nbsp;&mdash;&nbsp;The postpartum care of the umbilical cord in reducing the risk of infection (omphalitis) is dependent on the quality of the care at delivery and postnatally. If there is an increased risk for omphalitis especially in a clinical setting of low resources, the use of antiseptic agents (eg, triple dye, alcohol,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/36/9795?source=see_link\">",
"     silver sulfadiazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/9/44180?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    ) for cord care is an excellent and inexpensive option that reduces neonatal morbidity and mortality. However, in developed countries where aseptic care is routine in the clamping and cutting of the umbilical cord, additional topical care beyond dry-cord care is not needed to prevent omphalitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/47/41721?source=see_link&amp;anchor=H12#H12\">",
"     \"Care of the umbilicus and management of umbilical disorders\", section on 'Cord care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hepatitis B vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Universal vaccination of newborns regardless of maternal hepatitis B virus surface antigen (HBsAg) status is recommended (",
"    <a class=\"graphic graphic_table graphicRef60075 \" href=\"mobipreview.htm?1/60/1998\">",
"     table 1",
"    </a>",
"    ). Infants of HBsAg-positive mothers should receive hepatitis B immunoglobulin (HBIG) in addition to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/17/15639?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    (HBV) shortly after birth, preferably within 12 hours of age (",
"    <a class=\"graphic graphic_table graphicRef76345 \" href=\"mobipreview.htm?23/39/24189\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=see_link&amp;anchor=H10#H10\">",
"     \"Standard immunizations for children and adolescents\", section on 'Hepatitis B vaccine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Newborn screening",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H696434\">",
"    <span class=\"h3\">",
"     Hearing loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Universal screening for hearing loss is recommended to detect infants with hearing loss. It is legally mandated in most of the United States. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27865?source=see_link\">",
"     \"Screening the newborn for hearing loss\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H696441\">",
"    <span class=\"h3\">",
"     Metabolic and genetic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition, screening for disorders that are threatening to life or long-term health in asymptomatic newborns is recommended so that interventions can be initiated to prevent or reduce morbidity and mortality. Universal screening of newborns for congenitally acquired infections, metabolic disorders, and genetic disorders, including phenylketonuria, congenital hypothyroidism, galactosemia, toxoplasmosis, and hemoglobinopathies occurs throughout the entire United States. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/2/2088?source=see_link\">",
"     \"Newborn screening\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H696448\">",
"    <span class=\"h3\">",
"     Critical congenital heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2011, a report from the United States Health and Human Services Secretary&rsquo;s Advisory Committee on Heritable Disorders in Newborns and Children recommended routine pulse oximetry newborn screening to detect infants with critical congenital heart disease (CHD), defined as CHD requiring surgery or catheter based intervention in the first year of life. This report has been endorsed by the American Heart Association, American Academy of Pediatrics, and the American College of Cardiology Foundation. The implementation of a universal screening program has been challenging because of the costs to train personnel needed to perform testing and establish diagnostic services to perform and interpret high-quality echocardiography in a timely manner for infants with positive test results. However, several states currently require mandatory pulse oximetry screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33482?source=see_link&amp;anchor=H2707728#H2707728\">",
"     \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\", section on 'Pulse oximetry screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants should be fed early and frequently to avoid hypoglycemia. The frequency, duration, and volume of feeds will be dependent upon whether the infant is breastfed or receives formula. Each feeding should be recorded, and if the infant is fed formula, the volume of feeding should also be recorded.",
"   </p>",
"   <p>",
"    Breastfeeding is recommended because of its increased benefits for both the infant and mother compared to formula feeding, except when medically contraindicated, such as in infants with mothers with human immunodeficiency viral (HIV) infection or in some cases of maternal drug abuse. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/47/32505?source=see_link\">",
"     \"Infant benefits of breastfeeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/27/1461?source=see_link\">",
"     \"Maternal and economic benefits of breastfeeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/4/28746?source=see_link&amp;anchor=H7#H7\">",
"     \"Infants of mothers with substance abuse\", section on 'Breastfeeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breastfed infants should be fed as soon as possible after delivery, preferably in the delivery room. They should receive 8 to 12 feeds per day during the newborn hospitalization. Rooming-in, skin-to-skin contact, frequent demand feedings in the early postpartum period, and lactation support increase the rate of successful breastfeeding. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/39/42616?source=see_link\">",
"       \"Breastfeeding: Parental education and support\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8217?source=see_link\">",
"       \"Initiation of breastfeeding\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Healthy infants who are fed formula should be offered standard 20",
"      <span class=\"nowrap\">",
"       cal/oz",
"      </span>",
"      iron containing formula. They are fed on demand, but the duration between feedings should not exceed four hours. The volume of feedings should be at least 0.5 to 1 oz per feed during the first few days of life.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight loss is normal after delivery particularly in the breastfed infant. However, weight loss beyond 7 percent requires medical attention and should be evaluated with a complete feeding assessment. Normal infants stop losing weight by five days of age and typically regain their birth weight by 10 to 14 days. The expected weight loss is up to 7 percent. Greater weight loss in the breastfed infant should prompt ongoing lactation assessments and interventions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8217?source=see_link&amp;anchor=H19#H19\">",
"     \"Initiation of breastfeeding\", section on 'Weight loss'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Glucose screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although neonatal hypoglycemia may contribute to brain injury, healthy asymptomatic term infants born after an uncomplicated pregnancy and delivery are at a low risk for significant hypoglycemia. As a result, blood glucose measurement is not routinely performed in these neonates.",
"   </p>",
"   <p>",
"    Monitoring of serum glucose in the normal nursery is performed in the following infants who are at risk for significant hypoglycemia.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Premature infants",
"     </li>",
"     <li>",
"      Infants who are large or small for gestational age",
"     </li>",
"     <li>",
"      Infants of diabetic mothers",
"     </li>",
"     <li>",
"      Infants whose mothers were treated with beta adrenergic or oral hypoglycemic agents",
"     </li>",
"     <li>",
"      Infants who require intensive care",
"     </li>",
"     <li>",
"      Infants with polycythemia",
"     </li>",
"     <li>",
"      Infants with symptoms consistent with hypoglycemia such as jitteriness, tremors, hypotonia, irritability, lethargy, stupor, apnea, poor feeding, hypothermia or seizures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations, evaluation, and management of neonatal hypoglycemia are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17673?source=see_link\">",
"     \"Neonatal hypoglycemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Newborn circumcision",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risks, benefits, and procedures for newborn circumcision are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41705?source=see_link\">",
"     \"Neonatal circumcision: Risks and benefits\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/57/15256?source=see_link\">",
"     \"Techniques for neonatal circumcision\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hyperbilirubinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperbilirubinemia with a total serum bilirubin level greater than 25",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    (428",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    is associated with an increased risk for bilirubin-induced neurologic dysfunction (BIND). As a result, during the birth hospitalization, infants should be routinely assessed every 8 to 12 hours and at discharge for the presence of jaundice. In patients who present with jaundice within the first 24 hours of life, or who have jaundice in excess for their age, bilirubin measurement should be performed either by transcutaneous bilirubin or total serum bilirubin measurement. Because visual assessment is not as reliable as measurement of total serum bilirubin, most birthing centers include routine bilirubin testing either by transcutaneous bilirubin or total serum bilirubin measurement. The most reliable predictor for subsequent development of significant hyperbilirubinemia combines a predischarge bilirubin screen with an assessment of risk factors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/39/11898?source=see_link&amp;anchor=H4#H4\">",
"     \"Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Which infants require evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations, evaluation, and management of neonatal hyperbilirubinemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/63/25593?source=see_link\">",
"     \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/39/11898?source=see_link\">",
"     \"Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/59/21434?source=see_link\">",
"     \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Education",
"    </span>",
"    &nbsp;&mdash;&nbsp;The parents or primary care giver should receive training and demonstrate competence or understanding of the following infant care tasks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The importance and benefits of breastfeeding. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/39/42616?source=see_link\">",
"       \"Breastfeeding: Parental education and support\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/47/32505?source=see_link\">",
"       \"Infant benefits of breastfeeding\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/27/1461?source=see_link\">",
"       \"Maternal and economic benefits of breastfeeding\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Positioning the infant and determining adequate latch-on and swallowing, if breastfeeding. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8217?source=see_link\">",
"       \"Initiation of breastfeeding\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Appropriate frequency of urination, and defecation and appearance of urine and stool.",
"     </li>",
"     <li>",
"      Cord, skin, and genital care.",
"     </li>",
"     <li>",
"      Recognition of the signs of common neonatal illnesses, particularly hyperbilirubinemia and sepsis.",
"     </li>",
"     <li>",
"      Proper infant safety, including supine sleeping position, and installation and use of car safety seat.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     LENGTH OF HOSPITAL STAY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal length of stay varies for each mother-infant pair and should be long enough to permit detection of early neonatal problems and to ensure that the family is able and prepared to care for the infant at home [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/26\">",
"     26",
"    </a>",
"    ]. Factors involved in this decision include the health of the mother, the health and stability of the infant, the ability and confidence of the mother to care for the infant, the adequacy of support systems at home, and access to appropriate follow-up care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All efforts should be made to keep the infant-mother dyad together to promote maternal-infant bonding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Discharge criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decision for discharge is made jointly with the family, and the obstetric and neonatal care providers and is based upon the perception that the infant-mother dyad are ready for discharge. Factors associated with a need for increased hospital stay include first time mother, chronic maternal illness, in-hospital neonatal illness, breastfeeding, mothers with inadequate prenatal care and poor social support, and black non-Hispanic maternal ethnicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics Committee on Fetus and Newborn issued the following recommended minimum criteria and conditions that should be met before discharge of the newborn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No neonatal abnormality requiring continued hospitalization was detected during the hospital course and physical examination at discharge. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/21/24922?source=see_link\">",
"       \"Assessment of the newborn infant\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The infant's vital signs are within normal ranges and are stable for at least 12 hours before discharge (respiratory rate &lt;60 per min; heart rate between 100 and 160 beats per minute; axillary temperature 36.5 to 37.4&ordm;C [97.7 to 99.3&ordm;F]).",
"     </li>",
"     <li>",
"      The infant has urinated and passed at least one stool spontaneously. Almost all term infants will have urinated and passed at least one stool by the first 24 hours of life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The infant has completed at least two successful feedings and is able to coordinate sucking, swallowing, and breathing while feeding. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/4/21576?source=see_link\">",
"       \"Sucking and swallowing disorders in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the infant was circumcised, there is no evidence of excessive bleeding at the circumcision site for at least two hours.",
"     </li>",
"     <li>",
"      If the infant was jaundiced, the clinical significance has been determined and appropriate plans for management and follow-up have been instituted. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/39/11898?source=see_link\">",
"       \"Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The infant has been screened and monitored for sepsis based upon maternal risk factors and guidelines for the prevention of perinatal group B streptococcal disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19354?source=see_link\">",
"       \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/31/2552?source=see_link&amp;anchor=H5#H5\">",
"       \"Management of the infant whose mother has received group B streptococcal chemoprophylaxis\", section on 'Management approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The mother has received training and demonstrated competency in the care of her infant as described above. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Education'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Family members or other support persons, including health care professionals, are available to the mother and her infant after discharge.",
"     </li>",
"     <li>",
"      Maternal test results were reviewed including maternal syphilis, hepatitis B surface antigen status, and, in some states, HIV screening. When clinically indicated, test results for cord or infant blood-type, and neonatal direct Coombs test results were obtained and reviewed. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/21/24922?source=see_link\">",
"       \"Assessment of the newborn infant\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Initial",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/17/15639?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      is administered. Hepatitis B immunoglobulin also is given to infants with mothers who are hepatitis B virus surface antigen positive. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=see_link&amp;anchor=H10#H10\">",
"       \"Standard immunizations for children and adolescents\", section on 'Hepatitis B vaccine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hearing and metabolic screening has been completed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27865?source=see_link\">",
"       \"Screening the newborn for hearing loss\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/2/2088?source=see_link\">",
"       \"Newborn screening\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Family, environmental, and social risk factors have been assessed and addressed (eg, substance abuse, child abuse or neglect, domestic violence, mental illness, lack of social support, lack of reliable income).",
"     </li>",
"     <li>",
"      Barriers to follow-up care are assessed and addressed (eg, transportation, telephone communication).",
"     </li>",
"     <li>",
"      A medical home for continuing infant care has been identified and timely communication of pertinent birth hospitalization information has been sent to the care providers of the medical home. If the infant is discharged before 48 hours after delivery, a follow-up appointment should occur at the medical home by a licensed health care professional no later than 72 hours after discharge and within 48 hours if there are identified risk factors. If an appropriately timed follow-up appointment cannot be ensured than discharge should be deferred until an appointment can be made.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These criteria are generally not achieved before the infant is 48 hours of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/26\">",
"     26",
"    </a>",
"    ]. Consideration of discharge before 48 hours of age should be limited to singleton infants who are born between 38 and 42 weeks of gestation, are appropriate weight for gestational age, and who meet the above criteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Discharge legislation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, because of concerns that early discharge could adversely affect maternal and infant health outcomes, both state and federal governments (Newborns' and Mothers' Health Protection Act [NMHPA]) passed postpartum discharge laws in the late 1990s to prevent extremely short length of hospital stay (LOHS). In general, these laws require insurance plans to cover postpartum stays of up to 48 hours for infants born by vaginal deliveries and up to 96 hours for cesarean deliveries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/31\">",
"     31",
"    </a>",
"    ]. The impact of legislation ensuring insurance coverage for a minimum of 48 hours has increased the LOHS of newborn infants and their mothers and appears to have decreased neonatal readmission rates and emergency room visits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     FOLLOW-UP VISIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A follow-up visit can take place in the home or clinical setting as long as the health care professional is competent in assessing newborns and communicates the results of the evaluation to the infant's physician.",
"   </p>",
"   <p>",
"    The follow-up visit includes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assess the general health of the neonate &mdash; Weigh the infant, assess for signs of dehydration and extent of jaundice, identify new problems, review feeding pattern including stool and urine output",
"     </li>",
"     <li>",
"      Assess the quality of mother-infant interaction",
"     </li>",
"     <li>",
"      Assess infant behavior",
"     </li>",
"     <li>",
"      Reinforce maternal and family education in infant care for feeding, supine sleeping position, child safety seats, and the benefits of breastfeeding (if appropriate)",
"     </li>",
"     <li>",
"      Review results of outstanding laboratory tests including the newborn screen",
"     </li>",
"     <li>",
"      Perform any necessary tests such as bilirubin check in an infant with clinically significant jaundice",
"     </li>",
"     <li>",
"      Verify the plan for health care maintenance and the medical home",
"     </li>",
"     <li>",
"      Assess parental well-being including any indications of post-partum depression in the mother (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/11/20666?source=see_link\">",
"       \"Postpartum blues and depression\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     READMISSIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite enactment of the Newborns' and Mothers' Health Protection Act, potentially preventable readmissions of newborns continue to occur. This was illustrated in an analysis of 2540 newborns readmitted in the first 10 days of life who were identified from clinical discharge records collected by the Pennsylvania Health Care Cost Containment Council (PHC4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/16/36105/abstract/34\">",
"     34",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mean time to readmission was 111 hours since birth and 62 hours since nursery discharge",
"     </li>",
"     <li>",
"      Jaundice was the most common diagnosis occurring in 92 percent of the infants. The remaining infants were readmitted for dehydration, feeding problems,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      associated electrolyte abnormalities.",
"     </li>",
"     <li>",
"      Multivariate analysis demonstrated that infants were more likely to be readmitted with first-time compared to experienced mothers, mothers of Asian or Pacific Islander ancestry compared to other races, older mothers greater than 30 years of age compared to younger mothers, or mothers with diabetes or pregnancy-induced hypertension. In addition, nursery length of stay less than &lt;72 hours and prematurity also increased the risk of readmission.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results identified several predictors of newborn readmission that appear to be associated with early discharge, inexperienced parenting, difficulty establishing infant feeding, and in Asian and Pacific Islander infants, who have an increased risk of hyperbilirubinemia. These findings may be useful in providing additional support for at-risk families and anticipatory care, thereby decreasing the need for readmission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/31/31218?source=see_link\">",
"       \"Patient information: Newborn appearance (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most newborn infants make a successful transition to extrauterine life and require only routine care immediately after birth.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediately after an uncomplicated delivery, routine delivery care includes drying the infant, clearing the airway of secretions, and providing warmth. About 90 percent of infants will not require further intervention in the delivery room, and these infants should be given to their mothers for skin-to-skin contact. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Delivery room care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During the transitional period (first four to six hours of life), optimal routine care, which begins in the delivery room, includes promoting early bonding with skin-to-skin contact and early initiation of breastfeeding, and monitoring the clinical status of the infant every 30 to 60 minutes to determine whether further intervention is required. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Transitional period'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine care includes a thorough evaluation performed within 24 hours of birth to identify any abnormality that would alter the normal newborn course or identify a medical condition that should be addressed during the first days of life. The assessment includes a review of the maternal, family, and prenatal history and a complete examination. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/21/24922?source=see_link\">",
"       \"Assessment of the newborn infant\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend that all neonates are treated with an ophthalmic antibiotic agent shortly after birth to prevent gonococcal conjunctivitis (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). In our practice we use 0.5 percent",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/11/38064?source=see_link\">",
"       erythromycin",
"      </a>",
"      ointment (1 cm ribbon in each eye). Alternative medications, which are not available in the United States, include 1 percent",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/46/20194?source=see_link\">",
"       silver nitrate",
"      </a>",
"      solution, 1 percent",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/38/28262?source=see_link\">",
"       tetracycline",
"      </a>",
"      ointment, and 2.5 percent povidone-iodine solution. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Eye care'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/34/39462?source=see_link&amp;anchor=H6#H6\">",
"       \"Gonococcal infection in the newborn\", section on 'Ophthalmia neonatorum'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend that all neonates receive prophylactic administration of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/21/15701?source=see_link\">",
"       vitamin K1",
"      </a>",
"      oxide to prevent Vitamin K deficient bleeding (VKDB) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We recommend intramuscular versus oral preparations of vitamin K because of the superiority of the intramuscular route for prevention of both early and late VKDB (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Vitamin K'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend hepatitis B vaccination (HBV) of all newborns regardless of maternal hepatitis B virus surface antigen (HBsAg) status to prevent HB infection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We recommend that infants of HBsAg-positive mothers receive both hepatitis B immunoglobulin (HBIB) and HBV shortly after birth (",
"      <a class=\"graphic graphic_table graphicRef76345 \" href=\"mobipreview.htm?23/39/24189\">",
"       table 2",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=see_link&amp;anchor=H10#H10\">",
"       \"Standard immunizations for children and adolescents\", section on 'Hepatitis B vaccine'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=see_link\">",
"       \"Hepatitis B virus vaccination\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the United States, universal newborn screening for hearing loss and disorders that are threatening to life or long-term health is implemented in all fifty states. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27865?source=see_link\">",
"       \"Screening the newborn for hearing loss\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/2/2088?source=see_link\">",
"       \"Newborn screening\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Routine care includes assessing infants for hyperbilirubinemia and hypoglycemia, which may result in significant morbidity. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Glucose screening'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Hyperbilirubinemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Minimum criteria and conditions established by the American Academy of Pediatrics should be met prior to discharge. These include normal and stable vital signs for at least 12 hours before discharge, evidence of urination and defecation, completion of two successful feedings, no physical abnormalities requiring continued care, no evidence of excessive bleeding (especially in infants who are circumcised), and successful training of the family to provide ongoing care at home. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Discharge criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the United States, legislation requires insurance plans to cover postpartum stays up to 48 hours for infants born by vaginal deliveries and up to 96 hours for cesarean deliveries with complications. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Discharge legislation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At discharge, a medical home should be identified and an appropriately timed follow-up visit should be made. Infants who are discharged before 48 hours after delivery should be assessed within 48 hours, and no later than 72 hours after discharge. The follow-up visit should be include assessment of the general health of the infant, the infant-mother interaction, parent's well-being, and infant behavior, verification of ongoing health care, and parental education. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Follow-up visit'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5553016\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Lori Sielski, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Academy of Pediatrics, American College of Obstetricians and Gynecologists. Guidelines for Perinatal Care, 6th ed, American Academy of Pediatrics and American College of Obstetricians, Elk Grove Village, IL.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/2\">",
"      Kattwinkel J, Perlman JM, Aziz K, et al. Neonatal resuscitation: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Pediatrics 2010; 126:e1400.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Overview and principles of resuscitation. In: Textbook of Neonatal Resuscitation, 5th ed, Kattwinkel J (Ed), American Academy of Pediatrics, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/4\">",
"      American Heart Association, American Academy of Pediatrics. 2005 American Heart Association (AHA) guidelines for cardiopulmonary resuscitation (CPR) and emergency cardiovascular care (ECC) of pediatric and neonatal patients: neonatal resuscitation guidelines. Pediatrics 2006; 117:e1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/5\">",
"      Greenwell EA, Wyshak G, Ringer SA, et al. Intrapartum temperature elevation, epidural use, and adverse outcome in term infants. Pediatrics 2012; 129:e447.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Prevention of neonatal ophthalmia. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering, LK (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.880.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/7\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration. Current drug shortages. file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050792. (Accessed January 20, 2010).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. CDC Guidance on Shortage of Erythromycin (0.5%) Ophthalmic Ointment - September 2009. file://www.cdc.gov/std/treatment/2006/erythromycinOintmentShortage.htm (Accessed January 20, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/10\">",
"      Binenbaum G, Bruno CJ, Forbes BJ, et al. Periocular ulcerative dermatitis associated with gentamicin ointment prophylaxis in newborns. J Pediatr 2010; 156:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/11\">",
"      Nathawad R, Mendez H, Ahmad A, et al. Severe ocular reactions after neonatal ocular prophylaxis with gentamicin ophthalmic ointment. Pediatr Infect Dis J 2011; 30:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/12\">",
"      Puckett RM, Offringa M. Prophylactic vitamin K for vitamin K deficiency bleeding in neonates. Cochrane Database Syst Rev 2000; :CD002776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/13\">",
"      Wariyar U, Hilton S, Pagan J, et al. Six years' experience of prophylactic oral vitamin K. Arch Dis Child Fetal Neonatal Ed 2000; 82:F64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/14\">",
"      von Kries R, Hachmeister A, G&ouml;bel U. Can 3 oral 2 mg doses of vitamin K effectively prevent late vitamin K deficiency bleeding? Eur J Pediatr 1999; 158 Suppl 3:S183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/15\">",
"      Zipursky A. Prevention of vitamin K deficiency bleeding in newborns. Br J Haematol 1999; 104:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/16\">",
"      Cornelissen M, von Kries R, Loughnan P, Schubiger G. Prevention of vitamin K deficiency bleeding: efficacy of different multiple oral dose schedules of vitamin K. Eur J Pediatr 1997; 156:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/17\">",
"      Golding J, Paterson M, Kinlen LJ. Factors associated with childhood cancer in a national cohort study. Br J Cancer 1990; 62:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/18\">",
"      Golding J, Greenwood R, Birmingham K, Mott M. Childhood cancer, intramuscular vitamin K, and pethidine given during labour. BMJ 1992; 305:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/19\">",
"      Passmore SJ, Draper G, Brownbill P, Kroll M. Case-control studies of relation between childhood cancer and neonatal vitamin K administration. BMJ 1998; 316:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/20\">",
"      Klebanoff MA, Read JS, Mills JL, Shiono PH. The risk of childhood cancer after neonatal exposure to vitamin K. N Engl J Med 1993; 329:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/21\">",
"      Carstensen J. Intramuscular vitamin K and childhood cancer. BMJ 1992; 305:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/22\">",
"      Ross JA, Davies SM. Vitamin K prophylaxis and childhood cancer. Med Pediatr Oncol 2000; 34:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/23\">",
"      American Academy of Pediatrics Committee on Fetus and Newborn. Controversies concerning vitamin K and the newborn. American Academy of Pediatrics Committee on Fetus and Newborn. Pediatrics 2003; 112:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/24\">",
"      Clarke P, Mitchell SJ, Wynn R, et al. Vitamin K prophylaxis for preterm infants: a randomized, controlled trial of 3 regimens. Pediatrics 2006; 118:e1657.",
"     </a>",
"    </li>",
"    <li>",
"     CCHD Screening Map. file://www.cchdscreeningmap.com/ (Accessed on November 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/26\">",
"      American Academy of Pediatrics. Committee on Fetus and Newborn. Hospital stay for healthy term newborns. Pediatrics 2010; 125:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/27\">",
"      Britton JR, Baker A, Spino C, Bernstein HH. Postpartum discharge preferences of pediatricians: results from a national survey. Pediatrics 2002; 110:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/28\">",
"      Bernstein HH, Spino C, Baker A, et al. Postpartum discharge: do varying perceptions of readiness impact health outcomes? Ambul Pediatr 2002; 2:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/29\">",
"      Clark DA. Times of first void and first stool in 500 newborns. Pediatrics 1977; 60:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/30\">",
"      Erenberg A, Lemons J, Sia C, et al. Newborn and infant hearing loss: detection and intervention.American Academy of Pediatrics. Task Force on Newborn and Infant Hearing, 1998- 1999. Pediatrics 1999; 103:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/31\">",
"      Liu Z, Dow WH, Norton EC. Effect of drive-through delivery laws on postpartum length of stay and hospital charges. J Health Econ 2004; 23:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/32\">",
"      Datar A, Sood N. Impact of postpartum hospital-stay legislation on newborn length of stay, readmission, and mortality in California. Pediatrics 2006; 118:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/33\">",
"      Meara E, Kotagal UR, Atherton HD, Lieu TA. Impact of early newborn discharge legislation and early follow-up visits on infant outcomes in a state Medicaid population. Pediatrics 2004; 113:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/16/36105/abstract/34\">",
"      Paul IM, Lehman EB, Hollenbeak CS, Maisels MJ. Preventable newborn readmissions since passage of the Newborns' and Mothers' Health Protection Act. Pediatrics 2006; 118:2349.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5068 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-BC92F1AF1C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_16_36105=[""].join("\n");
var outline_f35_16_36105=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DELIVERY ROOM CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Apgar score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Transitional period",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ROUTINE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Eye care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Vitamin K",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Preterm infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Umbilical cord",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hepatitis B vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Newborn screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H696434\">",
"      - Hearing loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H696441\">",
"      - Metabolic and genetic disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H696448\">",
"      - Critical congenital heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Feeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Weight loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Glucose screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Newborn circumcision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      LENGTH OF HOSPITAL STAY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Discharge criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Discharge legislation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      FOLLOW-UP VISIT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      READMISSIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5553016\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5068\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5068|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/60/1998\" title=\"table 1\">",
"      Recom doses of hepB vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24189\" title=\"table 2\">",
"      HBV immunoprophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?13/24/13697?source=related_link\" title=\"calculator 1\">",
"      Calculator: Apgar score",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/21/24922?source=related_link\">",
"      Assessment of the newborn infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/39/42616?source=related_link\">",
"      Breastfeeding: Parental education and support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/47/41721?source=related_link\">",
"      Care of the umbilicus and management of umbilical disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19354?source=related_link\">",
"      Chemoprophylaxis for the prevention of neonatal group B streptococcal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2442?source=related_link\">",
"      Clinical features, diagnosis, and treatment of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/63/25593?source=related_link\">",
"      Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33482?source=related_link\">",
"      Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/39/11898?source=related_link\">",
"      Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/34/39462?source=related_link\">",
"      Gonococcal infection in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/47/32505?source=related_link\">",
"      Infant benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/4/28746?source=related_link\">",
"      Infants of mothers with substance abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8217?source=related_link\">",
"      Initiation of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/11/22713?source=related_link\">",
"      Late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/31/2552?source=related_link\">",
"      Management of the infant whose mother has received group B streptococcal chemoprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/27/1461?source=related_link\">",
"      Maternal and economic benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41705?source=related_link\">",
"      Neonatal circumcision: Risks and benefits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17673?source=related_link\">",
"      Neonatal hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26346?source=related_link\">",
"      Neonatal resuscitation in the delivery room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/2/2088?source=related_link\">",
"      Newborn screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31511?source=related_link\">",
"      Overview of neonatal respiratory distress: Disorders of transition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15960?source=related_link\">",
"      Overview of vitamin K",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/31/31218?source=related_link\">",
"      Patient information: Newborn appearance (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/19/8502?source=related_link\">",
"      Physiologic transition from intrauterine to extrauterine life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/11/20666?source=related_link\">",
"      Postpartum blues and depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27865?source=related_link\">",
"      Screening the newborn for hearing loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/4/21576?source=related_link\">",
"      Sucking and swallowing disorders in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/57/15256?source=related_link\">",
"      Techniques for neonatal circumcision",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/59/21434?source=related_link\">",
"      Treatment of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_16_36106="Fixed drug eruption dark skin";
var content_f35_16_36106=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86671%7EDERM%2F52192%7EDERM%2F65991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86671%7EDERM%2F52192%7EDERM%2F65991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Fixed drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    On dark skin, fixed drug eruption presents as a dark brown/slate-gray patch.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fixed drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fixed drug eruption. An oval lesion occurred at the identical site where it had occurred previously. In both episodes, the rash emerged after this patient ingested a sulfonamide antibiotic. Note the eroded blister in the center of the lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP, MD. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fixed drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fixed drug eruption. An oval erosion on the glans penis occurred in this patient who was taking minocycline. According to the patient, an identical lesion appeared when he was given minocycline previously.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_16_36106=[""].join("\n");
var outline_f35_16_36106=null;
var title_f35_16_36107="5 year DFS node neg colon CA";
var content_f35_16_36107=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Predicted five year DFS estimates for patients with node-negative colon cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Disease Stage",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Low",
"grade",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        High",
"grade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Surgery alone, percent",
"       </td>",
"       <td class=\"subtitle2\">",
"        Surgery and CT, percent",
"       </td>",
"       <td class=\"subtitle2\">",
"        Surgery alone, percent",
"       </td>",
"       <td class=\"subtitle2\">",
"        Surgery and CT, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T3N0",
"       </td>",
"       <td>",
"        <p>",
"         73",
"        </p>",
"        <p>",
"         (69 to 76*)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         77",
"        </p>",
"        <p>",
"         (74 to 80)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         65",
"        </p>",
"        <p>",
"         (60 to 70)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         70",
"        </p>",
"        <p>",
"         (65 to 74)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T4N0",
"       </td>",
"       <td>",
"        <p>",
"         60",
"        </p>",
"        <p>",
"         (54 to 68)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         66",
"        </p>",
"        <p>",
"         (59 to 73)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         51",
"        </p>",
"        <p>",
"         (43 to 60)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         57",
"        </p>",
"        <p>",
"         (49 to 66)",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DFS: disease-free survival; CT: chemotherapy.",
"     <br>",
"      * 95 percent confidence intervals.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Based upon a model derived from 1440 patients with node-negative colon cancer enrolled on seven randomized trials comparing adjuvant 5-fluorouracil-based treatment with surgery alone. (Gill, S, et al. J Clin Oncol 2004; 22:1797.)",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_16_36107=[""].join("\n");
var outline_f35_16_36107=null;
var title_f35_16_36108="Firearm injuries and deaths";
var content_f35_16_36108=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Firearm gunshot nonfatal injuries and deaths, United States, all races, both sexes, ages 0 to 18",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age (in years)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of nonfatal firearm injuries*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of firearm deaths",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        153",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        53",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        316",
"       </td>",
"       <td>",
"        120",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        1116",
"       </td>",
"       <td>",
"        227",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        1672",
"       </td>",
"       <td>",
"        349",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        2249",
"       </td>",
"       <td>",
"        546",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        3997",
"       </td>",
"       <td>",
"        731",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Total",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         <span style=\"color: #ff0000;\">",
"          9981",
"         </span>",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         <span style=\"color: #ff0000;\">",
"          2251",
"         </span>",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Data from 2009.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Data from 2007.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     From: National Center for Injury Prevention and Control WISQARS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_16_36108=[""].join("\n");
var outline_f35_16_36108=null;
var title_f35_16_36109="Contents: Eosinophil related disorders";
var content_f35_16_36109=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?43/1/44061\">",
"       Allergy and Immunology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Eosinophil related disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Eosinophil related disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/24/30090\">",
"           Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/43/43703\">",
"           Eosinophilic gastroenteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/56/21383\">",
"           Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/14/1255\">",
"           Idiopathic acute eosinophilic pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/45/32474\">",
"           Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/33/35353\">",
"           Treatment and prognosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/18/25898\">",
"           Treatment of the hypereosinophilic syndromes",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-540FF5FBA0-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f35_16_36109=[""].join("\n");
var outline_f35_16_36109=null;
var title_f35_16_36110="Mechanisms of action of heparin LMW heparin and fondaparinux";
var content_f35_16_36110=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F64839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F64839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 479px\">",
"   <div class=\"ttl\">",
"    Mechanisms of action of heparin, LMW heparin, and fondaparinux",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 459px; height: 308px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the actions of unfractionated heparin, low molecular weight (LMW) heparin, and the heparin pentasaccharide analog fondaparinux. Unfractionated heparin binds to antithrombin (AT) at the site of the native pentasaccharide sequence (shown as \"5\"), changing its conformation and converting it from a slow to a rapid inactivator of several coagulation factors, particularly factor Xa (yellow circle, left upper panel). However, in order to inactivate thrombin (Th, factor IIa, red circle), heparin must bind to thrombin and AT simultaneously, an effect that occurs only when the molecule exceeds 18 monosaccharide units (greater than 6000 daltons) (lower left panel). LMW heparins have a similar mechanism of action and retain the ability to inactivate factor Xa (right upper panel). However, they have a lesser effect on thrombin because most of the molecules are not long enough to simultaneously bind to thrombin and AT (right lower panel). Fondaparinux, which contains only a more highly modified (sulfated) pentasaccharide unit with higher antithrombin affinity than the native pentasaccharide, inactivates factor Xa, but cannot inactivate thrombin because of its extremely short length.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Schafer AL, N Engl J Med 1996; 334:724.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_16_36110=[""].join("\n");
var outline_f35_16_36110=null;
var title_f35_16_36111="Early transition hormone";
var content_f35_16_36111=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F79769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F79769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Early transition hormone patterns",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 466px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urinary reproductive hormone patterns in a group of 11 midreproductive-age (norm, age 19 to 38) and 11 late reproductive-age (peri, age 43 to 52) women having ovulatory cycles. Note that, in late reproductive-age women, FSH (follicle-stimulating hormone) is consistently elevated throughout the cycle, estradiol metabolite excretion (estrone conjugates, or E1c) is overall elevated, and progesterone metabolites (pregnanediol glucuronide, or PDG) are decreased compared to the midreproductive-age women.",
"    <div class=\"footnotes\">",
"     LH: luteinizing hormone.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Santoro N, Brown JR, Adel T, Skurnick JH. Characterization of Reproductive Hormonal Dynamics in the Perimenopause. J Clin Endocrinol Metab 1996; 81:1495. Copyright &copy; 1996 by The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_16_36111=[""].join("\n");
var outline_f35_16_36111=null;
